CA1340567C - Heterocyclic amide derivatives - Google Patents

Heterocyclic amide derivatives

Info

Publication number
CA1340567C
CA1340567C CA000506885A CA506885A CA1340567C CA 1340567 C CA1340567 C CA 1340567C CA 000506885 A CA000506885 A CA 000506885A CA 506885 A CA506885 A CA 506885A CA 1340567 C CA1340567 C CA 1340567C
Authority
CA
Canada
Prior art keywords
formula
group
compound
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000506885A
Other languages
French (fr)
Inventor
Peter Robert Bernstein
Frederick Jeffrey Brown
Victor Giulio Matassa
Ying Kwong Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca Pharmaceuticals LP
Original Assignee
Zeneca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858509882A external-priority patent/GB8509882D0/en
Priority claimed from GB858525658A external-priority patent/GB8525658D0/en
Application filed by Zeneca Inc filed Critical Zeneca Inc
Application granted granted Critical
Publication of CA1340567C publication Critical patent/CA1340567C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The invention concerns novel) pharmaceutically useful, amide derivatives of certain benzoheter-ocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof) wherein the radicals R1, R2, L, X, Y, Z, A1, Q, A2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula. I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. The compounds of the invention are particularly useful leukotriene antagonists, and in the treatment of allergic diseases, inflammatory diseases, eridotoxic conditions or traumatic shock conditions.

Description

- t- 13e1567 HETEROCYCLIC A2~4IDE DERIVATIVES
SUMMARY AIdD BACKGROUIdD OF THE INVENTION
This invention concerns novel heterocyclic amide derivatives and, more particularly, novel amides derived from benzoheterocyclylalkanoic acids (and re-lated tetrazoles and acylsulphonamides), which antago-nise the pharmacological actions of one or more of the arachidonic acid metabolites known as leukotrienes (hereafter referred to as "leukotriene antagonist pro-perties"). The novel derivatives are useful whenever such antagonism is desired. Thus, such compounds may be of value in the treatment of those diseases in which leukotrienes are implicated, for example in the treatment of allergic or inflammatory diseases, or of endotoxic or traumatic shock conditions. The inven-tion also provides pharmaceutical compositions con-taining the novel derivatives for use in such treat-ments, and processes and intermediates for the manu-facture of the novel derivatives.
In United States Patents 3,271,416 and 3,470,298 there are described 5-acetamido-1-benzyl-alpha,2-dimethylindole-3-acetic acid derivatives and (5-acetamido-1-benzyl-1H-indazol-3-yl)oxyacetic acid derivatives, respectively, as antiinflammatory com-pounds; N-acyl derivatives of 6-amino-1-benzylindazole have been described (see E. Hannig) et al., Pharmazie, (1974), 29: 685-7); and 6-(acetylamino)-2,3-dihydro-4H-1,4-benzoxazine-4-propanoic acid methyl ester has been registered (Chemical Abstracts Registry Number 27802-53-5) Chem. Abs. 74: 4635(P~s). We have now dis-ICI Americas Inc.
Docket No. 1740S
(Version 5.2) covered a series of benzoheterocyclic derivatives which have an amidic substituent in the benzenoid ring and which unexpectedly possess the property of antago-nising one or more of the arachidonic acid metabolites S known as leukotrienes and this is the basis for our invention.
DESCRIPTION OF THE INVEI~dTION
According to the invention there is provided a compound of the formula I
(Formula set out on pages following Examples) I
wherein the group >X-Y-Z- is selected fron the group consisting of:
(a) >CRc-CRaRb-NRd-(b) >C=PI-Za-(c) >C=CRa-Zb-(d) >N-CRa=N-(e) >Id-CRbRe-CRcRf-Zb-(f) >N-N=N-(g) >Pd-rdRg-CO-(h) >N-N=C.ORd-in which ">" indicates two separate bonds) Ra is hydrogen or (1-4C)alkyl;

I34t~~G'~
Rb and Rc are each hydrogen or, together with the existing carbon to carbon bond, form an un-saturated linkage;
Rd is hydrogen or (1-lOC)alkyl optionally containing one or two double or triple bonds and in which a carbon atom may optionally be replaced by oxy-gen or sulphur, said (1-lOC)alkyl additionally option-ally bearing a substituent selected from the group consisting of (1-4C)alkoxy, cyano) carboxy, 1H-tetra-zol-5-yl, carbamoyl, Pd-(1-4C) alkylcarbannyl, N,N-di(1-4C)-alkyl]carbamoyl, and (1-4C)alkoxycarbonyl, or Rd is (3-8C)cyclo~lkyl, (3-8C)cycloalkyl-(1-4C)alkyl) (2-6C)alkanoyl or phenyl-(1-4C)alkyl, the phenyl moiety of which optionally bears a substituent selected from the group consisting of cyano, halogeno) (1-4C)alkyl, (1-4C)alkoxy and trifluoromethyl;
Re and Rf are independently hydrogen or (1-4C)alkyl;
Rg is (1-4C)alkyl;
Za is oxy, thio) or substituted imino of the formula -N(Rd)- in which Rd has any of the meanings defined above;
Zb is oxy or thio;
the group R1.L- stands for amidic radicals of the formula: Rl.W.CO.NH- or Rl.W.CS.NH-, in which R1 is (2-lOC)alkyl optionally containing 1 or more fluorine substituents; or Rl is phenyl-(1-6C)alkyl in which the (1-6C)alkyl rioiety may optionally bear a fluoro or (1-4C)alkoxy substituent and in which the phenyl moiety may optionally bear a substituent selected from the group consisting of halogeno, (1-" -w l3~aj~' 4C)alkyl, (1-4C)alkoxy and trifluoromethyl; or R1 is (3-8C)cycloalkyl or (3-8C)cycloalkyl-(1-6C)alkyl, the cyclic moiety of any of which optionally may contain one unsaturated linkage and may optionally bear 1 or 2 (1-4C)alkyl substituents;
W is oxy, thin, imino or a direct link to Rls R2 is hydrogen, halogeno, (1-4C)alkyl or (1-4C)alkoxy;
Q is phenylene optionally bearing 1 or more substituents independently selected from the group consisting of halogeno, hydroxy) (1-4C)alkyl, (1-4C) alkoxy and trifluoromethyl;
A1 is (1-2C)alkylene or vinylene;
A2 is methylene) vinylene or a direct link to M; and M is an acidic group selected from the group consisting of carboxy, an acylsulphonamide residue of the formula -CO. NH.SOmR3 and 1H-tetrazol-5-yl in which m is the integer 1 or 2 and R3 is (1-6C)alkyl, (3-8C)-cycloalkyl) (6-12C)aryl, heteroaryl comprising 5-12 atoms at least one of which is carbon and at least one of which is selected from oxygen, sulfur, and nitro-gen, (6-12C)aryl-(1-4C)alkyl, in any of which the aro-matic or heteroaromatic moiety may bear 1 or 2 sub-stituents selected from the group consisting of halo-geno, (1-4C)alkyl, (1-4C)alkoxy, trifluoromethyl, nitro and amino;
or a pharmaceutically acceptable salt thereof.

1340e7 It will be appreciated that certain of the compounds of formula I, for example those wherein R1 contains an asymmetrically substituted carbon atom, may exist in, and be isolated in, optically-active and racemic forms. In addition, it will be appreciated that certain compounds of formula I) for example, those wherein Rd or the linkage -A1.Q.A2- contains a vinylene group, may exist in, and be isolated in, separate stereoisomeric forms ('E' and 'Z') about that group. Some compounds may exist in more than one tautomeric form. Some compounds may exhibit poly-morphism. It is to be understood that the present invention encompasses any racemic) optically-active, tautomeric) polymorphic or stereoisomeric form, or mixtures thereof, which form possesses leukotriene antagonist properties) it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form or by synthesis from optically-active starting materials) and to prepare individual 'E' and 'Z' stereoisomers (for example) by chromatographic separation of a mixture thereof) and how to determine the leukotriene antagonist properties by the standard tests described hereinafter.
In this specification Ra, Rb) Rc et cetera stand for generic radicals and have no other signifi-cance. It is to be understood that the generic term "(1-6C)alkyl" includes both straight and branched chain alkyl radicals but references to individual alkyl radicals such as "propyl" embrace only the straight chain ("normal") radical, branched chain isomers such as "isopropyl" being referred to specifi-cally. A similar convention applies to other generic groups, for example) "alkylene" and "alkenylene" et cetera.
Particular values for the generic radicals described as ranges above under Ra, Rb, Rc et cetera are as follows:
A particular value for Ra, Re, Rf) Rg or R~
when it is (1-4C)alkyl is, for example, methyl, ethyl or propyl.
A particular value for R2 when it is (1-4C) alkoxy is, for example) methoxy or ethoxy; and when it is halogeno is, for example, fluoro) chloro or bromo.
A particular value for Rd when it is (1-lOC)alkyl is) for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, 3-methylbutyl, pentyl or hexyl; when it is alkyl containing 1 or 2 double or triple bonds is, for example, vinyl) allyl, 1-propenyl, 2-methylallyl, 3-methylbut-2-enyl, 1,3-pentadienyl, 2-propynyl or 3-butynyl; and when it is alkyl in which one or two carbon atoms are replaced by oxygen or sulphur a particular value is, for example, 2-methoxyethyl or 2-methylthioethyl.
A particular value for an optional substitu-ent on Rd is) for example:
for (1-4C)alkoxy) methoxy or ethoxy;
for N-(1-4C)alkylcarbamoyl, N-methyl- or N-ethylcarbamoyl;
for N,N-di(1-4C)alkylcarbamoyl) N,N-dimeth-ylcarbamoyl;
for (1-4C)alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl.

13~~~~7 _, _ A particular value for Rd when it is (3-8C) cycloalkyl is, for example, cyclopropyl) cyclopentyl or cyclohexyl; when it is (3-8C)cycloalkyl-(1-4C)alkyl a particular value is) for example, cyclopropylmethyl, cyclopentylmethyl or cyclohexylmethyl; when it is (2-6C)alkanoyl a particular value is, for example, acetyl or propionyl; and when it is phenyl-(1-4C)alkyl a par-ticular value is, for example, benzyl, 1-phenylethyl or 2-phenylethyl.
A particular value for R1 when it is (2-lOC)alkyl is, for example) ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl) 1-ethyl-propyl) hexyl, heptyl, 1-ethylpentyl or nonyl; and when it contains 1 or more fluorine substituents a particular value is, for example, 2,2,2-trifluoroethyl or heptafluoropropyl.
Particular values for R1 when it is phenyl-(1-6C)alkyl include) for example, benzyl, 1-phenyl-ethyl, 2-phenylethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl) 1-methyl-1-phenylethyl, 1-phenylbutyl and 1-phenylpentyl; and a particular value for an optional (1-4C)alkoxy substituent on the (I-6C)alkyl moiety is) for example, methoxy or ethoxy.
Particular values for certain optional sub-stituents which may be present on a phenyl moiety of R1 or Rd, or as a part thereof, as defined above, include, for example:
for halogen: a member selected from the group consisting of fluoro, chloro and bromo;
for (1-4C)alkyl: a member selected from the group consisting of methyl and ethyl; and z~zo~s~
_8_ for (1-4C)alkoxy: a member selected from the group consisting of methoxy and ethoxy.
A particular value for R1 when it is (3-8C) cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; when it is (3-8C)cycloalkyl-(1-6C)alkyl a particular value is, for example, cyclobutylmethyl, cyclopentylmethyl) cyclohexylmethyl) 1-cyclopentylethyl, 2-cyclopentyl-ethyl, 1-cyclopentylpropyl) 1-cyclohexylpropyl, 1-cyclopentylbutyl, 1-cyclohexylbutyl; and a particular value for a radical containing an unsaturated linkage in the cycloalkyl ring is, for example, cyclohexenyl or cyclohexenyl-(1-6C)alkyl (such as cyclohexenylmeth-yl or 1-(cyclohexenyl)butyl); and a particular value for an optional (1-4C)alkyl substituent on the cyclic moiety of such a radical is) for example, methyl, ethyl or isopropyl.
A particular value for Q is m-phenylene or p-phenylene, preferably bearing a fluoro, chloro, (1-4C)alkyl) (1-4C)alkoxy or trifluoromethyl substituent.
A particular value for A1 when it is (1-2C)-alkylene is, for example, methylene, ethylene or ethylidene.
A particular value for R3 when it is (1-6C)-alkyl is, for example, methyl, ethyl, propyl) isopro-pyl or butyl; when it is (3-8C)cycloalkyl a particular value is) for example, cyclopentyl or cyclohexyl; when it is (6-12C)aryl a particular value is, for example, phenyl, 1-naphthyl or 2-naphthyl; when it is hetero-aryl a particular value is, for example, furyl) thien-yl or pyridyl; when it is (6-12C)aryl-(1-4C)alkyl a 13~U~67 particular value is, for example, benzyl, 1-naphthyl-methyl or 2-naphthylmethyl.
Particular values for optional substituents which may be present on an aromatic or heteroaromatic moiety of P.3, or on a part thereof, include those defined above in connection with a phenyl moiety in R1.
More particular values for the groups listed above include by way of example those selected from the groups consisting of:
for R1 ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, 1-ethylpropyl, hexyl, heptyl, 1-ethylpentyl, nonyl, heptafluoropropyl, benz-yl, 4-chlorobenzyl) 4-trifluoromethylbenzyl) 4-methyl-benzyl, 1-phenylethyl) 2-phenylethyl, 1-methyl-1-phen-ylethyl) 1-phenylpropyl, 1-phenylpentyl) alpha-fluoro-benzyl) alpha-methoxybenzyl, cyclobutyl, cyclopentyl, cyclohexyl) cyclopentylmethyl, cyclohexylmethyl, 2-cyclopentylethyl, 1-cyclopentylbutyl) 1-cyclohexylpro-pyl) 1-cyclohexylbutyl, S-methyl-2-(1-methylethyl)-cyclohexyl, and 1-cyclohexen-4-yl;
for R2: hydrogen, fluoro, chloro, bromo) methyl and methoxy;
for R3 methyl, isopropyl, butyl, cyclopentyl, phenyl) 4-chlorophenyl, 4-methylphenyl) 2-methyl-phenyl, naphthyl, thien-2-yl and 6-chloropyrid-3-yl;
for Ra: hydrogen and methyl;
6~

13~Q5b'~

for Rb and Rc: hydrogen, Rb and Rc together with the existing carbon to carbon bond form an unsaturated linkage;
for Rd: hydrogen) methyl, ethyl) propyl) butyl, pentyl, hexyl, allyl, propargyl, 3-methylbutyl, 3-methylbut-2-enyl, 2-carbamoylethyl, carboxymethyl, carboxyethyl, N-ethylcarbamoylmethyl, N,rI-dimethyl-carbamoylmethyl, 2-carboxyvinyl, 2-(methoxycarbonyl)-vinyl, 2-methoxyethyl, 3-methoxypropyl, cyclopentyl, cyclopropylmethyl, acetyl, benzyl, 3-cyanobenzyl and 4-chlorobenzyl;
for Re and Rf: hydrogen, methyl and ethyl;
fo- r Rg methyl, ethyl, and propyl;
for A~~ methylene and ethylene;
for A . a direct linkage and methylene;
for m-phenylene and p-phenylene (optionally bearing a fluoro) chloro, hydroxy, methyl, methoxy or trifluoromethyl substituent); and for W: oxy) imino, thio and a direct linkage.
Examples of specific groups which are of special interest include those selected from the groups consisting of:
for R1 butyl) pentyl, 1-ethylpentyl, 1-phenylpropyl, alpha-fluorobenzyl, alpha-methoxybenzyl, cyclopentyl, and cyclopentylmethyl;
for R2 hydrogen;
for R~ phenyl and 2-methylphenyl;
for Ra: hydrogen;
for Rb and Rc: hydrogen, and Rb and P.c together with the existing carbon to carbon bond form an unsaturated linkage;

1~40~a~

for Rd: hydrogen, methyl, ethyl) propyl) hexyl, allyl, propargyl) 3-methylbutyl, 3-methylbut-2-enyl, carboxymethyl, carboxyethyl, IJ-ethylcarbamoylmethyl, N,N-dimethylcarbamoylmethyl, 2-methoxyethyl, cyclopen-tyl, cyclopropylmethyl, acetyl) benzyl) and 3-cyano-benzyl;
for Re or Rf: hydrogen;
fo- r-=P.g propyl;
for A~: methylene;
for a direct linkage;
for : m-phenylene and p-phenylene (optionally bearing an hydroxy or methoxy substituent); and for W: oxy, imino and a direct linkage.
It will be appreciated that within the above definitions there are included a number of sub-groups of compounds, for example:
(i) indoles and indolines of formula Ia;
(Formula set out on pages following Examples) Ia (ii) benzisoxazoles, benzisothiazoles and indazoles of formula Ib;
(Formula set out on pages following Examples) Ib 13~05~'~

(iii) benzo[b]furans and benzo[b]thiophenes of formula Ic;
(Formula set out on pages following Examples) Ic (iv) benzimidazoles of formula Id;
(Formula set out on pages following Examples) Id (v) 1,4-benzoxazines and 1,4-benzothiazines of formula Ie;
(Formula set out on pages following Examples) Ie (vi) benzotriazoles of formula If;

~~~05~7 (Formula set out on pages following Examples) If (vii) indazolones of formula Ig; and (Formula set out on pages following Examples) Ig (viii) indazoles of formula Ih;
(Formula set out on pages following Examples) Ih and wherein, in each sub-group, m, R1-R3, Ra-Rg, Za, Zb, A1, A2) Q, 47 and M have any of the above defined meanings; together with the pharmaceu-tically acceptable salts thereof.
Within the above sub-groups yet further sub-groups of compounds of the invention comprise the following:

(ix) those compounds of formula Ia wherein Rb and Rc, together with the existing carbon to carbon bond, form an unsaturated linkage;
(x) those compounds of formula Ie wherein Zb is oxy or thin, and Rb and Rc are hydrogen;
and wherein, in each sub-group (ix) and (x) the remaining generic radicals have any of the above defined meanings; together with the pharmaceutically acceptable salts thereof.
In the above sub-groups a preferred value for A1 is, for example, methylene; a preferred value for A2 is, for example, a direct link to ti; a pre-ferred value for Q is, for example, p-phenylene (optionally substituted with methoxy, especially meth-oxy in the ortho-position relative to Al); and a pre-ferred value for 2-i is carboxy, 1H-tetrazol-5-yl or a radical of the formula -CO.NH.S02R4 wherein R4 is phenyl, optionally substituted as defined above for R3, for example) 2-methylphenyl. In general) it is preferred for the group P,1.L- to be attached to the benzene raoiety of formula I in such a way that it bears a meta-relationship to the group X but does not bear an ortho-relationship to the group Z. A prefer-red value for R1.L- is, for example) Rl.W.CO.NH-; a preferred value for W is) for example, oxy, imino or a direct linkage; a preferred value for Rl when W is oxy or imino is, for example, cyclopentyl; and a pre-ferred value for R1 when W is a direct linkage is, for example, cyclopentylmethyl.

1~40fi57 Preferred groups of compounds of the inver~-tion comprise the indole derivatives of the following formula IIa) (Formula set out on pages following Examples) IIa the indazole derivatives of the following formula IIb, (Formula set out on pages following Examples) IIb the benzo[b]thiophene derivatives of the following formula IIc, (Formula set out on pages following Examples) IIc the benzimidazole derivatives of the following formula IId, 13405e (Formula set out on pages following Examples) IId the 2,3-dihydrobenz-1,4-oxazine derivatives of the following formula IIe, (Formula set out on pages following Examples) IIe the benzotriazole derivatives of the following formula IIf , (Formula set out on pages following Examples) IIf and the indazole derivatives of the following formula IIg, (Formula set out on pages following Examples) IIg wherein R1) R2, Ra, Rd, Re) Rf, W, Q) A2 and M have any of the meanings defined hereinbefore; together with the pharmaceutically acceptable salts thereof.
Particularly preferred values of Rd for the deriva-tives of formula IIa and IIb when M is carboxy include methyl, propyl, 2-methoxyethyl) N-ethylcarbamoyl-methyl, and cyclopentyl. Particularly preferred values of Rd for the derivatives IIa and IIb when M is a radical of the formula -CO.NH.S02R4 wherein R4 is phenyl include hydrogen, methyl, 2-methoxyethyl and N-ethylcarbamoylmethyl. Particularly preferred values of Rd for the derivatives IIa and IIb when M is a ZO radical of the formula -CO.NH.S02R4 wherein R4 is 2-methylphenyl include methyl and N,N-dimethylcarbamoyl-methyl. For the derivatives IIg when R1.L- is R1.W.CO.NH- wherein R1.W- is cyclopentyloxy and M is carboxy or -CO. NH.S02R4 wherein R4 is phenyl) a parti-cularly preferred value of Rd is methyl. For the derivatives IIg when R1.L- is R1.W.CO.NH- wherein R1 is cyclopentylmethyl and td is a direct linkage and M
is carboxy or -CO. NH.S02R4 wherein R4 is 2-methyl-phenyl, a particularly preferred value of Rd is N-ethylcarbamoylmethyl.
Specific compounds of the invention are described in the accompanying examples. However, of 13~0~~7 these the compounds N-[4-[5-(cyclopentyloxycarbonyl)-amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]ben-zenesulphonamide, N-[4-[5-(cyclopentyloxycarbonyl)-amino-1-(N-ethylcarbamoylmethyl)indol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide, PI-[4-[5-(cyclopen-tyloxycarbonyl)amino-1-methylindazol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide, N-[4-[5-(cyclopen-tyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-meth-oxybenzoyl]-2-methylbenzenesulphonamide, N-[4-[5-(2-cyclopentylacetamido)-1-(N,N-dimethylcarbamoylmethyl)-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzene-sulphonamide, N-[4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenz-oyl]benzenesulphonamide, N-[4-[6-(2-cyclopentylaceta-I5 mido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-meth-oxybenzoyl]benzenesulphonamide, N-[4-[5-(cyclopentyl-oxycarbonyl)aminobenzo[b]thien-3-ylmethyl]-3-methoxy-benzoyl]benzenesulphonamide, N-[4-[6-(2-cyclopentyl-acetamido)benzimidazol-1-ylmethyl]-3-methoxybenzoyl]-benzenesulphonamide, N-[4-[6-(2-cyclopentylacetamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenz-oyl]-2-methylbenzenesulphonamide, N-[4-[6-(cyclopen-tyloxycarbonyl)amino-3-methoxyindazol-1-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide, N-[4-[5-(N'-cyclo-pentylureido)-1-methylindol-3-ylmethyl]-3-methoxybenz-oyl]-2-methylbenzenesulphonamide) N-[4-[6-(2-cyclopen-tylacetamido)benzotriazol-1-ylmethyl]-3-methoxybenz-oyl]benzenesulphonamide, N-[4-[5-(cyclopentyloxycar-bonyl)aminoindol-3-ylmethyl]-3-methoxybenzoyl]benzene-sulphonamide, N-[4-[5-(cyclopentyloxycarbonyl)amino-1-(2-methoxyethyl)indol-3-ylmethyl]-3-r_Zethoxybenzoyl]-1310y7 benzenesulphonamide) N-[4-[5-(2-cyclopentylacetamido)-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide) Ld-[4-[6-(2-cyclopentylacetamido)-3-(N-eth-ylcarbamoylmethoxy)indazol-1-ylmethyl]-3-methoxybenz-oyl]-2-methylbenzenesulphonamide) and N-[4-[6-(cyclo-pentyloxycarbonyl)aminobenzimidazol-1-ylriethyl]-3-methoxybenzoyl]benzenesulphonamide are particularly preferred and may be used either in the free acid form.
or as their corresponding pharmaceutically acceptable salts.
Examples of suitable pharmaceutically acceptable salts are salts formed with bases which form a physiologically acceptable cation) such as al-kali metal (especially sodium and potassium), alkaline earth metal (especially calcium and magnesium), alumi-num and ammonium salts, as well as salts made with appropriate organic bases such as triethylamine, mor-pholine, piperidine and triethanolamine. For those compounds of formula I which are sufficiently basic, examples of suitable pharmaceutically acceptable salts include acid-addition salts such as those made with a strong acid, for example hydrochloric, sulphuric or phosphoric acid.
The compounds of formula I may be made by processes well known in the chemical art for the production of structurally analogous heterocyclic compounds. Such processes for the manufacture of a compound of formula I as defined above are provided as further features of the invention and are illustrated by the following procedures in which the meanings of generic radicals are as defined above) T is defined as a group selected from the group consisting of COORh (wherein Rh has the values defined below), CN, and the 1~4U~~7 values defined above for M; U is defined as a suitable leaving group, for example, halogeno (especially chloro, bromo, or iodo) or alkane- or arene-sulphonyl-oYy (especially methanesulphonyloxy or p-toluenesul-phonyloxy); and Hal is defined as halogeno, especially chloro) bromo or iodo.
(A) For those compounds wherein rI is a carboxylic acid group, decomposing a suitable ester of formula III
(Formula set out on pages following Examples) III
wherein Rh is a conveniently removed acid protecting group, for example, (1-6C)alkyl optionally bearing an acetoxy, (1-4C)alkoxy or (1-4C)alkylthio substituent, or is phenyl or benzyl.
A particular value for Rh is, for example) methyl, ethyl, propyl, t-butyl, acetoxymethyl, meth-oxymethyl, 2-methoxyethyl, methylthiomethyl, or phenyl or benzyl.
Certain of the starting esters of formula III may be active in their own right as Ieukotriene antagonists (such as, for example, by in vivo conver-sion to the corresponding carboxylic acid), for example, those wherein Rh is (1-6C)alkyl, and these are included within the scope of the invention.
It will be appreciated that the decomposi-tion can be performed using any one of a variety of ~~~0 ~' 7 procedures well known in the art of organic chemistry.
Thus, it may be carried out, for example, by conven-tional hydrolysis under acid or base conditions, ad-justed as necessary to minimize any hydrolytic removal of other functional groups in the molecule. Also, when Rh is methyl, the ester may be decomposed by nucleophilic demethylation with, for example, lithium thioethoxide in N,N'-dimethylpropyleneurea. Alterna-tively, it may in certain circumstances, for example, when Rh is t-butyl, be possible to carry out the de-composition by thermal means, for example, by heating the ester of formula III at a temperature of, for example, 100-l50~C.) alone or in a suitable solvent or diluent such as diphenylether. In addition, when Rh is t-butyl the decomposition may be performed, for example, by using trimethylsilyl triflate and then water, in a conventional manner. Still further, in certain circumstances) for example) when Rh is benzyl) it may be possible to carry out the decomposition by reductive means, for example, by the use of hydrogen at about atmospheric pressure in the presence of a suitable catalyst, such as palladium or platinum, con-veniently on charcoal as a support.
A preferred method for decomposing an ester of formula III comprises reacting the ester with a suitable base, for example, an alkali or alkaline earth metal hydroxide or carbonate (such as lithium hydroxide, potassium hydroxide, sodium hydroxide, calcium hydroxide or potassium carbonate) in a suitable, aqueous solvent or diluent, for example) water, optionally together with a water-miscible 1340e7 alkanol, glycol, ketone or ether (such as methanol, ethanol, ethylene glycol, 2-methoxyethanol, acetone, methyl ethyl ketone, tetrahydrofuran or 1,2-dimethoxy-ethane), at a temperature of, for example, 15-100~C
and conveniently at or near ambient temperature. When such a method is employed, the resultant carboxylic acid of formula I, wherein t2 is a carboxy group, is initially obtained as the corresponding salt of the base used for the hydrolysis and may be isolated as such or converted to the free acid form by a conven-tional acidification procedure, for example, by reaction with a suitable strong acid such as hydro-chloric or sulphuric acid.
(B) Acylating ar. amine of the formula IV) (Formula set out on pages following Examples) IV
but wherein T is chosen from the values defined for PZ.
A suitable acylating agent when W is oxy, thio or a direct link is, for example, an acid halide of the formula Rl.Xa.C0.Ha1 wherein Xa has one of above-mentioned values for W.
A suitable acylating agent when W is imino is, for example, an isocyanate of the formula R1.NC0.
When an acid halide is used as the acylating agent, a suitable base such as triethylamine, N-meth-ylmorpholine, pyridine, 2,6-lutidine or 4-(dimethyl-13~O~b7 amino)pyridine is conveniently also employed, prefer-ably together with a suitable inert solvent or dilu-ent, for example) dichloromethane) diethyl ether, tetrahydrofuran or 1,2-dimethoxyethane. The same or similar inert solvents or diluents may be used when an isocyanate or isothiocyanate is employed as the acylating agent.
When W is a direct link, the acylating agent may also be a carboxylic acid of the formula R1.C02H.
In which case a suitable condensing agent, for exam-ple) a carbodiimide (such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, or a salt thereof) or 1,1'-carbonyldiimidazole, is also employed, preferably together with a suitable inert solvent or diluent, for example) one of those men-tioned above for use with an acid halide.
In general, the acylations are carried out at a temperature in the range of, for example, -20 to 60~C. and, conveniently, at or near ambient tempera-ture.
(C) For a compound of formula I wherein >X-Y-Z- has the value (a) or (b) as defined herein-above, but wherein Za is a substituted imino of the formula -N(Rd)-, reacting an imino compound of the formula V) (Formula set out on pages following Examples) V

~3~0~~7 wherein >D-E-G- is a group of the formula >CRc-CRbRa-NH- or >C=N-NH-, but wherein T is chosen from the values defined for M, with an alkylating agent of the formula Rd. U.
This procedure is particularly suitable for the production of) for example, compounds of formula IIa.
The reaction is preferably performed in the presence of a suitable base, for example, an alkali metal hydride such as sodium or potassium hydride in a suitable inert solvent or diluent, for example, tetra-hydrofuran, 1,2-dimethoxyethane) N-methylpyrrolidone, or N,N-dimethylformamide. Alternatively, the compound of formula V may be used in the form of its preformed anhydrous alkali metal salt, for example, by prior reaction with a suitable base such as sodium or potassium methoxide) t-butoxide or hydride, or butyl lithium; in which case a wider range of conventional solvents or diluents may be employed for the reaction with the alkylating agent.
In either case, the alkylation is generally performed at a temperature in the range, for example, -10 to 40~C. and, conveniently, at or near ambient temperature.
(D) For a compound of formula I wherein >X-Y-Z- has the value (a) defined hereinabove) but wherein Rb and Rc) together with the existing carbon-to-carbon bond, form an unsaturated linkage, reacting an indole of formula VI

1~40~~7 (Formula set out on pages following Examples) VI
with an alkylating agent of the formula U.Al.Q.A2.M in the presence of a suitable Lewis acid.
A particularly suitable Lewis acid is, for example, silver oxide, silver carbonate) silver fluoroborate, silver trifluoroacetate) silver tri-fluoromethanesulfonate) zinc chloride, ferric chloride or stannic chloride.
The process is generally best performed in a suitable solvent or diluent, for example, in acetone, dichloromethane, acetonitrile or an ether solvent such as 1,2-dimethoxyethane, dioxane or tetrahydrofuran, optionally together with a hydrocarbon diluent such as toluene or xylene, and at a temperature in the range of, for example, 15-100~C. and) more preferably, in the range 40-80~C.
(E) For a compound of formula I wherein M
is a 1H-tetrazol-5-yl radical, reacting a cyano deriv-ative of formula VII
(Formula set out on pages following examples) VII

with an azide.
A particularly suitable azide is, for example, an alkali metal azide such as sodium or potassium azide, preferably together with an ammonium halide, for example, ammonium chloride or ammonium bromide or, especially, with triethylammonium chlo-ride. The reaction is preferably performed in a suitable polar solvent, for example, N,N-dimethylform-amide or N-methylpyrrolidone, and conveniently at a temperature in the range of, for example, 50 to 160~C.
(F) For a compound of formula I wherein R1.L- stands for a group of the formula Rl.Wa.CO.NH-or Rl.Wa.CS.NH- in which Wa is oxy, imino or thin, reacting an isocyanate or isothiocyanate of the form-ula VIII, (Formula set out on pages following Examples) VIII
but wherein T is chasm from the values defined for Pi and wherein Xb is oxygen or sulphur, with the appro priate compound of the formula Rl.WaH, for example, an amine of the formula Rl.PdII2, an alcohol of the formula R1.OH or a thiol of the formula R1.SH.
In general, the process is performed at a temperature in the range of, for example, 0-60~C. and, conveniently in a suitable inert diluent or solvent such as dichloromethane) diethyl ether, methyl t-butyl 1340~ti'~

ether, tetrahydrofuran or dioxane. The starting iso-cyanate or isothiocyanate of formula VIII may conve-niently be obtained by reaction of the corresponding amine of formula IV with phosgene or thiophosgene (or an equivalent reagent, such as trichloromethyl chloro-formate for the production of an isocyanate) in a con-ventional manner.
(G) For a compound of formula I wherein Ti is a group of the formula CO.NH.SOm.R3, reacting a compound of formula I wherein M is carboxy (which com-pound is hereinafter referred to as "acid of formula I") with a sulphonamide derivative of the formula R3.SOm.NH2, in the presence of a dehydrating agent.
Thus, for example, a free acid of formula I
may be reacted with a suitable dehydrating agent, for example, with dicyclohexylcarbodiimide or 1-(3-dimeth-ylaminopropyl)-3-ethylcarbodiimide, or with a hydro-chloride or hydrobromide salt thereof optionally to-gether with an organic base, for example, 4-(dimethyl-amino)pyridine, in the presence of a suitable solvent or diluent, for example, dichloromethane, at a temper-ature in the range of, for example, 10 to 50~C., but preferably at or near ambient temperature.
Alternatively, a reactive derivative of an acid of formula I, for example) an acid halide (such as the acid chloride), acid anhydride or a mixed acid anhydride (such as that formed from N,N-diphenylcar-bamic acid and the acid of formula I by reaction of the sodium salt of the latter acid with N,N-diphenyl-carbamoylpyridinium chloride), may be reacted with an alkali metal salt (such as the lithium, sodium or ~.~~4~~i7 potassium salt) of the appropriate sulphonamide of the formula R4.S02.NH2, conveniently at or near room temperature and in a suitable solvent or diluent) for example) tetrahydrofuran) N,N-dimethylformamide or dichloromethane.
(H) An alternative process to procedure (D) mentioned above for a compound of formula I, wherein >X-Y-Z- has the value (a) defined above, but wherein Rb and Rc, together with the existing carbon-to-carbon.
bond, form an unsaturated linkage, reacting an indole of formula VI with an alkylating agent of the formula U.A1.Q.A2.M.
The process is generally best performed in a suitable solvent or diluent, for example, in a polar solvent (such as N,N-dimethylformamide, N,N'-dimethyl-propyleneurea or N-methylpyrrolidone), or in an ether solvent (such as dioxane or 1,2-dimethoxyethane), op-tionally together with an hydrocarbon diluent such as toluene or xylene.
The alkylation is generally best performed at a temperature in the range, for example 50-160~C.) and, preferably, in the range 70-100~C.
(I) For a compound of formula I wherein >X-Y-Z- has the value (b) defined hereinabove, but wherein Za is a substituted imino of the formula -N(Rd)-, dehydration of an amino-oxime of the formula IX, (Formula set out on pages following Examples) IX
but wherein T is chosen from the values defined for t2, by first reacting a compound of formula IX with a suitable condensing agent, for example, a carboxylic acid anhydride (such as acetic or propionic anhy-dride), preferably together with a suitable solvent or diluent, for example a chlorinated hydrocarbon solvent (such as dichloromethane or dichloroethane) in the presence of an organic base (for example, 4-(dimethyl-amino)pyridine), followed by heating the resulting 0-acyloxime, preferably in the absence of solvent or diluent, but which heating may also be carried out in a suitable inert solvent or diluent, for example, a hydrocarbon solvent (such as toluene or xylene), and at a temperature in the range of 80-2S0~C.) but pre-ferably in the range of 140-200~C.
The dehydration of compounds of formula IX
may also be carried out without prior derivatization to the acyl derivatives by heating, preferably in the absence of solvent or diluent, but which heating may also be carried out in a suitable solvent or diluent) such as these mentioned above, at a temperature in the range 150-300~C., but preferably in the range 150-250~C. Compounds of formula IX, but wherein T is chosen from the values defined for M, may be obtained, 13~05~~

by standard procedures known in the art, from com-pounds of formula X, (Formula set out on pages following Examples) X
but wherein T is chosen from the values defined for M, such compounds of formula X having been obtained from compounds of formula Ia, wherein Rb and Rc, together with the existing carbon-to-carbon bond, form an un-saturated linkage, by oxidative cleavage of the said unsaturated linkage, using techniques known in the art.
(3) For a compound of formula I, wherein >X-Y-Z- has the value (c) defined above, but wherein Zb is oxy, by dehydration of an hydroxy compound of formula XI, (Formula set out on pages following Examples) XI
but wherein T is chosen from the values defined for t-i, for example, by treatment with an acid (such as para-toluenesulphonic acid or hydrochloric acid) in a suit-able inert solvent, or diluent) for example a hydro-1~~05~7 carbon solvent (such as toluene or xylene), or in an ether solvent (such as dioxane or tetrahydrofuran).
In general, the reaction may be carried out at a temperature in the range of, for example, 50-150~C., but preferably in the range of 80-120~C.
Compounds of formula XI may be obtained, by standard oxidative procedures known in the art, from corresponding compounds of formula XII, (Formula set out on pages following Examples) XII
but wherein T is chosen from the values defined for M.
(Y.) For a compound of formula I) wherein >X-Y-Z- has the value (b) defined hereinabove, but wherein Za is oxy, by dehydration of an hydroxy-oxime of formula XIII) (Formula set out on pages following Examples) XIII
but wherein T is chosen from the values defined for M, by methods similar to those described hereinabove in process (I).

13~0~~7 Compounds of formula XIII, wherein T is chosen from the values defined for M, may be obtained) by standard procedures known in the art, from com-pounds of formula XIV) (Formula set out on pages following Examples) XIV
wherein T is chosen from the values defined for ri) themselves obtained from compounds of formula Ic) wherein Zb is oxy, by oxidative cleavage of the un-saturated linkage bearing Ra, using techniques known in the art.
(L) For a compound of formula I wherein >X-Y-Z- has the value (c) defined above, but wherein Zb is oxy or thio, by reacting a benzofuran or a ben-zothiophene of the formula XV
(Formula set out on pages following Examples) XV
with an alkylating agent of the formula U.A1.Q.A2.M, defined above, by methods similar to those described hereinabove in process (D).

~3~0~~7 (ri) For a compound of formula I wherein >~:-Y-Z- has the value (a) defined above, but wherein Rb and Rc are hydrogen, catalytic hydrogenation of an indole of formula I wherein >X-Y-Z- has the value (a) defined above, but wherein Rb and Rc, together with the existing carbon to carbon bond, form an unsatu-rated linkage.
Particularly suitable catalytic hydrogena-tion conditions are those of catalytic transfer hydro-genation, for example, palladium-on-carbon (10% w/w) and formic acid (99x) a temperature in the range of, for example, 15-100~C. and, more preferably in the range 70-85~C.
(Pd) For a compound of formula I wherein >~-Y-Z- has the value (b) defined above, but wherein Za has the value -N(Rd)- and A1 is methylene) a modi-fied version of process (A) or (E) described above comprising cross coupling an indazole of formula XVI, (Formula set out on pages following Examples) XVI
with a compound of formula Hal.CH2.Q.A2.T, but wherein T is COORh or CN, and wherein the Hal may be the same as that of XVI or different, to afford the correspond-ing III or VII, wherein >X-Y-Z- has the value (b) de-fined above, but wherein Za has the value -N(Rd)- and A1 is methylene; followed by conversion of the COORh ~~~4~~~

group or the CN group) respectively) into one of the values defined above for M by application of process (A) or (E), respectively.
The process may be carried out) for example, using a stoichiometric amount of activated zinc dust and a catalytic quantity of a transition metal cata-lyst, such as, for example, dichloro[1,1'-bis(diphen-ylphosphino)ferrocene]palladium (II) or dichlorobis-(triphenylphosphine)nickel (II) to couple, for example, 3-bromo-5-(cyclopentyloxycarbonyl)amino-1-methylindazole with, for example, methyl 4-bromometh-yl-3-methoxybenzoate to afford methyl 4-(5-(cyclo-pentyloxycarbonyl)amino-1-methylindazol-3-ylmethyl]-3-methoxybenzoate; followed by decomposition of the ester to afford 4-(5-(cyclapentyloxycarbonyl)amino-1 methylindazol-3-ylmethyl]-3-methoxybenzoic acid.
(0) For a compound of formula I wherein >X-stands for the group >N-, alkylation of an amino com-pound of formula XVII, (Formula set out on pages following Examples) XVII
with an alkylating agent of the formula U.A1.Q.A2.M in the presence of a suitable base, such as potassium carbonate or sodium methoxide in a solvent such as acetone, methanol or dimethylformamide.

1~~~5~~

In general, when a compound of formula I
wherein M is a carboxylic acid is required, it is pre-ferred to carry out one of the procedures (B), (C), (D), (F), (H), (I), (J), (K)) (L), (M), (N) and (0) mentioned above using an appropriate carboxylic ester and liberating the required acid as a final step using procedure (A) above.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example) by reacting a compound of formula I
with a suitable base affording a physiologically acceptable cation or by reacting a sufficiently basic compound of. formula I with a suitable acid affording a physiologically acceptable anion.
The necessary starting materials for the above procedures may be made by procedures which are selected from standard techniques of heterocyclic chemistry, techniques which are analogous to the syn-thesis of known, structurally similar compounds, and techniques which are analogous to the above described procedures. Thus, for example, certain of the start-ing esters of formula III and certain of the starting nitriles of formula VII) respectively, may be made using general procedures similar to these described in (D)) (H), (L) and (0) by using U.A1.Q.A2.COORh and U.Al.Q.A2.CN) respectively, as alkylating agents.
Also, certain of the starting esters of formula III
and certain of the starting nitriles of formula VII, may be made using similar general procedures to those described in (B), (C), (F), (I), (J), and (K), using corresponding intermediates IV, V, VIII, IX, XI, and 13~~a~7 XIII, but wherein T stands for COORh and CN, as appro-priate, in said intermediates. The intermediates IX) wherein T stands for COORh and CN, may respectively be obtained from corresponding intermediates X, wherein T
stands for COORh and CN; and the intermediates X, wherein T stands for COORh and CN, may respectively be obtained from the corresponding compounds III and VII, wherein >X-Y-Z- stands for >CRc-CRaRb-NRd- and Rb and Rc, together with the existing carbon-to-carbon bond, form an unsaturated linkage. The intermediates XI) wherein. T stands for COORh and CN, may respectively be obtained from the corresponding intermediates XII, wherein T stands for COORh and Cr3. The intermediates XIII, wherein T stands for COORh and CP3, may respec-tively be obtained from the corresponding interme-diates XIV) wherein T stands for COORh and C23; and the intermediates XIV) wherein T stands for COORh and CN, may respectively be obtained from corresponding inter-mediates III and VII, wherein >X-Y-Z- stands for >C=CRa-Zb- wherein Zb is oxy.
As an illustration, the amines of formula IV, wherein >X-Y-Z- stands for the group >C=CRa-NRd-, may be obtained, for example, by alkylating an appro-priate nitroindole of formula XVIII
(Formula set out on pages following Examples) XVIII

13~0~~7 using a corresponding alkylating agent of the formula U.A1.Q.A2.T in the presence of a suitable Lewis acid such as silver oxide and in a solvent such as dioxane, followed by a conventional reduction, as illustrated in the accompanying examples. As an additional, similar illustration, the amines of formula IV, wherein T stands for COORh, CId, or one of the values defined for M and wherein >X-Y-Z- stands for >C=CRa-Zb- wherein Zb is S, may be obtained, for example, by alkylating an appropriate nitrobenzothiophene of structure XIX
(Formula set out on pages following Examples) XIX
using a corresponding alkylating agent of the formula 2G U.A1.Q.A2.T in the presence of a suitable Lewis acid such as stannic chloride and in a solvent such as di-chloromethane, followed by a conventional reduction, as illustrated in the accompanying examples. As further illustration, the amines of formula IV wherein >X- stands for the group >N- may be obtained, for example) by alkylation of an appropriate nitrobenz-imidazole, nitrobenzoxazine, nitrobenzotriazole) or nitroindazole of formula XX

~.~~Q5ai7 (Formula set out on pages following Examples) XX
using a corresponding alkylating agent of the formula U.A1.Q.A2.T in the presence of a suitable base, such as potassium carbonate or sodium methoxide, in a sol-vent such as acetone or methanol, followed by a con-ventional reduction to give the required amine of formula IV) as illustrated in the accompanying exam-ples.
The nitriles of formula VII may be obtained from the corresponding compounds of formula I wherein M is carboxy by treatment with, for example, chloro-sulphonyl isocyanate and N,N-dimethylformamide. Al-ternatively) the cyano compounds of formula VII may be obtained by conventional dehydration of the primary amide of the corresponding carboxylic acid of formula I wherein M is carboxy.
It will be recognized that the starting materials of formula V for procedure (C) are also com-pounds of formula I wherein P.d is hydrogen, and may be obtained by any of the procedures described above for such compounds.
The starting materials of formula VI may be obtained by catalytic reduction of the appropriate nitroindole of formula VIII, followed by acylation of the resultant aminoindole using the same general pro-cedure as described in (B) above.
Starting materials of formula XV, but where-in Zb has the value thio, may be obtained by conven-tional reduction of the nitro group of the correspond-ing nitrobenzothiophene of formula XIR, followed by conversion of the resultant aminobenzothiophene into the said starting material XV by processes analogous to those described in process (B) or process (F).
Starting materials of formula XVI may be ob-tained by conventional reduction of the vitro group of appropriate nitroindazole of formula XXI, (Formula set out on pages following Examples) XXI
followed by conversion of the resultant aminoindazole into the said starting material XVI by processes anal-ogous to those described in process (B) and process (F).
The majority of the starting materials of formula III, IV (and its vitro precursors), VI (Rd other than hydrogen), VII, VIII, IX, X, XI, XII, XIII) XIV, XV, XVI, and XVII are novel and are provided as further features of the invention based on their utility as chemical intermediates.
As stated previously, the compounds of formula I possess leukotriene antagonist properties.

~~~05~~

Thus, they antagonise the actions of one or more of the arachidonic acid metabolites known as leukotrienes, for example, C4, D4, and/or E4, which are known to be powerful spasmogens (particularly in the lung)) to increase vascular permeability and have been implicat-ed in the pathogenesis of asthma and inflammation (see J. L. Marx, Science, 1982) 215, 1380-1383) as well as of endotoxic shock (see J. A. Cook) et al., J. Pharma-col. Exp. Ther., 1985, 235, 470) and traumatic shock (see C. Denzlinger, et al., Science, 1985, 230) 330).
The compounds of formula I are thus useful in the treatment of diseases in which leukotrienes are impli-cated and in which antagonism of their action is de-sired. Such diseases include, for example, allergic pulmonary disorders such as asthma, hay fever and allergic rhinitis and certain inflammatory diseases such as bronchitis, ectopic and atopic eczema, psoria-sis, as well as vasospastic cardiovascular disease, and endotoxic and traumatic shock conditions.
The compounds of formula I are potent leukotriene antagonists and are useful whenever such activity is desired. For example, the compounds of formula I are of value as pharmacological standards for the development and standardization of new disease models and assays for use in developing new therapeu-tic agents for treating the diseases in which the leukotrienes are implicated.
When used in the treatment of one or more of the above mentioned diseases, a compound of formula I
is generally administered as an appropriate pharma-ceutical composition which comprises a compound of 13~05~i~

formula I as defined hereinbefore together with a pharmaceutically acceptable diluent or carrier) the composition being adapted for the particular route of administration chosen. Such compositions are provided as a further feature of the invention. They may be obtained employing conventional procedures and excipi-ents and may be in a variety of dosage forms. For example, they may be in the form of tablets, capsules, solutions or suspensions for oral administration; in the form of suppositories for rectal administration;
in the form of sterile solutions or suspensions for administration by intravenous or intramuscular injec-tion or infusion; in the form of aerosols or nebuliser solutions or suspensions for administration by inhala-Lion; and in the form of powders together with pharma-ceutically acceptable inert solid diluents such as lactose for administration by insufflation.
For oral administration a tablet or capsule containing up to 250 mg. (and typically 5 to l00 mg.) of a compound of formula I may conveniently be used.
Similarly, for intravenous or intramuscular injection or infusion a sterile solution or suspension con-taining up to 10% w/w (and typically 0.05 to 5% w/w) of a compound of formula I may conveniently be used.
The dose of compound of formula I to be administered will necessarily be varied according to principles well known in the art taking account of the route of administration and the severity of the condi-tion and the size and age of the patient under treat-meat. However, in general) a compound of formula I
will be administered to a warm-blooded animal (such as 13~~~~~

man) so that a dose in the range of, for example, 0.05 to 25 mg./kg. (and usually 0.5 to 10 mg./kg.) is re-ceived.
The leukotriene antagonist properties of a compound of formula I may be demonstrated using stan-dard tests. Thus, for example, they may be demon-strated in vitro using the standard guinea-pig tra-cheal strip preparation described by Krell (J. Pharma-col. E~ Ther. 1979, 2l1, 436). Using this proce-dure, tracheal tissue strips are set up in groups of eight, four being used as time/vehicle controls and four for each test compound. A11 of the strips are exposed to 8x10 9M leukotriene E4(LTE4) following the 50 minute equilibration period, and the response is recorded. This 8x10 9M concentration of LTE4 is that which produces a contraction equal to about 70-80% of the maximal effect of the agonist in this tissue. The LTE4 is washed out for 40-45 minutes and the procedure is repeated twice to ensure that reproducible re-sponses are being obtained with LTE4. Leukotriene C4(LTC4) or D4(LTD4), at a concentration of 8x10 Sri, may be substituted for LTE4 in the same procedure.
Once tissue reproducibility has been estab-lished) test compounds are added to four baths follow-ing the 40-45 minute washout period. After a 10 minute incubation with test compound or vehicle, 8x10 9M LTE4) LTD4 or LTC4 is added and the response recorded. The percentage inhibition by the test compound or the percentage change in vehicle controls is calculated, for each tissue, according to the following equation: % inhibition = 100 multiplied by 1~40h~~

(mg. tension increase of preceding response minus mg.
tension increase in presence of compound) divi_deu by mg. tension increase of preceding response. The mean percentage change for vehicle controls and test com-pound are calculated and evaluated for significant differences by Students' t-test for unpaired data.
Tissues exposed to test compounds were retested for responsiveness to LTE4, LTD4 or LTC4 following a 25 minute washout period. If tissue responsiveness was equal to responsiveness preceding exposure to the test compound additional studies were conducted. If responsiveness was not restored by the washing proce-dure, the tissues were discarded. The cyclooxygenase inhibitor, indomethacin, is present at 5x10 6M in a11 the determinations.
In general, the compounds of formula I
demonstrate statistically significant activity as LTC4, LTD4 and/or LTE4 antagonists in the above test at a concentration of about 10 5M or much less.
The selectivity of action as leukotriene antagonists as opposed to non-specific smooth muscle depressants may be shown by carrying out the above in vitro procedure using the non-specific spasmogen barium chloride at a concentration 1.5x10 3M, again in the presence of indomethacin at 5x10 6M.
Activity as a leukotriene antagonist may also be demonstrated in vivo in laboratory animals) for example, in a routine guinea-pig aerosol test in which guinea-pigs are pre-dosed with test compound (generally between 15 minutes to 1 hour) before an aerosol challenge of leukotriene LTD4 (30 micrograms/

1305a7 ml.) and the effect of the test compound on the aver-age time of leukotriene initiated change in breathing pattern (such as onset of dyspnoea) recorded and compared with that in undosed, control guinea-pigs.
In general, compounds of formula I produce a signifi-cant increase in the time of onset of leukotriene initiated breathing changes following either oral or intravenous administration or by inhalation at a dose of 100 mg./kg., or much less) without any indication of untoward side-effects at several multiples of the minimum effective dose.
The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
(i) a11 operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25~C.;
(ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals; 4.5-30 mm. Hg) with a bath temperature of up to 60~C.;
(iii) flash chromatography was carried out on Merck Kieselgel (Art 9385) and column chromatography on Merck Kieselgel 60 (Art 7734); [these materials were obtained from E: Merck, Darmstadt, W. Germany];
thin layer chromatography (TLC) was carried out on 0.25 mm. silica gel GHLF plates (Art 21521), obtainable from Analtech, I~Tewark, DE) USA;
(iv) the course of reactions was followed by TLC and reaction times are given for illustration only;

~~~~W 7 (v) melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as de-scribed; polymorphism may result in isolation of materials with different melting points in some preparations;
(vi) a11 final products were essenti411y pure by TLC and had satisfactory nuclear magnetic resonance (NriR) spectra and microanalytical data;
(vii) yields are given for illustration only and, for crystalline end-products, refer to the weight of recrystallized solid;
(viii) when given, NMR data is in the form of delta values for major diagnostic protons) given in parts per million (ppm) relative to tetramethylsilane (TTZS) as internal standard, determined at 80 MHz or 250 MHz using CDC13, DMSO-d6 or CD30D as solvent;
conventional abbreviations for signal shape are used for example, s) singlet; d, doublet; m, multiplet; br, broad; ete.; in addition "Ar" signifies an aromatic signal;
(ix) reduced pressures are given as absolute pressures in Pascals; other pressures are giver. as gauge pressures in bars; and (x) chemical symbols have their usual meanings; the following abbreviations have also been used: v (volume), w (weight); m.p. (melting point), 1. [liter(s)], ml. (milliliters), g. [gram(s)]; in certain Examples and Tables *, -, and ~ are used to indicate that an explanatory footnote applies, and ir.
certain. Tables formula 1 and formula 2 indicate those set out.

~~405~7 (Formula set out on pages following Examples) 1 (Formula set out on pages following Examples) 2 i3~:0~~'~

Examp le 1 Methyl 4-(5-hexanamidoindol-3-ylmethyl)-3-methoxyben-zoate A stirred solution of methyl 4-(5-amino-indol-3-ylmethyl)-3-methoxybenzoate (A) (0.2 g.) in dichloromethane (5 ml.) under an atmosphere of nitrogen) was treated with N-methylmorpholine (0.25 g.), followed by hexanoyl chloride (0.103 g.). After being stirred for 2 hours, the mixture was poured into 1M hydrochloric acid (20 ml.). This mixture was extracted with ethyl acetate (2x20 ml.). The combined organic extracts were dried (MgS04) and evaporated.
The yellow oil obtained was purified by flash chroma-tography on silica gel (75 ml.), eluting with 6:4 v/v ethyl acetate: hexane, to give the title compound (0.24 g., 92%) as a colorless oil; NMR: 0.83(t,3H, CH2.CH3), 1.36(m,4H, CH2.CH2.CH3), 1.57(quintet,2H) CH2.CH2.COPI), 2.24(t, 2H, CH2.CON), 3.80(s,3H, COOCH3), 3.90(s,3H) OCH3), 3.99(s,2H, CH~.Ar), 7.1(m, 2H), 7.21(m,2H), 7.44(m,2H), 7.69(s,lH,H -indole)) 9.59(s,lH, CONH), 10.77(s,lH, H1-indole).
The amino ester (A) was obtained as follows:
(a) Silver (I) oxide (7.15 g.) was added to a solution of 5-nitroindole (5 g.) and methyl 4-bromo-methyl-3-methoxybenzoate (B) (7.99 g.) in dioxane (30 ml.), under a nitrogen atomosphere. The mixture was stirred at 60~C. for 20 hours, dioxane removed by evaporation and ethyl acetate (50 ml.) added to the residue. The resulting suspension was separated by ~~~o5s~

filtration through diatomaceous earth. The filtrate was evaporated to give a dark viscous oil, which was purified by flash chromatography on silica gel (600 ml.), eluting with 3:7 v/v ethyl acetate:hexane. The viscous yellow oil obtained was crystallized from a mixture of dichloromethane and hexane to give methyl 3-methoxy-4-(5-nitroindol-3-ylmethyl)benzoate (C) (4.6 g., 45%) as yellow needles, m.p. 153-155~C.
NMR: 3.83(s,3H, COOCH3), 3.93(s,3H) OCH3), 4.12(s,2H, CH2.Ar), 7.25(d,lH), 7.43(d,lH), 7.49(m,3H), 7.95(dd, 1H, H6-indole)) 8.47(d,lH, H4-indole), 11.65(broad s,lH, H1-indole).
(b) Palladium-on-carbon (10% w/w; 0.25 g.) was added to a solution of (C) (1.5 g.) in tetrahydro-furan (50 ml.) in a hydrogenation bottle. The mixture was hydrogenated at 3.45 bars for 2 hours. The cata-lyst was removed by filtration through diatomaceous earth and the filtrate was evaporated. The residual oil was purified by flash chromatography on silica gel (Z00 ml.) eluting with 1:1 v/v ethyl acetate: hexane, to give methyl 4-(5-aminoindol-3-ylmethyl)-3-methoxy-benzoate (A) (1.12 g. , 82%) as a viscous oil; T~TP,:
3.29(br,2H,NH2), 3.88(s,3II, CO.OCH3), 3.91(s,3H, OCH3), 4.03(s,2H, CH2.Ar)) 6.64(dd,lH), 6.78(m,2H), 7.10(m,2H), 7.44(m,2H), 7.68(br,lH, H1-indole).
The starting bromomethyl compound (B) was itself obtained as follows:
(c) A solution of 3-methoxy-4-methylbenzoic acid (6.0 g.) in methanol (120 ml.) was treated with acetyl chloride (6 ml.) and stirred for 36 hours. The solution was evaporated. The residue was dissolved in ~~~(~~67 methanol (100 ml.) and the solution evaporated. This procedure was repeated to give methyl 3-methoxy-4-methylbenzoate (6.34 g., 98%) as a colorless oil; t~tR:
2.2(s,3H) CH3)) 3.9(2s,6H, 2 x OCH3), 7.1(d,lH), 7.5 (m,2H).
(d) A stirred solution of the ester from (c) (121.2 g.) in carbon tetrachloride (1.4 1.) was heated under gentle reflux with a 350 watt tungsten lamp and subjected to an air purge by means of a T-tube attached to a water aspirator. A solution of bromine (107.2 g.) in carbon tetrachloride (500 ml.) was added dropwise over 4 hours. Evaporation of the solvent gave a light yellow solid which was triturated with 500 ml. of 1:9 v/v ether:hexane. The solid was collected by filtration to give methyl 4-bromomethyl-3-methoxybenzoate (B) (11l.7 g., 64%) as a pale yellow solid, m.p. 87-90~C; NMR: 3.9(2s,6H, 2 x UCH3), 4.5 ( s , 2H, BrCH~, ) , 7 . 4 (m, 3~i) .
Example 2 Methyl 4-[5-(2-ethylhexanamido)indol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 1) but starting from 2-ethylhexanoyl chlor-ide and (A), there was obtained the title compound in 76% yield; partial NfiR: 0.84(m,6H, 2xCH3)) 1.24[m,6H, (CH2)3], 2.24(m,lH, CHCON), 10.78(d,lH, NH).

13~05~7 Example 3 Methyl 4-(5-(cyclopentyloxycarbonyl)aminoindol-3-yl-methyl]-3-methoxybenzoate Cyclopentyl chloroformate was added to a stirred solution of the amino ester (A) (0.15 g.) and N-methylmorpholine (0.27 g.) in dichloromethane (3 ml.) at 0-5~C, under an atmosphere of nitrogen. The mixture was stirred for 30 minutes at 0-5~C, the cooling bath removed, and stirring continued for 1 hour. The mixture was then poured into ltT hydrochlo-ric acid (15 ml.), and extracted with ethyl acetate.
The combined extracts were dried (MgS04) and evaporated. The residual oil was purified by flash chromatography on silica gel (50 ml.), eluting with 3:7 v/v ethyl acetate: hexane, to give the title com-pound (0.18 g., 89%) as a colorless oil; NMR: 1.66(m, 6H), 1.82(m,2H), 3.83(s,3H, CO.OCH3), 3.92(s,3H, OCH3), 3.97(s,2H, CH2.Ar), 5.04(m,lH, -CHO-), 7.09(m, 3H), 7.22(d,lH), 7.42(dd,lH), 7.48(d,lH), 7.57(br,lH), 9.18(br,lH, CONH), 10.57(s,lH, H1-indole).
Example 4 Methyl 4-(5-hexanamido-1-methylindol-3-ylmethyl)-3-methoxybenzoate Hexanoylchloride (0.029 g.) was added to a stirred solution of methyl 4-(5-amino-1-methylindol-3-ylmethyl)-3-methoxybenzoate (D) (0.05 g.) and N-meth-13~U5~~

ylmorpholine (0.05 g.) in dichloromethane (3 ml.), under an atmosphere of nitrogen. The mixture was stirred for 2 hours and then poured into 1M hydro-chloric acid (15 m1.). This mixture was extracted with ethyl acetate (2x20 ml.). The combined extracts were dried (MgS04), and evaporated. The residual oil was purified by flash chromatography on silica gel (50 ml.), eluting with 4:6 v/v ethyl acetate:hexane, to give a colorless oil, which was crystallized from a mixture of toluene and hexane to give the title com-pound (0.05 g, 65%) as a white powder; NMR: 0.86(t, 3H) CH2.CLI3)) 1.28(m,4H, CH2.CH2.CH3), 1.57(quintet, 2H, CH2.CH2.CON), 2.25(t,2H, CH2.CH2.CON)) 3.69(s,3H, NCH3)) 3.82(s,3H, CO.OCH3), 3.92(s,3H, OCH3), 3.97(s, 2H, CH2.Ar), 7.05(s,lH), 7.13(d,lH), 7.27(d,lH), 7.28(d,lH), 7.40(dd,lH), 7.48(s,lH), 7.74(s,lH), 9.61(s,lH).
The amino-ester (D) was prepared as follows:
(a) Methyl 3-methoxy-4-(5-nitroindol-3-yl-methyl)benzoate (C) (0.44 g.) was added to a stirred suspension of oil-free sodium hydride (0.031 g.) in dry tetrahydrofuran (10 ml.), under an atmosphere of nitrogen. The dark-red solution was stirred for 10 minutes, ar~d iodomethane (0.18 g.) was added. The mixture was stirred for 30 minutes) and was poured into 1M hydrochloric acid (30 ml.). The mixture ob-tained was extracted with ethyl acetate (2x50 ml.).
The combined extracts were washed with brine (25 ml.), then dried (MgS04), and evaporated. The yellow oil obtained was purified by flash chromatography on silica gel (50 ml.), eluting with 50:45:5 v/v/v 1340e7 hexane:dichloromethane:ethyl acetate) to give methyl 3-methoxy-4-(1-methyl-5-nitroindol-3-ylmeth-yl)benzoate (E) (0.33 g., 72~) as a yellow oil, which was crystallized from dichloromethane/hexane to give a yellow solid, m.p. l44-146~C; NMR: 3.81(s,3H, IZ.CH3), 3.83(s,3H, CO.OCH3), 3.92(s,3H) OCH3), 4.11(s,2H, C_H2.Ar), 7.27(d,lH), 7.37(s,lH) H2-indole), 7.49(m,2H), 7.60(d,lH), 8.01(dd,lH) H6-indole), 8.50(d,lH, H4-indole).
(b) A solution of (E) (0.56 g.) in tetrahy-drofuran (30 ml.) was hydrogenated in the presence of palladium-on-carbon (10% w/w; 0.1 g.), as described for the amino ester (A) in Example 1, to give methyl 4-(5-amino-1-methylindol-3-ylmethyl)-3-methoxybenzoate (D) (0.50 g.) 98~) as pale yellow foam; NMR: 3.6(s, 3H, NCH3), 3.8(s,3H) CO.OCH3), 3.9(br s,SH, 0CH3 and CH2.Ar), 4.45(br,2H) NH2)) 6.54(m,2H), 6.86(s,lH)) 7.04(m,2H), 7.40(m,2H).
Example 5 Methyl 4-[5-(2-ethylhexanamido)-1-methylindol-3-yl-methyl]-3-methoxybenzaate Using a similar procedure to that described in Example 4, but starting from 2-ethylhexanoyl chlor-ide and (C), there was obtained the title compound in 80% yield as a viscous oil; partial NMR: 0.84(m,6H, 2xCH3), 1.24[m,6H, (CH2)3], 2.23(m,lH, CH. CON), 3.70 (s,3H, NCH3).

Example 6 Methyl 4-(1-benzyl-5-hexanamidoindol-3-ylmethyl)-3-methoxybenzoate Potassium t-butoxide (0.04 g.) was added to a stirred solution of methyl 4-(5-hexanamidoindol-3-ylmethyl)-3-methoxybenzoate (0.15 g.) in dry tetrahy-drofuran (5 ml.)) under an atmosphere of nitrogen.
The resulting dark-green mixture was stirred for 30 minutes. Benzyl bromide (0.062 g.) was added, causing the color to change to light brown. After 1 hour, the mixture was poured into 1M hydrochloric acid (20 ml.).
This mixture was extracted with ethyl acetate (2x25 ml.). The combined extracts wexe dried (TigS04) and evaporated. The brown oil obtained was purified by flash chromatography on silica gel (50 ml.)) eluting with 3:7 v/v ethyl acetate: hexane) to give the title compound (0.04 g) 17x) as an oil; NriR: 0.86(t,3H) CH2.CH3), 1.27(m,4H, CH2.CH2.CH3), 1.57(m,2H) CH2.CH2.COPd), 2.24(t,2H, CH2.CH2.CON), 3.82(s,3H) CO.OCH3), 3.91(s,3H, OCH3)) 3.99(s,2H, CH2.Ar), 5.32 (s,2H, NCH2Ph), 7.21(m,lOH), 7.44(m,2H), 7.75(d, 1H), 9.64(s,lH, NH).
Example 7 Methyl 4-(1-allyl-5-hexanamidoindol-3-ylmethyl)-3-methoxybenzoate Using a similar procedure to that described in Example 6, but using a11y1 bromide in place of 13~05~'~

benzyl bromide) there was obtained the title compound in 36% yield, as a viscous oil; partial NMR: 0.86(t, 3H) CH2.CH3), 1.27(m,4H, CH2.CH2.CH3)) 1.57(quintet, 2H, CH2.CH2.CON), 2.24(t,2H, CH2.CON), 4.72(d,2H, NCH2)) 5.07(dd,2H, CH.CH2), 5.99(m,lH) CH.CH2).
Example 8 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxybenzoate Cyclopentyl chloroformate (0.11 g.) was added to a stirred solution of methyl 4-(5-amino-1-methylindol-3-ylmethyl)-3-methoxybenzoate (D) (0.25 g.) and N-methylmorpholine (0.23 g.) in dichloro-methane (3 ml.), under an atmosphere of nitrogen.
The mixture was stirred for 2 hours and then poured into 1M hydrochloric acid (20 ml.). This acid mixture was extracted with ethyl acetate (2x30 ml.). The combined extracts were washed with saturated brine (20 mI.)) dried (MgS04)) and evaporated to give a viscous oil. This was purified by flash chromatography on silica gel (50 ml.), eluting with 3:7 v/v ethyl acetate: hexane, to give the title compound as a foam (0.2S g.) 74%); NMR: 1.62[m,8H, (0i2)4], 3.68(s,3H, NCH3), 3.83(s,3H, CO.OCH3), 3.91(s,3H, OCH3), 3.95(s, 2H, CH2.Ar), 5.05(m,lH, -CHO-), 7.11(m,2H), 7.26(d, 1H), 7.43(m,2H), 7.59(br,lH), 9.18 (br,lH) NH).

13~0~~'~

Example 9 4-[5-(Cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmeth~l]-3-methoxybenzoic acid A stirred solution of methyl 4-[5-(cyclo-pentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoate (0.25 g.) in methanol (5 ml.) and tetrahydrofuran (4 ml.), under an atmosphere of nitrogen) was treated with a solution of lithium hydroxide monohydrate (0.12 g.) in water (2 ml.). The mixture was stirred for 20 hours and then concentrated to remove tetrahydrofuran. The resulting aqueous solution was acidified with 1M hydrochloric acid (20 ml.). The white precipitate which formed was separat-ed by filtration, washed with a little water) and recrystallized from a mixture of toluene and hexane to give the title compound (0.212 g., 88%) as an off-white powder; m.p. l57-1S8~C.
Analysis calculated for:
C24H26r~2C5~ C~ 68.23; H, 6.20; rz, 6.63 Found: C, 68.36; H, 6.19; rd, 6.36 Examples 10-19 Using a similar procedure to that described in Example 9, the following acids of formula 1 were obtained by hydrolysis of the corresponding methyl esters:

m~.~ ~ s ~

m.p. yield E Rl x. W Rd ( (7) C.) 10 pentyl - H 205-210* 77 11 1-ethyl- - H 202-203 87 pentyl 12 cyclopent- 0 H 184-186 80 yl 13 pentyl - methyl 227-228 66 14 1-ethyl- - methyl 204-208 66 pentyl 15 cyclopent- 0 methyl 157-158 88 yl 16 pentyl - allyl 203-204 39 17 pentyl - benzyl 210-211 67 18 alpha- - methyl 188-l90 83 fluoro-benzyl 19 alpha-meth- - methyl 124-126* 53 oxybenzyl * Isolated as a partial hydrate (0.2.5 H20) - Direct link to Rl The starting methyl esters for Examples and 19 were made by conventional acylationof methyl 4-(5 -amino-1-methylindol-3-ylmethyl)-3-methoxybenzoate (D) with alpha-fluorophenylacetic acid alpha-and meth oxyphenylacetic acid, respectively, the pres-in ence of 1-[3-(dimethylamino)propyl]-3-ethylcarbodi-imid e hydrochloride and 4-(dimethylamino)pyridine, in dich loromethane at ambient temperature.
The methyl 1~~05~ti~

esters were obtained as viscous oils having satisfac-tory NMR spectra.
Example 20 N-[4-[5-(Cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide N,N-Diphenylcarbamoylpyridinium hydrochlo-ride (0.132 g.) was added to a stirred solution of 4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoic acid (obtained as described in Exam-ple 9) (0.15 g.) and sodium hydroxide (0.35 ml.
of 1M aqueous solution) in absolute ethanol (6 ml.), under an atomosphere of nitrogen. The mixture inas stirred for 15 minutes, and was then partitioned bet-ween ethyl acetate t50 ml.) and water (30 ml.). The organic layer was washed successively with 1M hydro-chloric acid (20 ml.) and saturated brine (20 ml.), then dried (MgSO~), and evaporated to give 4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmeth-yl]-3-methoxybenzoic N,I3-diphenylcarbamic anhydride, as a white foam. This foam was dissolved in N,N-di-methylformamide (DMF) (3 ml.), and added to a stirred solution of the sodium salt of benzenesulphonamide (0.19 g.) in DMF (6 ml.), under an atmosphere of ni-trogen. The mixture was stirred for 1 hour and then poured into 1M hydrochloric acid (40 ml.). The acid mixture was extracted with ethyl acetate (2x30 ml.).
The combined extracts were dried (MgS04) and evapo-13~O~b'~
._ rated. The yellow oil obtained was purified by the following successive procedures:
(a) flash chromatography on silica gel (50 ml.) eluting with 3:7 v/v acetonitrile:dichloro-methane;
(b) crystallization fron a mixture of dichloromethane aild hexane;
(c) flash chromatography on silica gel (50 ml.), eluting with dichloromethane (200 ml.), then 3:1 v/v dichloromethane:ethyl acetate (200 ml.), and then 1:1 v/v dichloromethane:ethyl acetate; and (d) crystallization from a mixture of ethyl acetate and hexane to give the title compound (15.9 mg., 8Z), as a white solid; m.p. 125-130~C.
Analysis calculated for:
C30Ti31T~3C6s~ C, 64.15; H, 5.56; N, 7.48 Found: C, 64.18; H, 5.33; N, 7.36 Example 21 N-[3-Methoxy-4-[5-(2-ethylhexanamido)-1-methylindol-3-ylmethyl]benzoyl]benzenesulphonamide Using a similar procedure to that described in Example 20, the title compound was obtained in 20~
yield as a solid, m.p. 169-171~C., starting from 4-[5-(2-ethylhexanamido)-1-methylindol-3-ylmethyl]-3-meth-oxybenzoic acid.

1~40~~~

Example 22 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-cyclopro-pylmethylindol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 8, the title compound was obtained in 90%
yield, as a viscous oil; partial NMR: 0.32(m,2H), 0.46(m,2H), 2.18(m,lH)) 1.67(m,6H), 3.82(s,3H, OCH3), 3.92(s,3H, OCH3). The compound was made by starting from methyl 4-(5-amino-1-cyclopropylmethylindol-3-yl-methyl)-3-methoxybenzoate (itself made by analogy with (D) in Example 4, that is by reaction of the nitroin-dole derivative (C) with cyclopropylmethyl bromide in the presence of sodium hydride, followed by catalytic hydrogenation of the product);
Example 23 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-(3-methyl-but-2-enyl)indol-3-~lmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 8) the title compound was obtained in 70%
yield, as a viscous oil; partial NMR: 1.64(m,4H), 1.69(s,3H, CH3)) 1.78(s,3H, CH3), 3.82(s,3H, OCH3), 3.92(s,3H, OCH3), 4.64(d,2H, NCH2). The compound was made by starting from methyl 4-[5-amino-1-(3-methyl-but-2-enyl)indol-3-ylmethyl]-3-methoxybenzoate (F).
The amino-indole derivative (F) was obtained as follows:

13~05e~

A slurry of methyl 4-[1-(3-methylbut-2-enyl)-5-nitroindol-3-ylmethyl]-3-methoxybenzoate (0.22 g.) and stannous chloride dehydrate (1.6 g.) in absolute ethanol (8 ml.) was heated and stirred under reflux under an atmosphere of nitrogen for 24 hours.
The cooled mixture was poured into saturated sodium bicarbonate solution (30 ml.). The mixture obtained was extracted with dichloromethane (2x30 ml.). The combined extracts were washed with saturated brine (25 ml.), dried and evaporated to give methyl 4-(5-amino-1-(3-methylbut-2-enyl)indol-3-ylmethyl]-3-methoxybenz-oate (F) (0.14 g.; 69%) an oil; NMR: 1.68(s,3H, =C-CH3), 1.76(s,3H, =C-CH3)) 3.82(s,3H, CO.OCH3), 3.89 (s,2H, CH2.Ar), 3.91(s,3H, OCH3), 4.57(d,2H, CH2N), 5.27(t,lH, CH2CH), 6.48(m,2H), 6.91(s,lH)) 7.04(d,lH), 7.08(d,lH), 7.46(m,2H).
Examples 24-25 Using a similar procedure to that described in Example 9) but starting from the corresponding methyl ester, the following acids of formula 1 were obtained:
Example 24: 4-[5-(cyclopentyloxycarbonyl)amino-1-cyclopropylmethylindol-3-ylmethyl]-3-methoxybenzoic acid in 72% yield, as a solid, m.p. 177-l79~C.; and Example 25: 4-(5-(cyclopentyloxycarbonyl)amino-1-(3-methylbut-2-enyl)indol-3-ylmethyl]-3-methoxybenzoic acid ir. 52% yield) as a solid, m.p. 179-180~C.

~~~05~7 Example 26 Methyl 4-(6-hexanamido-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)-3-methoxybenzoate Hexanoyl chloride (0.084 g.) was added to a stirred solution of methyl 4-(6-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)-3-methoxybenzoate (L) (0.2 g.) in dichloromethane (20 ml.), under an atmosphere of nitrogen. The mixture was stirred for one hour and then diluted with dichloromethane (40 ml.). This mixture was washed with water) dried (MgS04) and evaporated.- The residual oil was dissolved in 3:7 v/v ethyl acetate:hexane, and the solution obtained was allowed to filter through a short column of silica gel) washing with one column volume of the same solvent mixture. Evaporation of the column eluate gave the title compound (0.2l2 g., 827), as a foam;
NMR (250 I~Iz, CDC13): 0.9(t,3H, CH2CH3), 1.3(m,4H, CH3.CH2.CH2), 1.6(m,2H, CH2.CH~.CON), 2.2(t,2H, CH2.CON), 3.35(t,2H, OCH2.CI-I2N), 3.9(br s,6H, OCH3+CO.OCH3), 4.2(t,2H, OCH2.CH2N), 4.5(s,2H, CH2-Ar), 6.8(m,3H), 6.9(br s,lH, NH)) 7.2(m,IH), 7.5(m, 2H).
The starting amino-ester (L) was itself obtained as follows:
(a) A mixture of 6-nitro-2,3-dihydrobenz-1,4-oxazine (0.45 g.), methyl 4-bromomethyl-3-methoxy-benzoate (B) (0.65 g.), anhydrous potassium carbonate (0.35 g.), sodium iodide (0.38 g.) and acetone (25 ml.) was stirred and heated under reflux for 48 hours, ~3~05~7 under an atmosphere of nitrogen. The cooled reaction mixture was separated by filtration. The residue was washed with acetone, and the filtrate and washings were evaporated. The resulting solid was dissolved ir.
dichloromethane and residual solid removed by filtra-tion. The filtrate was evaporated. The product was purified by flash chromatography on silica gel (3 cm.
diameter calumny, eluting with 1:10 v/v ethyl acetate:
toluene, to give methyl 3-methoxy-4-(6-vitro-2,3-di-hydrobenz-1,4-oxazin-4-ylmethyl)benzoate (G) (0.75 g., 84~), m.p. 13d-132~C; NMR (80 MHz) CDC13): 3.0(t,2H, OCH2.CH2N), 3.8(s,3H, OCH3), 3.95(s,3H) OCH3), 4.3(t, 2H, OCH2.CH2N), 4.5(s,2H) CH2.Ar), 6.8(d,lH), 7.5(m, 5H).
(b) Palladium-on-carbon (10~ w/w, 0.2 g.) was added to a solution of (G) (0.69 g.) in ethyl acetate (50 ml.) in a hydrogenation bottle and the mixture hydrogenated at a pressure of 3.17 bars of hydrogen. When the uptake of hydrogen had ceased) catalyst was removed by filtration through diatoma-ceous earth. The filter pad was washed with ethyl acetate and the filtrate and washings were evaporated to give methyl 4-(6-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)-3-methoxybenzoate (0.625 g., 91~) as a foam; NriR: 3.1(br s,2H, NH2), 3.3(t,2H) OCH2CH2N), 3.85(m,6H, OCH3+C02CH3)) 4.2(t,2H, OCH2CH2N), 4.45(s) 2H, CH2-Ar)) 6.0(m,2H), 6.55(d,lH), 7.3(d,lH), 7.55(m, 2H).

13~~~~7 Example 27 tiethyl 4-[6-(2-ethylhexanamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 26 but starting from 2-ethylhexanoyl chlor-ide, the title compound was obtained in 957 yield as a viscous oil; partial NriR: 0.89(m,6H, 2xCH3), 1.97(m, 1H, CHCON), 3.91(s,6H, OCH3+CO.OCH3), 4.47(s,2H, CH2-Ar).
Example 28 t~iethyl 4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihy-drobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoate Cyclopentyl chloroformate (0.5 g.) was added in a single portion to a stirred solution of methyl 4-(6-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)-3-methoxybenzoate (L) (1.0 g.) and N-methylmorpholine (0.314 g.) in dichloromethane (30 ml.), under an atmosphere of nitrogen. After one hour, the mixture was diluted with dichloromethane and washed succes-sively with lri hydrochloric acid, 57 w/v sodium bicarbonate solution, and saturated brine, then dried (MgS04) and evaporated. The residue was purified by flash chromatography on silica gel (4 cm. diameter column), eluting with dichloromethane to give the title compound (0.7 g, 52~) as an oil; NriR (80 MHz, CDC13): 1.69[m,8H, (CH2)4], 3.39(t,2H, OCH2CH2N), 134o~b7 3.90(s,3H, OCH3), 3.9l (s,3H, OCH3), 4.23(t,2H) OCH2CH2N), 4.45(s,2H, CH2.Ar), 5.10(m,lH) -CHO-), 6.2(br s,lH, NHCO)) 6.59-7.62(m,6H).
Exam le 29 4-[6-(Cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoic acid Lithium hydroxide monohydrate (0.267 g.) was added as a solid to a stirred solution of methyl 4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoate (0.7 g.) in methanol (15 ml.) and water (2 ml.). The mixture was stirred for 12 hours then diluted with water and acidified to pH 3.35 with 3M hydrochloric acid. The precipitate which formed was isolated by filtration, washed with water and crystallized from methanol to give the title compound as a solid (0.457 g., 67Z), m.p. 22l-222~C.
Analysis calculated for:
C23H26N206: C, 64.78; H, 6.14; ra, 6.57 Found: C, 64.77; H, 5.97; N, 6.57 Examples 3G-31 Using a similar procedure to that described in Example 29, but starting from the corresponding methyl esters) there were obtained:

~~40~~;~

Example 30: 4-[6-hexanamido-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoic acid in 77% yield as a solid hemi-hydrate, m.p. 207-208~C.; and Example 31: 4-[6-(2-ethylhexanamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoic acid in 88% as a solid, m.p. 190-192~C.
Example 32 T:-[4-[6-(Cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide Benzenesulphonamide (0.037 g.) was added to a stirred solution of 4-[6-(cyclopentyloxycarbonyl)-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-meth-oxybenzoic acid (0.1 g.)) 1-(3-dimethylaminapropyl)-3-ethylcarbodiimide hydrochloride (0.046 g.) and 4-(di-methylamino)pyridine (0.029 g.) in dichloromethane (5 ml.), under an atmosphere of nitrogen. The mixture was stirred for 21 hours and then diluted with di-chloromethane. This mixture was washed successively with 1M hydrochloric acid (2x10 ml.), 5% w/v sodium bicarbonate solution (2x10 ml.), and saturated brine (20 ml.). It was then dried (MgS04) and evaporateu.
The residue was purified by flash chromatography on silica gel (3 cm, diameter column) eluting with 1:1 v/v ethyl acetate:hexane. The solid obtained was re-crystallized from ethyl acetate to give the title com-1~40~h7 pound as a white powder (Q.071 g., 547), m.p) 186-187~C.
Analysis Calculated for C29H31r~3C7s: C, 61.58; ii, 5.52; N) 7.43 Found: C, 61.18; H) 5.18; N, 7.00 Example 33 Methyl 4-(5-hexanamidobenzo[b]thien-3-ylmethyl)-3-methoxybenzoate Hexanoyl chloride (U.024 g.) was added to a stirred solution of methyl 4-(5-aminobenzo[b]thien-3-ylmethyl)-3-methoxybenzoate (H) (0.06 g.), and N-meth-ylrsorpholine (0.1 ml.) in dichloromethane (3 ml.).
The mixture was stirred for 1 hour and then poured into water (20 ml.). The aqueous mixture was extract-ed with dichloromethane (2x20 ml.). The combined ex-tracts were dried (MgS04), and evaporated. The mix-ture was recrystallized from a mixture of ethyl ace-tate and hexane to give the title compound (0.05 g., 750) as a colorless solid; NMR (250 MHz, DMSO-d6):
0.87(t,3H) CH2CH3), 1.28(m,4H, CH2.CH2.CH3), 1.59 (quintet,2H, CH2CH2CON), 2.29(t,2H, CH2CON), 3.84(s, 3H) OCH3)) 3.91(s,3H) OCH3), 4.11(s,2H, CH2-Ar), 7.14 (d,IH), 7.34(s,lH)) 7.49(ni,3H), 7.86(d,lH)) 8.11(d, 1H), 9.95(s,lH).
The amino ester (H) was obtained as follows:
(a) Stannic chloride (0.41 g.) was added to a stirred solution of 5-nitrobenzo[b]thiophene (0.28 g.) and methyl 4-bromomethyl-3-methoxybenzoate (B) 13~~5b7 (0.61 g.) in dichloromethane (5 ml.). The mixture was heated under reflex for 18 hours. The cooled mixture was poured into water (10 ml.) and extracted with di-chloromethane (2x20 ml.). The combined extracts were dried (MgS04) and evaporated. The oil was purified by flash chromatography on silica gel (100 ml.) eluting with 1:9 v/v ethyl acetate: hexane. The solid obtained was crystallized from hexane to give methyl 3-methoxy-4-(5-nitrobenzo[b]thien-3-ylmethyl)benzoate (I) as a solid (0.16 g., 30~); NMR: (250 MHz) CDC13): 3.92(s, 3H, OCH3), 3.98(s,3H, OCH3), 4.28(s,2H, CH2-Ar), 7.15 (d,lH)) 7.22(s,lH), 7.56(m,2H), 7.93(d,lH), 8.19(dd, 1H); 8.73(d,lH).
(b) Stannous chloride dihydrate (0.38 g.) was added to a stirred solution of (I) (0.12 g.) in ethanol (5 ml.), under an atmosphere of nitrogen. The mixture was heated under reflex for 2 hours. The cooled mixture was basified with saturated aqueous sodium bicarbonate (15 ml.) and extracted with ethyl acetate (2x25 ml.). The extracts were dried (MgS04) and evaporated. The residual oil was purified by flash chromatography on silica gel (50 ml.), eluting with 3:7 v/v ethyl acetate:hexane to give methyl 4-(5-aminobenzo[b]thien-3-ylmethyl)-3-methoxybenzoate (H) (0.06 g., 54~) as an oil; NMR (80 MHz, DMSO-d6): 3.84 (s,3H) OCH3), 3.91(s,3H, OCH3), 4.03(s,2H, CH2-Ar), 5.0(br s,2H, NH2), 6.80(m,2H)) 7.14(m,2H), 7.52(m,3H).

Example 34 4-(5-Hexanamidobenzo[b]thien-3-ylmethyl)-3-methoxyben-~~;a Using a similar procedure to that described in Example 29, the title compound was obtained in 70%
yield as a powder, m.p. 234-235~C. (after recrystalli-zation from a mixture of tetrahydrofuran, hexane and ethyl acetate).
Analysis calculated for:
C23H25NS04: C, 67.13; H, 6.12; N, 3.40 Found: C, 67.05; H, 6.20; N, 3.17 Example 35 Methyl 4-[6-(cyclopentyloxycarbonyl)aminobenzinidazol-1-ylmethyl]-3-methoxybenzoate A solution of methyl 4-(6-aminobenzimidazol-1-ylmethyl)-3-metho>ybenzoate (J) (0.63 g.) and 2,6-lutidine (0.36 ml.) in dichloromethane (10 ml.) was treated with cyclopentyl chloroformate (0.33 g.).
After stirring for 24 hours the solution was diluted with dichloromethane. The mixture was washed succes-sively with 20% w/v sodium hydroxide, water, and brine, then dried (MgS04) and evaporated. The result-ant residue was purified by flash chromatography on a 6x20 cm. silica gel column using 1:3 v/v hexane: ethyl acetate as the eluent to give the title compound (0.57 g., 93%); NMR: 1.7[m,BH, (CH2)4], 3.8(s,3H) OCH3), 13~~5n~

3.9(s,3H, OCH3) 5.2(m,lH) CHO), 6.l7-7.0(br m,3H)) 7.5-7.8(br m,4H).
The starting amino ester (J) was obtained as follows:
(a) A solution of 6-nitrobenzimidazole (2.0 g.) and methyl 4-bromomethyl-3-methoxybenzoate (B) (3.5 g.) in methyl ethyl ketone (61 ml.) was treated with potassium carbonate (1.9 g.) and then heated under reflux for 24 hours. The solvent was then evaporated. The residue was extracted with ethyl acetate and inorganic material removed by filtration.
The filtrate was evaporated. The resultant residue was purified by flash chromatography on a 6x30 cm.
silica gel column using 1:1 v/v hexane: ethyl acetate as the eluent to give methyl 3-methoxy-4-(6-nitrobenz-imidazol-1-ylmethyl)benzoate (K) (1.07 g., 26%); NrTR:
3.9 (s,3H, OCH3), 4.0(s,3H, OCH3), 5.7(s,2H, NCH2), 7.4(d, 1H, Ar), 7.8(d,lH, H4-benzimidazole), 8.1(dd, 1H, H5-benzimidazole), 8.6(br s,2H, H2'7-benzimida-zole).
(b) A solution of (K) (0.77 g.) in anhy-drous ethanol (23 ml.) was treated with stannous chloride dihydrate (2.6 g.). The mixture was stirred for 18 hours at 80~C. and then diluted with ethyl acetate. This mixture was washed successively with saturated sodium bicarbonate solution, water) and brine, then dried (MgS04) and evaporated to give methyl 4-(6-aminobenzimidazol-1-ylmethyl)-3-methoxy-benzoate (J) (0.63 g., 90x): partial NMR: 3.4(br s, 2H, NH2), 5.2(s,2fi, NCH2).

13~05~7 Example 36 4-[6-(Cyclopentyloxycarbonyl)aminobenzimidazol-1-yl-methyl]-3-methoxybenzoic acid A stirred solution of methyl 4-[6-(cyclo-pentyloxycarbonyl)aminobenzimidazol-1-ylmethyl]-3-methoxybenzoate in 1:1 v/v tetrahydrofuran:methanol (7 ml.) was treated with water (1.4 ml.) and lithium hydroxide monohydrate (0.3 g.). Stirring was contin-ued at ambient temperature for 4 hours. The solvent was then evaporated. The resultant residue was dis-solved in water. The solution obtained was acidified with 10% v/v hydrochloric acid. The resultant preci-pitate was collected by filtration to give the title compound (0.43 g., 78%). An analytical sample was obtained as a white powder by recrystallization from aqueous ethanol; m.p. 241-242~C.
Analysis calculated for:
C22H23N305Ø6 H20: C, 62.87; H) 5.80; N, 10.0 Found: C, 62.87; H) 5.55; N, 9.63 Example 37 Methyl 4-[6-(butoxycarbonyl)aminobenzimidazol-1-yl-methyl]-3-methoxybenzoate Using a similar procedure to that described in Example 35, but using butyl chloroformate and (J)) the title compound was obtained as a solid in 34%

13405~i'~

yield; partial IQMR: 0.9(t,3H) CH3CH2) , 1.4(m,2I-I, CH3CH2), 1.6(m,2H, CH2CH20)) 4.1(t,2H, CH20).
Example 38 P~Iethyl 3-methoxy-4-[6-(2-phenylbutanamido)benzimida-zol-1-ylmethyl]benzoate A solution of l,l'-carbonyldiimidazole (0.23 g.) and 2-phenylbutyric acid (0.22 g.) in dichloro-methane (3 ml.) was heated under reflux for 30 minutes and then treated with a solution of (J) (0.41 g.) in dichloromethane (3 ml.). The mixture was heated under reflux for an additional 10 minutes and then diluted with dichloromethane. This mixture was washed successively with 107 v/v hydrochloric acid, water, and brine, then dried (MgS04) and evaporated.
The resultant residue was purified by flash chroma-tography on a 5x25 cm. silica gel column using 3:97 v/v methanol:dichloromethane as the eluent to give the title compound (0.15 g.) 25~): partial NMR: 2.0(br m,2H, CH3CH2), 3.4(t,lH) CH2CH)) 7.3(s,SH) Ar).
Examples 39-40 Using a similar procedure to that described in Example 36 the following compounds of formula I
were obtained by hydrolysis of the corresponding methyl esters:

1340~~~

Example 39: 4-[6-(butoxycarbonyl)aminobenzimidazol-1-ylmethyl]-3-methoxybenzoic acid in 22% yield as a hemihydrate) m.p. 184-185~C.; and Example 40: 3-methoxy-4-[6-(2-phenylbutanamido)benz-imidazol-1-ylmethyl]benzoic acid in 31% yield as a solid, m.p. 256-257~C. (d).
Example 41 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-(2-meth-oxyethyl)indol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 8 (see also Example 22), the title compound was obtained in 78% yield, as an oil; partial NMR (250 MHz, DrISO-d6): 1.4-1.9 [m,8H, (CH2)4]; 3.19(s,3H) CH20Me); 3.59(t,2H, CH20Me); 3.82(s,3H, OMe); 3.91(s, 3H, Orle); 3.96(s,2H, ArCH2); 4.22(t,2H) CH2~); 5.08(m, 1H, -CHO-); 9.20(br s,lH, PdH). The compound was made by starting from methyl 4-[5-amino-1-(2-methoxyethyl)-indol-3-ylmethyl]-3-methoxybenzoate (itself made by analogy with (D) in Example 4) that is by reaction of the nitroindole derivative (C) with 1-bromo-2-methoxy-ethane in Pd,N-dimethylformamide in the presence of sodium hydride, followed by catalytic hydrogenation of the product).

13~05~'~

Example 42 Methyl 4-[1-(N-ethylcarbamoylmethyl)-5-(cyclopentyl-oxycarbonyl)aminoindol-3-ylmethyl]-3-methoxybenzoatc Using a similar procedure to that described in Example 8 (see also Example 22), the title compound was obtained in 73x yield, as a white powder; m.p.
192-l94~C.; partial NMR (250 MHz, DMSO-d6): 1.01(t, J=
7.15Hz,3H, CH2CH3); 1.5-1.9[m,8H, (CH2)4]; 3.10(m,2H, NHCH2); 3.83(s,3H) OMe); 3.92(s,3H) Or~fe); 3.97(s,2H, ArCH2); 4.67(s,2H, -NCH2); 5.10(m,lH, -CHO-); 9.25(br s,lH) ArNH). The compound was made by starting frori methyl 4-[1-(N-ethylcarbamoylmethyl)-5-aminoindol-3-ylmethyl-3-methoxybenzoate (itself made by analogy with (D) in Example 4) that is by reaction of the nitroindole derivative (C) with 2-chloro-N-ethylacet-amide in N,N-dimethylformamide in the presence of sodium hydride, followed by catalytic hydrogenation of the product).
Exanip le 4 3 Methyl 4-(1-cyclopentyl-5-(cyclopentyloxycarbonyl)-aminoindol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 8 (see also Example 22), the title compound was obtained in 75~ yield, as a foam; partial NMR (2S0 MHz, DMSO-d6): 1.4-2.15 [m,l6H, 2x(CH2)4]; 3.82(s,3H) OMe); 3.92(s,3H, OMe); 3.96(s,2H) ArCH2); 4.80(m,lH, 1~~U5~~'~

-NCH); 5.10(m,lH) -CHO-); 9.20(br s,lH, NH). The com-pound was made by starting from methyl 4-[5-amino-1-cyclopentylindol-3-ylmethyl]-3-methoxybenzoate (itself made by analogy with (D) in Example 4, that is by reaction of the nitroindole derivative (C) with bromo-cyclopentane in N,N-dimethylformamide at 50~C. in the presence of sodium hydride) followed by catalytic hy-drogenation of the product).
Example 44 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-propylin-dol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 8 (see also Example 22), the title compound was obtained in 86% yield, as a foam; partial NMR (250 MHz, DMSO-d6): 0.80(t,J=7.30Hz,3H, CH2CH3); 1.4-1.9[m, lOli, (CH2)4 and CH2CH3]; 3.83(s,3H, OMe); 3.92(s,3H) OMe); 3.96(s,2H, ArCH2); 4.02(t,J=7.30Hz,2H, NCH2);
5.05(m,lH, -CHO-); 9.25(br s,lH, NH). The compound was made by starting from methyl 4-[5-amino-1-propyl-indol-3-ylmethyl]-3-methoxybenzoate (itself made by analogy with (D) in Example 4, that is by reaction of the nitroindole derivative (C) with allyl bromide in N,N-dimethylformamide in the presence of sodium hy-dride) followed by catalytic hydrogenation of the pro-duct resulting in reduction of both nitro and allyl substituents).

1340e7 Example 45 rlethyl 4-[5-(cyclo~~entyloxycarbonyl)amino-1-(3-methyl-butyl)indol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 8 (see also Example 22), the title compound was obtained in 71% yield, as a white solid; partial NMR (250 Mliz, DMSO-d6): 0.90(d,J=6.38Hz,6H, 2xCH3);
I.35-2.0 [m,llH, (CH2)4 and NCH2CH2CH]; 3.82(s,3li, OMe); 3.91(s,3H, OMe); 3.96(s,2H, ArCH2); 4.08(t,2H, NCH2); 5.10(m,lH) -CHO-); 9.20(br s,lH, NH). The com-pound was made by starting from methyl 4-[5-amino-I-(3-methylbutyl)indol-3-ylmethyl-3-methoxybenzoate (itself made by analogy with (D) in Example 4, that is by reaction of the nitroindole derivative (C) with 4-bromo-2-methyl-but-2-ene in N,N-dimethylformamide in the presence of sodium hydride, followed by catalytic hydrogenation of the product resulting in reduction of both nitro and 2-methylbut-2-er~yl substituents).
Example 46 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-hexylin-dol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 6, except using sodium hydride as base, and a mixture of N,N-dimethylformamide and N,N'-dimethyl-propyleneurea (80:20 v/v) as solvent, the title com-pound was obtained in 44% yield) as an oil; partial 13~0~~7 NMR (250 MHz, DMSO-d6): 0.81(t,J=6.70Hz,3H, CH2CH3);
1.21(m,6H); 1.4-2.0(m,lOH); 3.83(s,3H, OMe); 3.92(s, 3H, OMe); 3.96(s,2H, ArCH2); 4.05(t,J=6.85Hz,2H, NCH2); 5.04(m,lH, -CHO-); 9.20(br s,lH, NH); starting from methyl 4-[5-(cyclopentyloxycarbonyl)aminoindol-3-ylmethyl]-3-methoxybenzoate.
Example 47 Methyl 4-[5-(2-cyclopentylacetamido)-1-methylindol-3-ylmethyl]-3-methoxybenzoate A-mixture of methyl 4-(5-amino-1-methylin-dol-3-ylmethyl)-3-methoxybenzoate (D) (0.57 g.), cyclopentylacetic acid (0.23 g.)) 4-(dimethylamino)-pyridine (0.22 g.)) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.343 g.), was dis-solved in dichloromethane (25 ml.), under an atmo-sphere of nitrogen) and stirred at room temperature for 18 hours. The mixture was poured into 1M hydro-chloric acid (25 ml.), the separated aqueous layer extracted with dichloromethane (3x25 ml.)) the com-bined organic extracts washed with water) brine, dried (MgS04) and evaporated. The residual oil was crystal-lized from ethyl acetate to give the title compound (0.555 g. 73~) as a white powder; m.p. 180-181~C.;
partial NMR (250 MHz, DMSO-d6): 1.17(m,2H); 1.4-1.8 (m,6H); 2.25(m,3H); 3.70(s,3H, NMe); 3.82(s,3H, OMe);
3.92(s,3H, OMe); 3.97(s,2H, ArCH2); 9.62(br s,lH, NH).

13~t~~~~
_77_ Example 48A
tiethyl 4-[5-(2-cyclopentylacetamido)-1-propylindol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 47, the title compound was obtained in 76%
yield, as a foam; partial NMR (250 MHz, DMSO-d6):
0.81(t,J=7.30Hz,3H, CH2CH3); 1.15(m,2H); 1.4-1.7(m, 8H); 2.24(m,3H); 3.82(s,3H, OMe); 3.92(s,3H) OMe);
3.97(s,2H) ArCH2); 4.04(t,2H, NCH2); 9.61(br s,lH) NH). The compound was made by starting from methyl 4-[5-amino-1-propylindol-3-ylmethyl]-3-methoxyben-zoate.
Example 48B-56 Using a similar procedure to that described in Example 9, there were obtained the following acids of formula 1 in which W is oxy for Examples 48B-54 and a direct link to Rl for Examples 55) 56:
m.p, yield Ex. _R1 Rd (~C.) (%) 48B cyclopentyl propyl 157-158 89 49 cyclopentyl allyl 171-172 88 50 cyclopentyl hexyl 152-153 75 51 cyclopentyl 2-meth- 158-159 65 oxyethyl 134~~~7 _7$-52 cyclopentyl N-ethyl- 228-231 73 carbamoyl-methyl 53 cyclopentyl 3-methyl- 160-161 75 butyl 54 cyclopentyl cyclopen- 189-191 75 tyl 55 cyclopentyl- methyl 238-241 84 methyl 56 cyclopentyl- propyl 196-197 82 methyl Example 57 N-[4-[5-(Cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide A mixture of [5-(cyclopentyloxycarbonyl)-amino-1-methylindol-3-ylmethyl]-3-methoxybenzoic acid (6.0 g.), benzenesulphonamide (2.34 g.), 4-(dimethyl-amino)pyridine (1.84 g.)) and 1-(3-dimethylaminoprop-yl)-3-ethylcarbodiimide hydrochloride (2.86 g.) was dissolved in dichloromethane (250 ml.), under an atmosphere of nitrogen) and the mixture stirred at room temperature for 18 hours. The mixture was poured into 1M hydrochloric acid (100 ml.), the separated aqueous layer extracted with dichloromethane (2x100 ml.), the combined organic extracts washed with water, and brine, dried (MgS04) and evaporated. The residual oil was purified by flash chromatography on silica gel (700 ml.), eluting with 45:50:5 v/v/v hexane:dichloro-methane:ethyl acetate, to give a product which was precipitated from hot methanol by water, to give the l~~Oo'~

title compound (7.82 g., 987) as a white powder; m.p.
125-130~C. (m. p. 220-223~C., after recrystallization from methanol).
Analysis calculated for:
C30H31N3~6S~ C, 64.15; H, 5.56; N, 7.48 Found: C, 64.24; H, 5.66; N, 7.54 Examples 58-66 Using a similar procedure to that described in Example 57) the following sulphonamides of formula 2 were obtained in which W is oxy for Examples 58-65 and a direct link to R1 for Example 66:
1 m.p. yield R Rd Ex. ( (%) C.) 58 cyclopentyl propyl 109-1l5 84 59 cyclopentyl allyl 116-119 76 60 cyclopentyl hexyl 97-100 58 61 cyclopentyl hydrogen 244-245 30 62 cyclopentyl 3-methyl- 12S-135 83 butyl 63 cyclopentyl 2-methoxy- 107-117 65 ethyl 64* cyclopentyl N-ethyl- 132-140 60 carbamoyl-methyl *Exam le 64:
Ana ysis calculated for:
C33H36N4~7S~ C, 62.64; H, S.73; N, 8.85 Found: C, 62.22; H, 5.77; N, 8.78 13~0~~~7 65 cyclopentyl cyclo- 179-181 89 pentyl 66 cyclopentyl- methyl 132-137 86 methyl Example 67 Methyl 4-[6-(2-cyclopentylacetamido)-2,3-dihy_drobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 47) but starting from benzoxazine amine (L) (and avoiding the use of excess hydrochloric acid during the work-up), the title compound was obtained in 80% yield, as a white powder; m.p. 152-153~C.; par-tial P~2ZR (250 MHz, DMSO-d6): 1.l0-1.68[m,BH, (CH2)4];
2.14(m,3H, -CHCH2); 3.41(t,2H, NCH2CH2); 3.84(s,3H, OMe); 3.92(s,3H) OMe); 4.18(t,2H, OCH2); 4.41(s,2H, ArCH2)) 9.40(br s,lH, NH).
Example 68 4-[6-(2-Cyclopentylacetamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 29, the title compound was obtained in 97%
yield as a yellow powder; m.p. 224-225~C.

130 ~~~7 Example 69 N-[4-[6-(2-Cyclopentylacetamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]benzenesulpron-amide Using a similar procedure to that described in Example 32, the title compound was obtained in 61~
yield as a white powder; m.p. 190-192~C.
Example 70 Methyl 4-[5-(cyclopentyloxycarbonyl)aminobenzo[b]-thien-3-ylmethyl]-3-methoxybenzoate Starting from amine (H), and using a similar procedure to that described in Example 8, the title compound was obtained in 78% yield, as a white powder;
m.p. 163-164~C.; partial NMP, (250 MHz, DMSO-d6):
1.57-1.87[m,8H) (CH2)4]; 3.84(s,3H, OMe); 3.92(s,3H, OMe); 4.11(s,2H) ArCH2); 5.07(m,lH, -CHO-); 9.61(br s,lH, NH).
Example 71 4-[5-(Cyclopentyloxycarbon~l)aminobenzo[b]thien-3-yl=
methyl]-3-methoxybenzoic acid Using a procedure similar to that described in Example 9, the title compound was obtained in 95%
yield, as a white powder; m.p. 259-26l~C.

13405b7 Example 72 N-[4-[5-(Cyclopentyloxycarbonyl)aminobenzo[b]thien-3-~lmethyl]-3-methoxybenzoyl]benzenesulphonamide Using a similar procedure to that described in Example 57, the title compound was obtained in 51%
yield, as a white powder; m.p. 253-254~C.
Example 73 Methyl 4-[6-(2-cyclopentylacetamido)benzimidazol-1-yl-methyl]-3-methoxybenzoate Starting from amine (J)) anu using a similar procedure to that described in Example 47, the title compound was obtained in 847 yield) as a pink powder;
partial NMR (80 MHz, DMSO-d6): 1.57[br m,BH, (CH2)4];
2.26(br s,3H, -CHCH2); 3.83(s,3H, OMe); 3.94(s,3H, OMe); 5.42(s,2H, NCH2); 9.81(s,lH, NH).
Example 74 4-[6-(2-Cyclopentylacetamido)benzimidazol-1-ylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, the title compound was obtained in 62~
yield, as white crystalline needles; m.p. 280-281~C.
(d).

l3~OOb7 Examples 75-76 Using a similar procedure to that described in Example 57, the following sulphonamides were ob-rained:
Example 75: N-[4-[6-(cyclopentyloxycarbonyl)amino-benzimidazol-1-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide in 7% yield, as a white powder; m.p. 242-243~C.; and Example 76: N-[4-[6-(2-cyclopentylacetamido)benzimi-dazol-1-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide in 61% yield, as a white powder; m.p. 220-222~C.
(monohydrate).
Examp le 7 7 Methyl 4-(6-(cyclopentyloxycarbonyl)aminobenzotriazol-1-ylmethyl]-3-methoxybenzoate Using methyl 4-(6-aminobenzotriazol-1-yl-methyl)-3-methoxybenzoate (M), and a similar procedure to that described in Example 3 (see also Example 35), the title compound was obtained in 40% yield) as a solid; m.p. 142-143~C.
The starting amino ester (M) was obtained from methyl 3-methoxy-4-(6-nitrobenzotriazol-1-ylmeth-yl)benzoate (rl) by a similar procedure to that de-scribed in Exam le 1(b).

~~~o~~~

The methyl 3-methoxy-4-(6-nitrobenzotriazol-1-ylmethyl)benzoate was itself prepared from 5-nitro-benzotriazole using a procedure similar to that described in Example 35(a), in 26% yield, as a white solid; m.p. 165-166.5~C.
Example 78 4-[6-(Cyclopentyloxycarbonyl)aminobenzotriazol-1-yl-me_ thyl.]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, the title compound was obtained in 24%
yield, as a pink solid; m.p. 237-239~C. (partial hy-drate).
Exam le 79 Methyl 4-[1-(2-carbethoxyethyl)-5-(cyclopentyloxycar-bonyl)aminoindol-3-ylmethyl]-3-methox~benzoate Using a similar procedure to that of Example 1 (see also Example 22), the title compound was ob-tained in 85% yield, as a foam. Partial t~'IR (250 rl~Iz, DMSO-d6): 1.07(t,3H, -OCH2CH3); 1.7[m,8H) (CH2)4];
2.76(t,2H, -CH2C02Et); 3.82(s,3H, OCH3); 3.91(s,3H, OGIi3); 3.93(s,2H, ArCH2Ar); 3.94(q,2H, -OCH2CH3); 4.32 (t,2H, -CH2N); 5.10(m,lH, -OCH-). The compound was made by starting from methyl 4-[5-amino-1-(2-carbeth-oxyethyl)indol-3-ylmethyl]-3-methoxybenzoate (itself made by analogy with (D) in Example 4, that is by m~o~~~

reaction of the nitro-indole derivati~Te (C) with ethyl acrylate in N,N-dimethylformamide in the presence of sodium hydride) followed by catalytic hydrogenation of the product).
Example 80 Methyl 4-[5-(2-cyclopentylacetamido)-1-ethylindol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 47, the title compound was obtained in 90%
yield, as a solid; m.p. 144-146~C.; partial NriR (250 PZHz, DMSO-d6): 1.18(m,2H, cyclopentyl ring); 1.31(t, 3H) -CH2CH3); 1.59(m,6H) cyclopentyl ring); 2.24(m, 3H); 3.82(s,3H, OCH3); 3.92(s,3H, OCH3); 3.97(s,2H, ArCH2Ar); 4.09(q,2H, -CH2CH3). The compound was made by starting from methyl 4-(5-amino-1-ethylindol-3-yl-methyl)-3-methoxybenzoate (itself prepared by analogy with (D) in Example 4, except using iodoethane in place of iodomethane).
Examples 81-82 Using a similar procedure to that described in Example 9, there were obtained the following acids of formula 1:

m.p. yield Ex. R1 W Rd (~C.) (%) 81 cyclopentyl 0 2-carboxy- 109-119 84 ethyl 82 cyclopentyl- - ethyl 219-220 83 methyl - Direct link to R1 Example 83 (t)Methyl 4-[5-(2-cyclopentylacetamido)-1-ethyl-2,3-dihydroindol-3-ylmethyl]-3-methoxybenzoate Palladium-on-carbon (10% w/w, 0.5 g.) was added to a mixture of methyl 4-[5-(2-cyclopentyl-acetamido)-1-ethylindol-3-ylmethyl]-3-methoxybenzoate (0.5 g., prepared as described in Example 80), and formic acid (99%, 20 ml.), under an atmosphere of nitrogen. The mixture was vigorously stirred and heated at 80~C. for one hour. The cooled mixture was filtered through a pad of diatomaceous earth) the fil-ter coke washed with methanol, and the filtrate evapo-rated. The resulting oil was dissolved in ethyl ace-tate (30 ml.) washed with water, brine) then dried (MgS04) and evaporated. The product was purified by flash chromatography on silica gel (4 cm. diameter column), eluting with 2:3 v/v ethyl acetate:hexane) to give the title compound (0.37 g.) 80%) as a foam; NMR
(250 MHz, DriSO-d6): 1.04(t,3H, -CH2CH3); 1.15(m,2H, cyclopentyl ring); 1.4-1.8(m,6H, cyclopentyl ring);

_87_ 2.2(m,3H); 2.7(dd,lH); 2.85-3.2(m,SH); 3.45(m,lH);
3.86(s,3H, OCH3); 3.87(s,3H, OCH3); 6.43(d,lH); 7.20 (m,2H); 7.30(d,lH); 7.50(m,2H); 9.47(s,lH, NH).
Example 84 (t)-4-[5-(2-Cyclopentylacetamido)-1-ethyl-2,3-dihydro-indol-3-ylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 29 (see also Example 9), except using the ester described in Exam lp a 83, the title compound was obtained in 84% yield, m.p. 183-186~C., as a partial hydrate.
Example 85 N-[4-[6-(2-Cyclopentylacetamido)-2,3-dihydrobenz-1,4 oxazin-4-ylmethyl]-3-methoxybenzoyl]-2-methylbenzene sulvhonamide Using a similar procedure to that described in Example 32 (see also Example 69), except using o-toluenesulphonamide) the title compound was obtained in 45% yield, m.p. 207-208~C., (monohydrate).
Example 86 Methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-methylin-dazol-3-ylmethyl]-3-methoxybenzoate Methyl 4-[2-(acetoxyimino)-2-[5-(cyclopent-yloxycarbonyl)amino-2-(methylamino)phenyl]ethyl]-3-~.340~~'~
_88-methoxybenzoate (0) (1.3 g.) was placed in a 100 ml.
round-bottomed flask charged with a stirring bar, and the flask was maintained under high vacuum by means of a vacuum pump. The flask was immersed in a preheated (170~C.) oil bath until the solid melted and for 10 minutes thereafter. The cooled product was purified by flash chromatography on silica gel (5 cm. diameter column, compound applied to column by dissolution in a small volumn of dichloromethane), eluting with 2:3 v/v ethyl acetate: hexane, to give the title compound (1.1 g. , 96%) as a foam; T~IR (250 i~'IHz, DMSO-d6) : 1.5-1.9 [m,8H, (CH2)4]; 3.83(s,3H) CH3); 3.92(s,3H, CH3); 3.93 (s,3H, CH3); 4.19(s,2H, ArCH2Ar); 5.07(m,lH, -OCH-);
7.14(d,lH); 7.35(d,lH); 7.4S-7.49(m,3H); 7.78(br s) 1H); 9.46(br s,lH, NH).
The oxime-acetate ester (0) was obtained as follows, starting from methyl 4-[5-(cyclopentyloxycar-bonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenz-oate (P), itself prepared as described in Example 8:
(a) Rose Bengal (0.025 g.) was added to a solution of methyl 4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoate (P) (2.0 g.) in dry methanol (200 ml.). The resulting red solution was introduced, together with a magnetic stirring bar) into a quartz photolysis apparatus fitted with a gas bubbler, drying-tube, and a water-cooled immersion tube housing a quartz tungsten-halo-gen lamp (type DVY, 650 watts). Purified, dry oxygen gas was bubbled through the stirred solution while irradiating the solution. After 1.5 hours (TLC moni-toring), the methanol solution was removed from the ~3~~0~~~7 apparatus, evaporated, and filtered through a column of silica gel (6 cm. diameter column) eluting with 3:2 to 100:0 v/v ethyl acetate:hexane, to give methyl 4-[2-[5-(cyclopentyloxycarbonyl)amino-2-(formyl)(meth-yl)aminophenyl]-2-oxoethyl]-3-methoxybenzoate (Q) (2.12 g., 98.57) as a foam; NMR (250 MHz, DMSO-d6):
1.5-1.9[m,8H, (CH2)4]; 3.04(s,2.25H) td-Me, isomer A);
3.24(s,0.75H, N-rie, isomer B); 3.79) 3.82, 3.86(sing-lets,6H, 2xOMe); 4.12(s,0.5H, ArCH2C0, isomer B);
4.17(s,l.5H) ArCH2C0, isomer A); 5.11(m,lH) -OCH-);
7.27-8.15(2m,7H); 9.85(br s,0.25H, NH, isomer B);
9.91(br s,0.75H, NH, isomer A).
(b) A solution of the keto-formanilide (Q) (1.0 g., prepared as described in (a) above), and hydroxylamine hydrochloride (0.84 g.) in freshly-dis-tilled pyridine (100 ml.) was heated and stirred under reflux for 18 hours, under a nitrogen atmosphere. The cooled solution was concentrated, the residue dis-solved in ethyl acetate (100 ml.), washed with water (3x25 ml.), dried (MgS04) and evaporated. The product was purified by flash chromatography on silica gel (4 cm. diameter column), eluting with 1:1 v/v ethyl acetate: hexane to give methyl 4-[2-[5-(cyclopentyloxy-carbonyl)amino-2-methylaminophenyl]-2-(hydroxyimino)-ethyl]-3-methoxybenzoate (R) (0.57 g., 59%) as an off-white solid; NMR (DMSO-d6): 1.4-1.9[m,8H, (CH2)4];
2.81(distorted doublet,3H, NMe); 3.83(s,3H, OMe);
3.92(s,3H, OMe); 4.04(s,2H) ArCH2C0); 4.98(m,lH, -CHO-); 6.57(d,lH); 6.93(d,lH); 7.24(br m,2H); 7.46(m, 4H); 8.92 (br s,lH, NHCO).

1~40W~

(c) Acetic anhydride (0.27 ml.) 0.29 g.) was added to a solution of the amino-oxime (R) (1.3 g., prepared as described in (b) above) and 4-(dimeth-ylamino)pyridine (0.35 g.) in dichloromethane (120 ml.), under a nitrogen atmosphere. After 18 hours, the mixture was evaporated, the yellow residue dis-solved in ethyl acetate (50 ml.), washed with hydro-chloric acid (0.05N, 15 ml.), water (15 ml.), brine, dried (MgS04) and evaporated. Crystallization from ethyl acetate/hexane at -20~C gave methyl 4-[2-(acet-oxyimino)-2-[5-(cyclopentyloxycarbonyl)amino-2-methyl-aminophenyl]ethyl]-3-methoxybenzoate (0) (1.36 g., 96%), as a powder) m.p. 124-126~C.; NPZR (250 MHz, DriSO-d6): 1.5-1.9[m,8H, (CH2)4]; 2.12(s,3H) OCOMe);
2.83(distorted doublet,3H, N'Me); 3.83(s,3H, OMe);
3.88(s,3H, OMe); 4.17(s,2H) ArCH2C=N); 5.00(m,lH, -OCH-); 6.24(d,lH); 7.01(d,lH); 7.3-7.5(m,SH); 9.1(br s,lH, NHCO).
Example 87 4-(5-(Cyclopentyloxycarbonyl)amino-1-methylindazoi-3-ylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, except starting from methyl 4-[5-(cyclo-pentyloxycarbonyl)amino-1-methylindazol-3-ylmethyl]-3-methoxybenzoate, the title compound was obtained in 95% yield, as a white solid) m.p. 216-217~C.

13405i~~

Example 8~
N-[4-[5-(Cyclopentyloxycarbonyl)amino-1-methylindazol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide Using a similar procedure to that described in Example 57, except starting from the acid described in Example 87, the title compound was obtained in 63%
yield, as a white powder, m.p. 145~C. (hemi-hydrate).
Analysis calculated for:
C29H30N4~6S~0.5H20: C, 60.93; H, 5.46; N, 9.80 Found: C, 60.83; H, 5.30; N, 9.79 Example 89 Sodium Ld-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphonamide Sodium hydroxide solution (1 N, 10.69 ml.) was added to a stirred solution of N-[4-[5-(cyclopent-yloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-meth-oxybenzoyl]benzenesulphonamide (6.0 g.) in 1:1 v/v tetrahydrofuran:methanol (100 ml.)) under a nitrogen atmosphere. After 0.5 hours) the organic solvents were removed in vacuo and the resulting aqueous solu-tion lyophilised to give the title compound (6.1 g., 95%) as a white powder, rn.p. 168-175~C. (monohydrate).
Analysis calculated for:
C30H30N3~6SNa.H20: C, 59.89; H, 5.36; N, 6.98 Found: C) 59.74; H, 5.24; Pd) 6.90 Example 90 Methyl 4-[6-(cyclopentyloxycarbonyl)amino-3-metho~y-indazol-1-ylmethyl]-3-methoxybenzoate Cyclopentyl chloroformate (0.l7 ml.) was added to a cooled (-20~C) solution of methyl 4-(6-amino-3-methoxyindazol-1-ylmethyl]-3-methoxybenzoate (S) (0.381 g.) and pyridine (0.11 ml.) in dichloro-methane (3.0 ml.). After warming to ambient tempera-ture, the mixture was diluted with ethyl acetate, and washed with hydrochloric acid (1N), water, brine, dried (MgS04) and evaporated. The residue was puri-fied by flash chromatography on silica gel (56 g.), eluting with 5:9S v/v ethyl acetate:dichloromethane, to give the title compound (0.365 g.) 757) as an oil, with satisfactory NMR spectral data.
The amino-ester (S) was obtained as follows:
(a) 6-Nitroindazolol (0.206 g.) was added to a solution of sodium (0.026 g.) in methanol (1.5 ml.), and the mixture heated at 50~C. for 10 minutes.
A solution of methyl 4-bromomethyl-3-methoxybenzoate (B) (0.327 g.) in methanol (3.75 ml.) and N,N-dimeth-ylformamide (DMF) (l.25 ml.) was added, and the mix-ture was refluxed for 18 hours. The cooled mixture was diluted with ethyl acetate and DMF) and washed with water and brine, then dried (MgS04) and evapo-rated. The residue was triturated with 1:1 v/v ethyl acetate: ether to give methyl 4-[3-hydroxy-6-nitroin-dazol-1-ylmethyl]-3-methoxybenzoate (T) (0.1S8 g., 38~) as a yellow solid, m.p. 231-235~C.

(b) Indazole (T) (1.68 g.) was added to a solution of sodium (0.108 g.) in methanol (1.0 ml.).
After stirring for 5 minutes) iodomethane (0.32 ml.) was added and stirring continued for 18 hours. The mixture was diluted with ethyl acetate, washed with water and brine, then dried (MgS04) and evaporated.
The residue was purified by flash chromatography on silica gel (130 g.), eluting with 2:98 v/v ethyl acetate:dichloromethane to give methyl 4-[3-methoxy-6-nitroindazol-1-ylmethyl]-3-methoxybenzoate (U) (0.481 g., 287) as a yellow solid, with satisfactory NMR spectral data.
(c) Palladium-on-carbon (57 w/w) 0.24 g.) was added to a solution of indazole (U) (0.48 g.) in ethyl acetate (25 ml.). The mixture was hydrogenated at 1.1 bars for 3 hours. The catalyst was removed by filtration through diatomaceous earth, and the fil-trate evaporated. The residue was recrystallized from a hot ethyl acetate/petroleum ether mixture to give methyl 4-(6-amino-3-methoxyindazol-1-ylmethyl)-3-meth-oxybenzoate (S) (0.15 g., 347), as a pale-yellow solid, m.p. 188-l93~C.
Exam le 91 4-[6-(Cyclopent~loxycarbonyl)amino-3-methoxyindazol-1-ly methyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9) except starting from methyl 4-(6-(cyclo-pentyloxycarbonyl)amino-3-methoxyindazol-1-ylmethyl]-13~~~~7 3-methoxybenzoate, the title compound was obtained in 54~ yield, as a solid, m.p. 199-200.5~C.
Example 92 Pd-[4-[6-(Cyclopentyloxycarbonyl)amino-3-methoxyinda-zol-1-ylmethyl]-3-methoxybenzoyl]benzPnesulpher~amide Using a similar procedure to that described in Example 57) except starting from the acid described in Exam lp a 91, the title compound was obtained in 53%
yield, as a solid) m.p. 246-247.S~C, Example 93 5-(2-Cyclopentylacetamido)-1-methyl-3-[4-(1-H-tetra-zol-5-yl)-2-methoxybenzyl]indole Sodium hydroxide solution (1M, 1.9 ml.) and, second, palladium-on-carbon (l07 w/w; 0.05 g.) were added to a solution of nitro-tetrazole (V) (0.69 g.) in methanol (50 ml.), and the mixture hydrogenated at an initial pressure of 3.3 bar. After two hours, catalyst was filtered off, washed with methanol, and the combined filtrate evaporated. The residue was dissolved in water (30 ml.), excess saturated aqueous dihydrogen sodium phosphate added, and the precipitate collected and dissolved in tetrahydrofuran (20 mI.).
Charcoal was added, the solution heated and filtered through diatomaceous earth and the filter cake washed with tetrahydrofuran. The combined filtrate (which 1340e7 contained crude 5-amino-1-methyl-3-[2-methoxy-4-(1-II-tetrazol-5-yl)benzyl]indole) was added to a solution of 4-(dimethylamino)pyridine (0.244 g.), 1-(3-dimeth-ylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.384 g.) and cyclopentylacetic acid (0.256 g.) in dichloromethane (30 ml.). The mixture was stirred at ambient temperature for two days, the solvents evapo-rated, the residue partitioned between chloroform and water, the chloroform layer washed with water, dried (MgS04) and evaporated. The product was purified by flash chromatography on silica gel (using a 3 cm.
diameter column) eluting with 70:30:4 v/v/v toluene:
ethyl acetate:acetic acid, giving a product which was recrystallized from a mixture of methanol and water to give the title compound (hydrate) (0.064 g., 7.6~) as an off-white solid, m.p. 242-243~C.
The starting vitro tetrazole (V) was itself prepared as follows:
(a) A solution of chlorosulphonyl isocya-nate (5.35 ml.) in dichloromethane (3 ml.) was added over 45 minutes to a stirred suspension of 3-methoxy-4-methylbenzoic acid (9.97 g.) in dichloromethane (18 ml.) at reflux under an atomosphere of nitrogen. The resulting bright-red homogeneous solution was heated under reflux for 45 minutes) chilled in an ice-bath, and treated dropwise with N,N-dimethylformamide (9.5 ml.), over 15 minutes. After stirring for 30 minutes at 0~C, the orange solution was poured onto ice. The organic layer was separated, washed with water (5x20 ml.), dried (MgS04) and evaporated. The residue was purified by preparative HPLC (Si02, 10:90 v/v hexane:

toluene) to give 3-methoxy-4-methylbenzonitrile (5.28 g., 60%) as a white solid) m.p. 51-52.5~C.
(b) N-Bromosuccinimide (3.2 g.) and benzoyl peroxide (0.005 g.) were added to a solution of 3-methoxy-4-methylbenzonitrile (2.65 g.) in dry carbon tetrachloride (90 ml.). The mixture was heated to reflux for 15 minutes using a 250 watt tungsten lamp.
The cooled reaction mixture was diluted with petrolum ether (b.p. 60-80~C.) 90 ml.), insoluble material re-moved by filtration) and the filtrate evaporated. The solid residue was recrystallized from a mixture of di-chloromethane and petroleum ether to give 4-bromometh-yl-3-methoxybenzonitrile (~J) (2.64 g., 65%) as a white solid, m.p. 87-91~C.
(c) An efficiently stirred mixture of 5-nitroindole (3.24 g.), bromide (W) (4.57 g.) and silver (I) oxide (4.87 g.) in dry dioxane (90 ml.) was heated at 100~C for 5 hours. Additional silver oxide (2 g.) was added, and heating continued for 1 hour.
The cooled mixture was evaporated, the residue diluted with dichloromethane, filtered, washing the filter cake with dichloromethane until the washings were colorless, and the combined filtrate evaporated. The product was purified by flash chromatography on silica gel, eluting with 3:7 v/v ethyl acetate: hexane, giving a product which was crystallized from a mixture of ethyl acetate and hexane to give 3-(4-cyano-2-methoxy-benzyl)-5-nitroindole (1.87 g., 30%) as a yellow pow-der, m.p. 204-206~C.; partial NI~fR (80 MHz, DMSO-d6):
3.92(s,3H, OMe); 4.12(s,2H, ArCH2).

(d) Sodium hydride (60% w/w dispersion in mineral oil, 0.12 g.) was added to a stirred solution of 3-(4-cyano-2-methoxybenzyl)-5-nitroindole (0.85 g.) in dry N,N-dimethylformamide (10 ml.) under a nitrogen atmosphere. After about one hour, iodomethane (0.645 g.) was added dropwise, and stirring continued at ambient temperature for 5 hours. The mixture was poured onto saturated aqueous ammonium chloride solu-tion, extracted with ethyl acetate (2x20 ml.)) the extract washed with water, brine, dried (MgS04) and evaporated. The residue was crystallized from aceto-nitrile to give 3-(4-cyano-2-methoxybenzyl)-1-methyl-5-nitroindole (0.72 g., 81') as a yellow solid, m.p.
2U0-201~C.; partial N1~IR (250 MHz, DMSO-d6): 3.82(s, 3H, Nrie); 3.92(s,3H, OMe); 4.12(s,2H, ArCH2).
(e) A mixture of 3-(4-cyano-2-methoxybenz-yl)-1-methyl-5-nitroindole (0.458 g.), sodium azide (0.741 g.), and triethylamine hydrochloride (0.785 g.) in dry 2d-methyl-2-pyrrolidinone (6 ml.), under nitro-gen, was stirred and heated at 150~C. for 1.5 hours.
The mixture was cooled to ambient temperature, 1N
hydrochloric acid (25 ml.) added cautiously, while stirring, the precipitated solid isolated by filtra-tion, washed with water and dried in vacuo to give 3-[2-methoxy-4-(1-H-tetrazol-5-yl)benzyl]-1-methyl-5-nitroindole, (V) (0.484 g., 947) as a yellow powder, m.p. 249-250~C.; partial N~iR (250 MHz) DMSO-d6): 3.82 (s,3H, NMe); 3.97(s,3H, Orie); 4.13(s,2H, ArCH2).

.I~~O~b7 Example 94 Methyl 4-[5-(N'-cyclopentylureido)-1-methylindol-3-yl-methyl)-3-methoxybenzoate A solution of trichloromethyl chloroformate (0.66 g.) in dry dioxan (10 ml.) cvas added over 10 minutes to a stirred solution of methyl 4-(5-amino-1-methylindol-3-ylmethyl)-3-methoxybenzoate (D) (1.09 g.) in dry dioxane (15 ml.) at ambient temperature.
The reaction vessel was continuously purged with nitrogen gas, and the effluent bubbled through aqueous potassium hydroxide solution to destroy excess phos-gene. The in situ formation of the isocyanate of (D) was followed by TLC. After 30 minutes cyclopentyl-amine (0.574 g.) was added, the mixture heated to 70~C. for 20 minutes, then cooled and diluted with water (100 ml.). The precipitate which formed was collected by filtration, dissolved in 95:S v/v di-chloromethane:methanol (100 ml.), and the solution washed with water, brine, dried (MgS04) and evaporated to give a solid which was recrystallized from acetoni-trile to give the title compound (0.75 g., 56~) as a white solid, m.p. 210-212~C.; partial NMR (250 MHz, DMSO-d6): 1.25-1.80(3m,8H, cyclopentyl ring); 3.68(s, 3H, NMe); 3.83(s,3H, OMe); 3.90-4.0(2s+m,6H, OMe, ArCH2, -CHNH-); 5.93(d, 1H, -CH.NH-).

1340e7 Example 95 4-[5-(N'-Cyclopentylureido)-1-methylindol-3Jylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, except starting from the ester described in Example 94, the title compound was obtained in 70%
yield as a white powder, m.p. 203-206~C.
Example 96 N-[4-[5-(N'-Cyclopentylureido)-1-methylindol-3-ylmeth-yl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide Using a similar procedure to that described in Example 57, except using ortho-toluenesulphonamide and the acid described in Example 95, the title com-pound was obtained in 58% yield) as a white solid, m.p. 2l2-215~C., (monohydrate).
Example 97 Methyl 4-[5-(2-cyclopentylacetamido)-1-(Ld,N-dimethyl-carbamoylmethyl)indol-3-ylmethyl]-3-methoxybenzoate Using procedures similar to those described in Examples 47, 48 (see also Example 42), the title compound was obtained in 89% yield as a white powder, m.p. 129-132~C.; partial NMR (250 MHz, DMSO-d6):
1.15-1.30(m,2H, cyclopentyl ring); l.45-1.80(2m,6H, 2~~05~7 -loo-cyclopentyl ring); 2.25(m,3H, CH,,CONH and -CHCH2);
_' 2.83(s,3H, NMe); 3.06(s,3H, Nt~e); 3.83(s,3H, OMe);
3.92(s,3H, OMe); 3.98(s,2H, ArCH2); 5.03(s,2H, NCH2);
9.61(s,lH, NIi). The compound was made by starting from methyl 4-[5-amino-1-(td,td-dimethylcarbamoylmeth-yl)indol-3-ylmethyl]-3-methoxybenzoate (itself pre-pared by analogy with (D) in Example 4) that is by reaction of nitroindole derivative (C) with 2-chloro-N,N-dimethylacetamide in N,N-dimethylformamide in the presence of sodium hydride, followed by catalytic hy-drogenation of the product).
Example 98 flethyl 4-[1-(tert-butoxycarbonylmethyl)-5-(2-cyclo-pentylacetarmido)indol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 4, except using cyclopentylacetyl chloride, the title compound was obtained in 47o yield as a foam; partial NMR (DMSO-d6): 1.1-1.3(m,2H, cyclopent-yl ring); 1.40[s,9H, C(Me)3]; 1.45-1.8(2m,6H, cyclo-pentyl ring); 2.25(m,3H, CH2CONH and -CHCH2); 3.83(s) 3H) OMe); 3.92(s,3H, OMe); 3.98(s,2H, ArCH2); 4.90(s, 2H, NCH2); 9.63(s,lH, NH). The compound was made by starting from methyl 4-[5-amino-1-(tert-butoxycarbon-ylmethyl)indol-3-ylmethyl]-3-methoxybenzoate (itself prepared by analogy with (D) in Example 4, that is by reaction with vitro-indole derivative (C) with tert-butyl bromoacetate in N,N-dimethylformamide in the presence of sodium hydride, followed by catalytic hy-drogenation of the product).

Example 99 Methyl 4-[1-(3-cyanophenylr_zethYl)-5-(2-cyclo_pentyl-acetamido)indol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 4, except using cyclopentylacetyl chloride) the title compound was obtained in 30% yield as a yellow foam; partial rJriR (DrISO-d6 ) : 1. 05-1. 3 (m, 2H, cyclopentyl ring); 1.4-1.8(2m,6H, cyclopentyl ring);
2.24(m,3H, CH2C0 and -CHCH2); 3.83(s,3H) OMe); 3.91(s, 3H, OMe); 4.0(s,2H, ArCH2); 5.40(s,2H, NCH2); 9.63(s, 1H, NH). The compound was made by starting from meth-yl 4-[5-amino-1-(3-cyanophenylmethyl)indol-3-ylmeth-yl]-3-methylbenzoate (itself prepared by analogy with (D) in Example 4, that is by reaction of nitroindole derivative (C) with 3-cyanobenzyl bromide in N,N-di-methylformariide in the presence of sodium hydride, followed by catalytic hydrogenation (but using 5% w/w palladium-on-carbon as catalyst in 4:1 v/v tetrahydro-furan:methanol as solvent, and at atmospheric pres-sure) of the product.) Example 100 riethyl 4-[5-(2-cyclopentylacetamido)-1-propargylindol-3 ~lmethyl]-3-methoxybenzoute Using similar procedures to those described in Examples 4 and 23, the title compound was obtained in 60% yield) as a white solid, m.p. 160-16l~C.;
partial NriR ( 250 P~~~z , DMSO-d6 ) : 1.1-1. 3 (m, 2H , cyclo-pentyl ring); 1.45-1.8(2m,6H) cyclopentyl ring); 2.26 (m,3H, CH2C0 and -CHCH2); 3.37(t,lH) =C-H); 3.83(s,3H, OMe); 3.92(s,3H, OMe); 3.98(s,2H, ArCH2); 4.99(d,2H, NCH2); 9.66(s,lH) NH). The title compound was made by starting from methyl 4-(5-amino-1-propargylindol-3-yl-methyl)-3-methoxybenzoate (itself prepared by analogy with (F) in Example 23, that is by reaction of nitro-indole derivative (C) with propargyl bromide in N,1'I-dimethylformamide in the presence of sodium hydride, followed by stannous chloride reduction of the pro-duct.) Examples l01-104 Using a similar procedure to that described in Example 9, e::cept using the esters described in Examples 97-l00) the following acids of formula 1 in which W is a direct link to P,1 were obtained by hydro-lysis of the corresponding methyl esters:
m.p. yield Ex. R1 Rd (~C.) (%) 101 cyclopentyl- N,N-dimethyl- 223-226* 54 methyl carbamoylmethyl 102 cyclopEntyl- carboxymethyl~ 256-258 74 methyl 103 cyclopentyl- 3-cyanophenyl- 130-132* 89 methyl methyl 104 cyclopentyl- propargyl 226-227* 87 methyl * Isolated as a partial hydrate.
Hydrolyses of both methyl and tert-butyl esters.

13~OW'~

Example 105 N-[4-[5-(Cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphon-amide Using a similar procedure to that described in Example 57) except using ortho-toluenesulphonamide and the acid described in Example 9, the title com-pound was obtained in 69~ yield, as a white solid) m.p. 138-140~C.
Analysis calculated for:
C31H33N3~6S~ C, 64.68; H, 5.78; N, 7.30 Found: C, 64.49; H, 5.78; N, 7.21 Example 106 4-(6-Hexanamido-2,3-dihydrobenz-1,4-oxazin-4-ylmeth-yl)-3-hydroxybenzoic acid Lithium thioethoxide was prepared by the dropwise addition of n-butyllithium (4 ml. of l.53 molar solution in hexane) to a stirred solution of ethyl mercaptan (0.5 ml.) in dry N,N'-dimethylpro-pylene urea (DMPU) (9 ml.)) under a nitrogen atmo-sphere. A solution of methyl 4-(6-hexanamido-2,3-di-hydrobenz-1,4-oxazin-4-ylmethyl)-3-methoxybenzoate (prepared as described in Example 26) (0.3S g.) in DPZPU (3 ml.) was added, the mixture stirred at ambient temperature for 15 minutes) then heated to, and main-tained at) 130~C. for 4 hours. The cooled mixture was b ~' diluted with water, acidified with acetic acid, ex-tracted with ethyl acetate, the extracts washed with water, dried (MgS04) and evaporated. The product was purified by flash chromatography on silica gel, elut-ing with 80:20:2 v/v/v toluene: ethyl acetate: acetic acid, giving a white solid which was washed with hex-ane and dried, to give the title compound (0.114 g.) 36~) as a white solid) m.p. 183-184~C.
Example 107 Methyl 3-(6-hexanamido-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)benzoate Hexanoyl chloride (0.135 g.) was added drop-wise to a stirred solution of methyl 3-(6-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)benzoate (X) (0.3 g.), and N-methylmorpholine (0.101 g.) in dichloro-methane (30 ml.). After 0.5 hours, the mixture was diluted with dichloromethane, washed with water) dried (MgS04) and evaporated to give an oil which was fil-tered through a short column of silica gel using 35:65 v/v ethyl acetate:hexane to give the title compound as a syrup; partial NMR (80 tiHz, CDC13): 0.8-1.9[complex m,9H, CH3(CH2)3]; 2.2(m,2H, CH2CONH); 3.3(m,2H, N.CH2.CH2.0); 3.9(s,3H, 02~ie); 4.2(m,2H, N.CH2.CH20);
4.5(s,2H, N.CH2Ar).
The amino ester (X) was obtained as follows:

(a) A mixture of 6-vitro-2,3-dihydrobenz-1,4-oxazine (0.45 g.), methyl 3-bromomethylbenzoate%'~
(Y) (0.58 g.)) potassium carbonate (0.35 g.), and sodium iodide (d.38 g.) in dry 2-butanone (25 ml.) was stirred and heated under reflux for 48 hours. The cooled reaction mixture was filtered, the filter cake washed with 2-butanone, and the combined filtrate evaporated. The product was purified by flash chroma-tography on silica gel, eluting with 5:95 v/v ethyl acetate: toluene to give methyl 3-(6-vitro-2,3-dihydro-benz-1,4-oxazin-4-ylmethyl)benzoate (0.7 g., 85%) as a yellow oil; partial NMR (80 MHz, CDC13): 3.5(m,2H, N.CH2.CH20); 3.9(s,3H, Orie); 4.3(m,2H, N.CH2.CH20);
4.6(s,2H, NCH2Ar).
(b) A mixture of methyl 3-(6-vitro-2,3-di-hydrobenz-1,4-oxazin-4-ylmethyl)benzoate (0.65 g.) and palladium-on-carbon (10% w/w, 0.025 g.) in ethyl acetate (40 ml.) was hydrogenated at an initial pres-sure of 2.9 bar. The catalyst was removed by filtra-Lion through diatomaceous earth, washing the filter cake with ethyl acetate, and the filtrate was evapo-rated to give methyl 3-(6-amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl)benzoate (X) (0.3 g., 51%) as a gum;
partial NMR (80 rgiz) CDC13): 3.3(m,2H, N.CH2CH2.0);
*Methyl 3-bromomethylbenzoate (Y) was prepared from methyl 3-methylbenzoate by bromination using N-bromo-succinimide in an analogous manner to that used to prepare 4-bromomethyl-3-methoxybenzonitrile (W) as described in part (b) of Example 93.

1~4Q~~~

3.9(s,3H, OMe); 4.15(m,2H, N.CH2.CH2.0); 4.5(s,2H) NCH2Ar).
Example 108 3-(6-Hexanamido-2,3-dihydrobenz-1,4-oxazin-4-ylmeth-Y1)benzoic acid Lithium hydroxide monohydrate (0.2 g.) in water (5 ml.) was added to a stirred solution of meth-yl 3-(6-hexanamido-2,3-dihydrobenz-1,4-oxazin-4-yl-methyl)benzoate (ca. 400 mg.) in 1:1 v/v methanol:
tetrahydrofuran (10 ml.). When TLC (solvent system 80:20:2 v/v/v toluene:ethyl acetate:acetic acid) in-dicated complete disappearance of ester, the mixture was diluted with water, filtered to reu~ove any solids, and carefully acidified with 1N hydrochloric acid.
The precipitate was isolated by filtration and re-crystallized from a mixture of methanol and water to give the title compound (0.176 g.) 46% overall yield from amino ester (X)) as an off-white solid, m.p. 167-171~C. (hemihydrate).
Example 109 N-[4-[5-(2-Cyclopentylacetamido)-1-(N,N-dimethylcar-bamoylmethyl)indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide Using a similar procedure to that described in Example 57, except using ortho-toluenesulphonamide 1~~0 a~'~
-l07-and the acid described in Exam le 101, the title com-pound was obtained in 79% yield, as a white solid, m.p. 215-217.5~C. (hemihydrate).
Analysis calculated for:
C35H40N4~6S~O.SH20; C, 64.30; H) 6.32; N, 8.57 Found; C) 64.38; H, b.28; N, 8.55 Example 110 4-[1-Acetyl-5-(2-cyclopentylacetamido)indol-3-ylmeth-yl]-3-methoxybenzoic acid A solution of 4-(1-acetyl-5-aminoindol-3-yl-methyl)-3-methoxybenzoic acid (Z) (0.31 g.), cyclo-pentylacetic acid (0.1l7 g.), 4-(dimethylamino)pyri-dine (0.233 g.) and 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (0.35 g.) in dichlorometh-ane (20 ml.)) under a nitrogen atmosphere, was stirred at ambient temperature for two hours. The mixture was acidified with hydrochloric acid (1N, 30 ml.), extrac-ted with ethyl acetate (3x50 ml.), and the combined extracts dried (MgS04) and evaporated. The residual oil was purified by flash chromatography on silica gel (100 ml.), eluting with 50:45:5 v/v/v hexane:dichloro-methane:ethyl acetate, to give a product which was recrystallized from a mixture of tetrahydrofuran and ether, and then from a mixture of ethanol and water, to give the title compound (0.055 g., 14%), as a white solid, m.p. 245-247~C.
The starting amino acid (Z) was itself prepared as follows from vitro ester (C):

1~4~aci7 -los-(a) A solution of lithium hydroxide monohy-drate (1.2 g.) in water (20 ml.) was added to a sus-pension of nitro ester (C) (2.0 g.) in methanol (30 ml.). The mixture was stirred at ambient temperature for 18 hours and then acidified with hydrochloric acid (1N, 50 ml.). The yellow precipitate was isolated by filtration, washed with water, and dried to give 4-(5-nitroindol-3-ylmethyl)-3-methoxybenzoic acid; partial t~ (250 MHz, DMSO-d6): 3.92(s,3H, OMe); 4.12(s,2H, ArCH2); 11.64(br s,lH, NH).
(b) A solution of 4-(5-nitroindol-3-ylmeth-yl)-3-methoxybenzoic acid (0.6 g.) in N,N-dimethyl-formamide (DMF), (3 ml.) was added to a stirred sus-pension of oil-free sodium hydride (0.088 g.) in DMF
(8 ml.) under a nitrogen atmosphere at ambient temper-ature. The reci solution was stirred for ZO minutes, and acetic anhydride (0.187 g.) added. After 1 hour, the mixture was poured into hydrochloric acid (1N) 30 ml.), extracted with ethyl acetate (3x50 ml)) the combined extracts washed with water (2x20 ml.), brine, dried (MgS04) and evaporated. The product was crys-tallized from a mixture of tetrahydrofuran and ether to give 4-(1-acetyl-5-nitroindol-3-ylmethyl)-3-meth-oxybenzoic acid (0.455 g., 67~) as a yellow powder;
partial NMR (250 MHz; DMSO-d6): 2.68(s,3H, NC0CH3);
3.95(s,3H, OMe); 4.13(s,2H, ArCH3).
(c) Palladium-on-carbon (10~ w/w) 0.1 g.) was added to a solution of 4-(1-acetyl-5-nitroindol-3-ylmethyl)-3-methoxybenzoic acid (0.35 g.) in a mixture of 1:1 v/v methanol:tetrahydrofuran (50 ml.)) which solution had been deoxygenated by passing a stream of 1~4~~~~

nitrogen gas through it, and the mixture hydrogenated at an initial pressure of 50 psi. After 24 hours, the catalyst was removed by filtration through diatoma-ceous earth, and the filtrate evaporated to give 4-(1-acetyl-5-aminoindol-3-ylmethyl)-3-methoxybenzoic acid (Z) (0.31 g., 91~); partial NMR (250 MHz, CD30D):
2.53(s,3H, NCOCH3); 3.94(s,3H) OMe); 4.00(s,2H) ArCH2).
Example 11l Calcium N-[4-[5-(cyclopentyloxycarbonyl)amino-1-meth-ylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzene-sulphonamide Calcium oxide (0.0487 g.)) and distilled water (10 ml.) were added sequentially to a solution of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylin-dol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesul-phonamide (1.0 g.) in tetrahydrofuran (THF)) (8 ml.).
The turbid solution was heated at 50~C for 20-25 min-utes, and the cooled, clear, two-phase mixture evapo-rated (at about 50~C). The residue was redissolved in THF (20 ml.), the solution filtered through a pad of diatomaceous earth) washing the filter cake with a little THF, the filtrate added dropwise to stirred ether (175 ml.), and the resulting solution added dropwise to stirred ether (300 ml.). The precipitate was collected by filtration. The filtrate was evapo-3G rated, redissolved in THF (3.5 ml.) and added dropwise to stirred ether (150 ml.). The precipitate was 1~4U~e7 collected, combined with the first precipitate and dried to give the title compound (0.865 g., 84Z) as a white solid, and a partial hydrate, m.p. 220~C (ap-proximately).
Analysis calculated for C62H64N6012S2CaØ75H20: C, 61.91; H, 5.49; N, 6.99 Found: C, 61.83; H, 5.49; N, 6.87 Example 112 P~Zethyl 4-[5-(cyclopentyloxycarbonyl)amino-1-methylin-dol-3-ylmethyl]-3-methoxybenzoate A solution of 5-(cyclopentyloxycarbonyl)-amino-1-methylindole (AA) (1.3 g.) and methyl 4-bromo-methyl-3-methoxybenzoate (B) (1.3 g.) in N,N-dimethyl-formamide (25 ml.) was stirred and heated at l00~C., under a nitrogen atmosphere, while protecting the reaction vessel from light with aluminum foil, for 24 hours. The cooled mixture was poured onto saturated aqueous sodium bicarbonate solution (300 ml.), ex-tracted with ethyl acetate (3x100 ml.), the combined extracts washed with brine (50 ml.), dried (t~IgS04), and evaporated. The product was isolated by flash chromatography on silica gel (3.5 cm. diameter column) to give the title compound (P) (0.98 g., 457), identi-cal with that obtained in Example 8.
The starting cyclopentyl urethane (AA) was prepared from 5-nitroindole by methylation (using sodium hydride in N,2d-dimethylformamide) followed by catalytic reduction of the nitro compound to the ~~~45b'~

corresponding amino compound, and acylation of the amino compound using cyclopentyl chloroformate (using methods similar to those described in Example 1, part (b), and in Example 3).
Example 113 Methyl 4-[b-(2-cyclopentylacetamido)benzotriazol-1-yl-methyl]-3-methoxybenzoate Using a similar procedure to that described in Example 47, except starting from the amino-ester (M), the title compound was obtained in 58% yield as a white powder, m.p. 206-208~C.

Example 114 4-[6-(2-Cyclopentylacetamido)benzotriazol-1-ylmethyl]-3-methoxvbenzoic acid Using a procedure similar to that described in Example 29, except starting frou~ the ester de-scribed in Example 113, the title compound was ob-tained as a white powder in 98% yield) m.p. 235-238~C., as a partial hydrochloride salt.
Example 1Z5 N-[4-[6-(2-Cyclopentylacetamido)benzotriazol-1-ylmeth-yl]-3-methoxybenzoyl]benzenesulphonamide Using a similar procedure to that described in Example_32, except starting from the acid described l~~o~U7 in Exam le 114, and recrystallizing from a mixture of methanol and water, the title compound was obtained in 95% yield as a white powder) m.p. 211-213~C., as a partial hydrate.
Example 116 Methyl 4-[6-(2-cyclopentylacetamido)-3-hydroxyindazol-,l-ylmethyl]-3-methoxybenzoate A mixture of methyl 4-[3-benzyloxy-6-(2-cyclopentylacetamido)indazol-1-ylmethyl]-3-methoxyben-zoate (BB) (5.0 g.), and palladium-on-carbon (5% w/w, 1.25 g.)) in ethyl acetate (l90 ml.), was hydrogenated at 1.1 bar for 7.5 hours. The catalyst was removed by filtration through diatomaceous earth, washing the filter cake with ethanol, the filtrate partially evaporated, and the residue allowed to crystallize to give the title compound (2.56 g., 62%), as a solid, m.p. 242-245~C.
The ester (BB) was itself obtained as follows:
(a) Methyl 4-(3-hydroxy-6-nitroindazol-1-ylmethyl)-3-methoxybenzoate (T) (35.7 g.) was added to a mixture of sodium (2.3 g.) and methanol (200 ml.).
The mixture was stirred for 18 hours, and evaporated.
The residue was dissolved in N,N-dimethylformamide (l00 ml.)) cooled to 0~C.) and benzyl bromide (15.5 ml.) added. After 18 hours at ambient temperature, ethyl acetate and 1N sodium hydroxide solution were added. The precipitate was isolated by filtration, 1~'~Q~~'~

washed with ether, and chromatographed by HPLC on silica gel, eluting with dichloromethane, to give methyl 4-(3-benzyloxy-6-nitroindazol-1-ylmethyl)-3-methoxybenzoate (CC) (27 g., 60%) as a solid; PWR (250 MHz, DMSO-d6): 3.84(s,3H, Orie); 3.86(s,3H) OMe);
5.38(s,2H) rICH2); 5.65(s,2H, OCH2); 6.95(d,lH); 7.36 (m,3H); 7.46(m,5H); 7.86(m,2H); 8.66(s,lH).
(b) Zinc dust (0.065 g.) was added to a stirred mixture of methyl 4-(3-benzyloxy-6-nitroinda-zol-1-ylmethyl)-3-methoxybenzoate (CC) (0.043 g.) and acetic acid (0.9 ml.). The mixture was stirred for 2 hours, diluted with ether, and filtered. The filtrate was washed with water, brine, dried (MgS04), and evap-orated to give methyl 4-(6-amino-3-benzyloxyindazol-1-ylmethyl)-3-methoxybenzoate (DD) (0.034 g., 85%) as a brown oil, and was used without further purification as described below.
(c) Using a similar procedure to that described in Example 47, except starting from amino ester (DD), there was obtained methyl 4-[3-benzyloxy-6-(2-cyclopentylacetamido)indazol-1-ylmethyl]-3-meth-oxybenzoate (BB) in 32% yield, as a solid, m.p. 139-140~C.
Example 117 4-[6-(2-Cyclopentylacetamido)-3-hydroxyindazol-1-yl-methyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, but starting from methyl 4-[6-(2-cyclo-1340y7 pentylacetamido)-3-hydroxyindazol-1-ylmethyl]-3-meth-oxybenzoate) a crude product was obtained which was purified by flash chromatography on silica gel (40 g.), eluting with 3:7 v/v methanoi:dichloromethane.
The chromatographed product was suspended in a mixture of ethyl acetate and tetrahydrofuran and washed with 1N hydrochloric acid, water, and brine, dried (MgS04), evaporated and recrystallized from a mixture of metha-nol, dichloromethane, and petroleum ether to give the title compound in 16~ yield as a solid, m.p. 269-272~C. as a partial hydrate.
Example 1l8 I5 Met~l 4-[6-(2-cyclopentylacetamido)-3-(N-ethylcarbam oylmethoxy)indazol-1-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 42) except starting from methyl 4-[6-(2-cyclopentylacetamido)-3-hydroxyindazol-1-ylmethyl]-3-methoxybenzoate (that is reaction of this compound with 2-chloro-N-ethylacetamide in N,ZI-dimethylforma-mide in the presence of sodium hydride), and flash chromatography of the crude product on silica gel (75 g.), eluting with 1:1 v/v ethyl acetate:dichlorometh-ane) the title compound was obtained ir. 34% yield as a solid, m.p. 178-181~C.

1340y7 Example 119 4-[6-(2-Cyclopentylacetamido)-3-(N-ethylcarbamoylmeth-oxy)indazol-1-ylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, except using the ester from Example 118, the title compound was obtained in 80% yield, as a solid, m.p. 219-221~C.
Example 120 Methyl 4-[5-(hexanamido)-1-(methoxycarbonylmethyl)-indol-3-ylmethyl]-3-methoxybenzoate Using a similar procedure to that described in Example 4 (see also Exam Ip e__98)) the title compound was isolated in 867 yield, as an oil; partial NMR (250 MHz, DMSO-d6): 0.87(t,3H, CH2.CH3); 1.26-1.30(m,4H);
1.50-1.60(m,2H); 2.25(t,2H, CH2CON); 3.66(s,3H, OMe);
3.83(s,3H, OMe); 3.92(s,3H, OMe); 3.98(s,2H, ArCH2Ar);
5.04(s,2H) NCH2); 9.66(s,lH) NH); starting from 4-[5-amino-1-(methoxycarbonylmethyl)indol-3-ylmethyl]-3-methoxybenzoate (itself prepared by analogy with (D) in Example 4, that is by reaction of nitroindole derivative (C) with methyl bromoacetate, except in tetrahydrofuran, in the presence of sodium hydride, followed by catalytic hydrogenation of the product).

13~05~7 Example 121 4-[1-Carboxymethyl-5-(hexanamido)indol-3-ylmethyl]-3-methoxybenzoic acid Using a procedure similar to that described in Example 9) except starting from the ester described in Example 120, the title compound was obtained in 59%
yield, as a white solid, m.p. 235-240~C.
Example 122 N-[4-[6-(2-Cyclopentylacetamido)-3-(PJ-ethylcarbamoyl methoxy)indazol-1-ylmethyl]-3-methoxybenzoyl]-2-meth ylbenzenesulphonamide Using a similar procedure to that described in Exam le 57, except using ortho-toluenesulphonamide and the acid described in Example 119, the title com-pound was obtained as a partial hydrate in 32~ yield as a sAlid, m.p. 222-223.5~C.
Analysis calculated for:
C34h39N5~7SØ75H20: C, 60.47; H, 6.04; N, 10.37 Found: C, 60.41; H, 5.83; N, 10.31 Example 123 tTethyl 4-[5-(2-cyclopentylacetamido)indol-3-ylmethyl]-3-methoxybenzoate Starting from amino-ester (A), and using a similar procedure to that described in Example 4, 1340~~'~

except using cyclopentylacetyl chloride (see also Example 98), the title compound was obtained in quan-titative yield as a foam; partial NMP, (250 MHz, DMSO-d6): 1.2-1.8(3m,8H, cyclopentyl ring); 2.24(m,3H, CH2CONH and -CHCH2); 3.83(s,3H, OMe); 3.93(s,3H) 02~ie);
3.99(br s,2H) CH2Ar); 9.57(br s,lH, NHCO); 10.79(br d,lH, -NH-).
Example 124 4-(5-(2-Cyclopentylacetamido)indol-3-ylmethyl]-3-methoxybenzoic acid Using a similar procedure to that described in Example 9, except starting from the ester described in Example 123, the title compound was obtained in 83%
yield as a white solid, m.p. 218-219~C.
Example 125 N-[4-[5-(2-Cyclopentylacetamido)indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide Using a similar procedure to that described in Example 57, except starting from ortho-toluenesul-phonamide and the acid described in Example 124, the title compound was obtained in 56% yield as white powder, m.p. 248-2S0~C.

Example 126 Methyl 4-[6-(2-cyclopentylacetamida)-3-oxo-2-propyl-2H,3H-indazol-1-ylmethyl]-3-methoxybenzoate Palladium-on-carbon (57 w/w, 0.095 g.) was added to a solution of methyl 4-[2-allyl-6-(2-cyclo-pentylacetamido)-3-oxo-2H,3H-indazol-1-ylmethyl]-3-methoxybenzoate (0.462 g.) in ethyl acetate (20 ml.).
The mixture was hydrogenated at 1.1 bar for 5 hours.
The catalyst was removed by filtration through diato-maceous earth, the filtrate evaporated and the residue purified by flash chromatography on silica gel (40 g.)) eluting with 1:3:7 v/v/v acetic acid: ethyl ace-tate:dichloromethane. The chromatographed product was dissolved in acetone and toluene, and the solution evaporated to give the title compound in 84~ yield) as a solid glass, m.p. 74.5-77~C.
The starting ester methyl 4-[2-allyl-6-(2-cyclopentylacetamido)-3-oxo-2H,3H-indazol-1-ylmethyl]-3-methoxybenzoate was itself prepared as follows.
Using a similar procedure to that described in Example 42, except starting from methyl 4-[6-(2-cyclopentyl-acetamido)-3-hydroxyindazol-1-ylmethyl]-3-methoxyben-zoate (that is) reaction of this compound with allyl bromide in N,N-dimethylformamide in the presence of sodium hydride)) a mixture of methyl 4-[2-allyl-6-(2-cyclopentylacetamido)-3-oxo-2H,3H-indazol-1-ylmethyl]-3-methoxybenzoate, and methyl 4-[3-allyloxy-6-(2-cyclopentylacetamido)indazol-1-ylmethyl]-3-methoxy-benzoate was obtained. The mixture of compounds was 13~O~b7 heated neat at 200~C. for 18 hours, and the product isolated by flash chromatography on silica gel (60 g.)) eluting with 1:30:70 v/v/v acetic acid: ethyl acetate:dichloromethane) to give methyl 4-[2-allyl-6-(2-cyclopentylacetamido)-3-oxo-2H,3H-indazol-1-ylmeth-yl]-3-methoxybenzoate in 81% yield, as an oil with satisfactory NMR spectral data.
Example 127 4-[6-(2-Cyclopentylacetamido)-3-oxo-2-propyl-2H,3H-indazol-1-ylmethyl]-3-nethoxybenzoic acid Using a similar procedure to that described in Exam le 9, except starting from methyl 4-[6-(2-cyclopentylacetamido)-3-oxo-2-propyl-2H,3H-indazol-1-ylmethyl]-3-methoxybenzoate the title compound was obtained in 83% yield as a solid) m.p. 122.5-125~C.
Example 128 The following illustrates representative pharmaceutical dosages forms which may be used for the therapeutic or prophylactic administration of an acid-is compound of formula I (that is, t~i is an acidic group as defined hereinbefore) or of a pharmaceutical-ly acceptable salt thereof (hereinafter referred to as 'Compound X'):

13~~5b7 (i) Tablet 1 mg/tablet 'Compound X' 100 Lactose 182.75 Croscarmellose Sodium 12.0 Starch 2.25 Magnesium stearate 3.0 (ii) Tablet 2 mg/tablet 'Compound X' 20 Microcrystalline cellulose 420 Polyvinylpyrrolidone 14.0 Starch 43.0 Magnesium stearate 3.0 (iii) Capsule mg/capsule 'Compound X' 10 mg.

Lactose 488.5 Magnesium stearate 1.5 (iv) Injection 1 (10 mg./ml.) 'Compound X' (free acid form) 1.0% w/v Sodium phosphate 3.6% w/v 0.1M Sodium hydroxide solution l5.0% w/v Water for injection. . . .to 100%

(v) Injection 2 (buffered to pH 6) (1 mg./ml.) 'Compound X' (free acid form) 0.1% w/v Sodium phosphate 2.26% w/v Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v Water for injection. . . .to 100%

1340~~~

(vi) Aerosol mg./ml.
'Compound X' 0.2 Sorbitan trioleate 0.27 Trichlorofluoromethane 70.0 Dichlorodifluoromethane 280.0 Dichlorotetrafluoroethane 1094.0 It will be appreciated that the above pharmaceutical compositions may be varied according to well known pharmaceutical techniques to accommodate differing amounts and types of active ingredient 'Compound X'.
The aerosol (vi) may be used in conjunction with a standard, metered dose aerosol dispenser.

- 1305b7 Z~
R~ L \ ( j z X
~~.a.A~.M
R2 R a N Ra R~ L I ' ( Rb I a Rc A~.a.A=.M
R~
Za R~ L ~ ~ ~N z b A~.~.A=.M
Rz Zb R~ L ' I ~ a z c A~.~.A=.M
R~
N
R~ L ~~ I ~>-Ra Id N
~~.~.A= M

2 c R1 L " ( ~Rf I a Re N Rb A~.a.A=. M

-123- ~J~~~~~

R~ L I N N I f \ N~
A~.~.AZ. M .

R~ L ~ ( N-Rg Ig N
A~.~.AZ. M
R2 ORa \~
R~ L I ~ I ~ I n \ N
A~.~.A2. M
a a IIa t ~ ~ /
R.w.co.NH v cH2.a.A=. M
IIb R~ W.CO.N
H2.~.A=.M
R~
Ra I IIc \
R~.W.CO.N CH2.CZ.A=. M

1340y7 R~
N
IId R~iN.C O.N ~ N
~H?.Q.A=.M
R?
Q f IIP
R~.W.CO.N ~ N Re CH~.Q.A=. M
R?
NN
TIf R~ W.CO.N
H?-Q.A= M
R~ R a 'N
IIn R~ W.CO.N
CH?.Q.A:.M
Rz R~ L ' ~ y I I I
X~
A~.~.A:.C02Rh R~
Z~
H?N ' j I~
X
A~.a.A=.T

130 a~i7 R~
R~ L E v ~' I
\
~~.a.A=.T
Rz R a N Ra R1L _. I I vI
R~ L V I I
.A=.cN
;~zzz xb .CN
A=.T
Rz R a NCH
Rt L ~ I _ z ~H
A~.a.A=.T
R~ R a I N~-Ra ?;
R~ L
\ O
A~.a.A=.T

.~~40~~i'~

O Ra R~ L \ ~ x I
A~.Q.A=.'1' H
_v R~ L ~ xI I
Ra A~.Q.A=.T
OH
R~. L ' \ I X I I I
N~OH
~~.a.Az. T
H
R~ L ~ ~ XIv ,O
.Q.A=.'f _ Zb V
R~ L Rn ''' R~ R d N~
R~ L \ ' ~ xvI
Ha~

-12~- 13 ~: 0 5 a'~
R~
R~ L ~ I ~ xvI I
\ N
H
R2 R a N
02N a X V I I I
\

_ S
p2N ~ ( / RQ xIx Z
02N ( j ~X
N
H
Rz R d N
02N ~ I ~ XX I
Ha~
Ra / N \ 02H
\ I / Example 1 R.W.CO.N v Rd I
/ N I ~ \ CO.NH.S02Ph R~W.CO.N \ / example

Claims (46)

1. A compound of formula I
wherein the group >X-Y-Z- is selected from the group consisting of:
(a) >CRc-CRaRb-NRd-(b) >C=N-Za-(c) >C=CRa-Zb-(d) >N-CRa=N-(e) >N-CRbRe-CRcRf-Zb-(f) >N-N=N-(g) >N-NRg-CO-(h) >N-N=C.ORd-wherein Ra is hydrogen or (1-4C)alkyl;
Rb and Rc are each hydrogen or, together with the existing carbon to carbon bond, form an unsaturated linkage;
Rd is hydrogen or (1-10C)alkyl optionally containing one or two double or triple bonds and in which a carbon atom may optionally be replaced by oxygen or sulphur , said (1-10C) alkyl additionally optionally bearing a substituent selected from the group consisting of (1-4C)alkoxy, cyano, carboxy, 1H-tetrazol-5-yl, carbamoyl, N-(1-4C)alkylcarbamoyl, N,N-di[(1-4C)alkyl]carbamoyl, and (1-4C)alkoxycarbonyl, or Rd is selected from the group consisting of (3-8C)-cycloalkyl) (3-8C)cycloalkyl-(1-4C)alkyl, (2-6C)alkanoyl and phenyl-(1-4C)alkyl, the-phenyl moiety of which may optionally bear a substituent selected from the group consisting of cyano, halogeno, (1-4C)alkyl, (1-4C)alkoxy and trifluoromethyl;
Re and Rf are independently hydrogen or (1-4C)alkyl;
Rg is (1-4C)alkyl;
Za is oxy, thio, or substituted imino of the formula -N(Rd)- in which Rd has any of the meanings defined above;
Zb is oxy or thio ;
the group R1.L- stands for amidic radicals of the formula: R1.W.CO.NH- or R1.W.CS.NH-, in which R1 is selected from the group consisting of (a) (2-10C)alkyl optionally containing 1 or more fluorine substituents; (b) phenyl-(1-6C)alkyl in which the (1-6C)alkyl moiety may optionally bear a fluoro or (1-4C)alkoxy substituent and in which the phenyl moiety may optionally bear a substituent selected from the group consisting of halogeno, (1-4C)alkyl) (1-4C)alkoxy and trifluoromethyl; and (c) (3-8C)cycloalkyl or (3-8C)cycloalkyl-(1-6C)alkyl, the cyclic moiety of any of which optionally may contain one unsaturated linkage and may optionally bear 1 or 2 (1-4C)alkyl substituents;

W is oxy, thio, imino or a direct link to R1;
R2 is hydrogen, halogeno, (1-4C)alkyl or (1-4C)alkoxy;
Q is phenylene optionally bearing 1 or more substituents independently selected from the group consisting of halogeno, hydroxy) (1-4C)alkyl, (1-4C) alkoxy and trifluoromethyl;
A1 is (1-2C)alkylene or vinylene;
A2 is methylene) vinylene or a direct link to M; and M is an acidic group selected from the group consisting of carboxy, 1H-tetrazol-5-yl and an acyl-sulphonamide residue of the formula -CO.NH.SOmR3 in which m is the integer 1 or 2 and R3 is selected from the group consisting of (1-6C)alkyl) (3-8C)cycloalkyl) (6-12C)aryl, heteroaryl comprising 5-12 atoms at least one of which is carbon and at least one of which is selected from a group consisting of oxygen, sulfur and nitrogen) and (6-12C)aryl-(1-4C)alkyl) in any of which the aromatic or heteroaromatic moiety may bear 1 or 2 substituents selected from the group consisting of halogeno, (1-4C)alkyl) (1-4C)alkoxy, trifluoromethyl, vitro and amino;
or a pharmaceutically acceptable salt thereof.
2. A compound as claimed in Claim 1 wherein R1 is selected from the group consisting of ethyl, propyl, isopropyl, butyl) isobutyl, sec-butyl, t-butyl, pentyl, 1-ethylpropyl, hexyl, heptyl) 1-ethylpentyl, nonyl, heptafluoropropyl, benzyl, 4-chloro-benzyl, 4-trifluoromethylbenzyl, 4-methylbenzyl, 1-phenylethyl, 2-phenylethyl, 1-methyl-1-phenylethyl, 1-phenylpropyl, 1-phenylpentyl, alpha-fluorobenzyl, alpha-methoxybenzyl, cyclobutyl, cyclopentyl, cyclo-hexyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclo-pentylethyl, 1-cyclopentylbutyl, 1-cyclohexylpropyl, 1-cyclohexylbutyl, 5-methyl-2-(1-methylethyl)cyclohexyl, and 1-cyclohexen-4-yl;
R2 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl and methoxy;
R3 is selected from the group consisting of methyl, isopropyl, butyl, cyclopentyl, phenyl, 4-chlorophenyl, 4-methylphenyl, 2-methylphenyl, naphthyl, thien-2-yl and 6-chloropyrid-3-yl;
Ra is selected from hydrogen and methyl;
Rb and Rc are selected to each be hydrogen or Rb and Rc are taken together and form an unsaturated linkage with the existing carbon to carbon bond;
Rd is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, allyl, propargyl, 3-methylbutyl, 3-methylbut-2-enyl, 2-carbamoylethyl, carboxymethyl, carboxyethyl, N-ethylcarbamoylmethyl, N,N-dimethylcarbamoylmethyl, 2-carboxyvinyl, 2-(methoxycarbonyl)vinyl, 2-methoxy-ethyl,
3-methoxypropyl, cyclopentyl, cyclopropylmethyl, acetyl, benzyl, 3-cyanobenzyl and 4-chlorobenzyl;

Re and Rf are each independently selected from the group consisting of hydrogen, methyl and ethyl;
Rg is selected from the group consisting of methyl, ethyl, and propyl;
A1 is selected from methylene and ethylene;
A2 is selected from a direct linkage and methylene;
Q is selected from the group consisting of m-phenylene and p-phenylene, each of which optionally may bear a fluoro, chloro, hydroxy, methyl, methoxy or trifluoromethyl substituent; and W is selected from the group consisting of oxy, imino, thio and a direct linkage.
3. A compound as claimed in Claim 2 wherein R1 is selected from the group consisting of butyl, pentyl, 1-ethylpentyl, 1-phenylpropyl, alpha-fluorobenzyl, alpha-methoxybenzyl, cyclopentyl, and cyclopentylmethyl;
R2 is hydrogen;
R3 is phenyl or 2-methylphenyl;
Ra is hydrogen;
Rb and Rc axe selected to each be hydrogen or Rb and Rc are taken together and form an unsaturated linkage with the existing carbon to carbon bond;
Rd is selected from the group consisting of hydrogen, methyl, ethyl, propyl, hexyl, allyl, propargyl, 3-methylbutyl, 3-methylbut-2-enyl, carboxymethyl, carboxyethyl, N-ethylcarbamoylmethyl, N,N-di-methylcarbamoylmethyl, 2-methoxyethyl, cyclopentyl, cyclopropylmethyl, acetyl, benzyl, and 3-cyanobenzyl;
Re and Rf are each hydrogen;
Rg is propyl;
A1 is methylene;
A2 is a direct link;
Q is selected from the group consisting of m-phenylene and p-phenylene, each of which may optionally be substituted by a hydroxy or methoxy; and W is selected from the group consisting of oxy, imino and a direct linkage.
4. A compound as claimed in Claim 1 selected from the group consisting of (i) indoles and indolines of formula Ia;
(ii) benzisoxazoles, and indazoles of formula Ib;
(iii) benzo[b]furans and benzo[b]thiophenes of formula Ic;
(iv) benzimidazoles of formula Id;
(v) 1,4-benzoxazines and 1,4-benzothiazines of formula Ie;
(vi) benzotriazoles of formula If;

(vii) indazolones of formula Ig; and (viii) indazoles of formula Ih;
5. A compound as claimed in Claim 4 selected from the group consisting of (i) indoles and indolines of said formula Ia;
(ii) indazoles of said formula Ib;
(iii) benzo[b]thiophenes of said formula-Ic;

(iv) benzimidazoles of said formula Id;
(v) 1,4-benzoxazines of said formula Ie;
(vi) benzotriazoles of said formula If;
(vii) indazolones of said formula Ig; and (viii) indazoles of said formula Ih.
6. A compound as claimed in Claim 4 selected from the group consisting of:
(a) compounds of said formula Ia wherein Rb and Rc, together with the existing carbon to carbon bond, form an unsaturated linkage;
and (b) compounds of said formula Ie wherein Zb is oxy or thin and Rb and Rc are each hydrogen.
7. A compound as claimed in any one of Claims 4, 5 or 6 wherein:
A1 is methylene;
A2 is a direct link to M;
Q is p-phenylene optionally substituted by methoxy;
M is selected from the group consisting of carboxy, 1H-tetrazol-5-yl, and a radical of the formula -CO.NH.SO2R4 wherein R4 is phenyl which may bear 1 or 2 substituents selected from the group consisting of halogeno, (1-4C)alkyl, (1-4C)alkoxy, trifluoromethyl, nitro and ammo.
8. A compound as claimed in any one of Claims 1-3, wherein R1.L- is attached to the benzene moiety of formula I in such a way that it bears a meta-relationship to the group X and bears a para-relationship to the group Z.
9. A compound as claimed in Claim 1 selected from the group consisting of (a) indole derivatives of formula IIa:
(b) indazole derivatives of formula IIb:
(c) benzo(b]thiophene derivatives of formula IIc, (d) imidazole derivatives of formula IId, (e) 2,3-dihydrobenz-1,4-oxazine derivatives of formula IIe) (f) benzotriazole derivatives of formula IIf, and (g) indazole derivatives of formula IIg:

10. A compound as claimed in Claim 9 selected from the group consisting of (a) compounds of formula IIa and IIb wherein M is carboxy and Rd is selected from the group consisting of methyl, propyl, 2-methoxyethyl, N-ethylcarbamoylmethyl and cyclopentyl;
(b) compounds of formula IIa and IIb wherein M is a radical of the formula -CO.NH.SO2R4 wherein R4 is phenyl and Rd is selected from the group consisting of hydrogen, methyl, 2-methoxyethyl and N-ethylcarbamoylmethyl;

(c) compounds of formula IIa and IIb wherein M is a radical of the formula -CO.NH.SO2R4 wherein R4 is 2-methylphenyl and Rd is selected from the group consisting of methyl and N,N-dimethylcarbamoylmethyl;
(d) compounds of formula IIg wherein R1.L- is R1.W.CO.NH- wherein R1.W- is cyclopentyloxy, M is carboxy or -CO.NH.SO2R4 wherein R4 is phenyl, and Rd is methyl; and (e) compounds of formula IIg wherein R1.L- is R1.W.CO.NH- wherein R1 is cyclopentylmethyl, W is a direct linkage, M is carboxy or -CO.NH.SO2R4 wherein R4 is 2-methylphenyl, and Rd is N-ethylcarbamoyl-methyl.
11. A compound as claimed in Claim 1 wherein said compound is selected from the group consisting of (a) N-[4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide, (b) N-[4-[5-(cyclopentyloxycarbonyl)amino-1-(N-ethylcarbamoylmethyl)indol-3-ylmethyl]-3-methoxy-benzoyl]benzenesulphonamide, (c) N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindazol-3-ylmethyl]-3-methoxybenzoyl]benzene-sulphonamide, (d) N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methyl-benzenesulphonamide, (e) N-[4-[5-(2-cyclopentylacetamido)-1-(N,N-dimethylcarbamoylmethyl)indol-3-ylmethyl]-3-meth-oxybenzoyl]-2-methylbenzenesulphonamide, (f) N-[4-[6-(cyclopentyloxycarbonyl)amino-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenz-oyl]benzenesulphonamide, (g) N-[4-[6-(2-cyclopentylacetamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]-benzenesulphonamide, (h) N-[4-(5-(cyclopentyloxycarbonyl)amino-benzo[b]thien-3-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide, (i) N-[4-[6-(2-cyclopentylacetamido)benz-imidazol-1-ylmethyl]-3-methoxybenzoyl]benzenesulphon-amide, (j) N-(4-[6-(2-cyclopentylacetamido)-2,3-dihydrobenz-1,4-oxazin-4-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide, (k) N-(4-[6-(cyclopentyloxycarbonyl)amino-3-methoxyindazol-1-ylmethyl]-3-methoxybenzoyl]benzene-sulphonamide, (l) N-[4-[5-(N'-cyclopentylureido)-1-meth-ylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzene-sulphonamide, (m) N-[4-[6-(2-cyclopentylacetamido)benzo-triazol-1-ylmethyl]-3-methoxybenzoyl]benzenesulphon-amide, (n) N-[4-[5-(cyclopentyloxycarbonyl)amino-indol-3-ylmethyl]-3-methoxybenzoyl]benzenesulphon-amide, (o) N-[4-[5-(cyclopentyloxycarbonyl)amino-1-(2-methoxyethyl)indol-3-ylmethyl]-3-methoxybenzoyl]-benzenesulphonamide, (p) N-[4-[5-(2-cyclopentylacetamido)-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide, (q) N-[4-[6-(2-cyclopentylacetamido)-3-(N-ethylcarbamoylmethoxy)indazol-1-ylmethyl]-3-methoxy-benzoyl]-2-methylbenzenesulphonamide, and (r) N-[4-[6-(cyclopentyloxycarbonyl)amino-benzimidazol-1-ylmethyl]-3-methoxybenzoyl]benzenesul-phonamide, wherein each of these compounds may be in the form of a free acid or as its corresponding pharmaceutically acceptable salt.
12. The compound N-[4-[5-(cyclopentyloxy -carbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methyl-benzenesulphonamide.
13. A compound of formula III
wherein Rh is selected from the group consisting of (a) (1-6C)alkyl optionally bearing an acetoxy, (1-4C)-alkoxy or (1-4C)alkylthio group; (b) phenyl; and (c) benzyl; and wherein A1, A2, Q, R1.L, R2 and the group > X-Y-Z- are defined as in Claim 1.
14. A compound of formula VII
wherein A1, A2, Q, R1.L, R2 and the group > X-Y-Z- are as defined as in Claim 1.
15. A leukotriene antagonist of formula I
wherein the group >X-Y-Z- is selected from the group consisting of:
(a) >CRc-CRaRb-NRd-(b) >C=N-Za-(c) >C=CRa-Zb-(d) >N-CRa=N-(e) >N-CRbRe-CRcRf-Zb-(f) >N-N=N-(g) >N-NRg-CO-(h) >N-N=C.ORd-wherein Ra is hydrogen or (1-4C)alkyl;
Rb and Rc are each hydrogen or, together with the existing carbon to carbon bond, form an unsaturated linkage;
Rd is hydrogen or (1-10C)alkyl optionally containing one or two double or triple bonds and in which a carbon atom may optionally be replaced by oxygen or sulphur, said (1-10C)alkyl additionally optionally bearing a substituent selected from the group consisting of (1-4C)alkoxy, cyano) carboxy, 1H-tetrazol-5-yl) carbamoyl) N-(1-4C)alkylcarbamoyl, N,N-di[(1-4C)alkyl]carbamoyl) and (1-4C)alkoxycarbonyl, or Rd is selected from the group consisting of (3-8C)-cycloalkyl, (3-8C)cycloalkyl-(1-4C)alkyl, (2-6C)alkanoyl and phenyl-(1-4C)alkyl, the phenyl moiety of which may optionally bear a substituent selected from the group consisting of cyano, halogeno, (1-4C)alkyl, (1-4C)alkoxy and trifluoromethyl;
Re and Rf are independently hydrogen or (1-4C)alkyl;
Rg is (1-4C)alkyl;
Za is oxy, thio, or substituted imino of the formula -N(Rd)- in which Rd has any of the meanings defined above;
Zb is oxy or thio;
the group R1.L- stands for amidic radicals of the formula: R1.W.CO.NH- or R1.W.CS.NH-, in which R1 is selected from the group consisting of (a) (2-10C)alkyl optionally containing 1 or more fluorine substituents; (b) phenyl-(1-6C)alkyl in which the (1-6C)alkyl moiety may optionally bear a fluoro or (1-4C)alkoxy substituent and in which the phenyl moiety may optionally bear a substituent selected from the group consisting of halogeno) (1-4C)alkyl, (1-4C)alkoxy and trifluoromethyl; and (c) (3-8C)cycloalkyl or (3-8C)cycloalkyl-(1-6C)alkyl, the cyclic moiety of any of which optionally may contain one unsaturated linkage and may optionally bear 1 or 2 (1-4C)alkyl substituents;

W is oxy, thio, imino or a direct link to R1;
R2 is hydrogen, halogeno, (1-4C)alkyl or (1-4C)alkoxy;
Q is phenylene optionally bearing 1 or more substituents independently selected from the group consisting of halogeno, hydroxy, (1-4C)alkyl, (1-4C) alkoxy and trifluoromethyl;
A1 is (1-2C)alkylene or vinylene;
A2 is methylene, vinylene or a direct link to M; and M is an acidic group selected from the group consisting of carboxy, an acylsulphonamide residue of the formula -CO.NH.SOmR3 and 1H-tetrazol-5-yl in which m is the integer 1 or 2 and R3 is (1-6C)alkyl, (3-8C)-cycloalkyl) (6-12C)aryl, heteroaryl comprising 5-12 atoms at least one of which is carbon and at least one of which is selected from oxygen, sulfur, and nitrogen, (6-12C)aryl-(1-4C)alkyl, in any of which the aromatic or heteroaromatic moiety may bear 1 or 2 substituents selected from the group consisting of halogeno, (1-4C)alkyl, (1-4C)alkoxy, trifluoromethyl, nitro and amino;
or a pharmaceutically acceptable salt thereof.

-145a-
16. A leukotriene antagonist as claimed in Claim 15, wherein the group R1.L- is attached to the benzene moiety of formula I in such a way that it bears a meta-relationship to the group X and bears a para-relationship to the group Z;
the group R1.L- stands for R1.W.CO.NH- in which either R1 is cyclopentyl and W is oxy or imino, or R1 is cyclopentylmethyl and W is a direct linkage;
A1 is methylene;
A2 is a direct link to M; and Q is p-phenylene substituted by methoxy in the ortho-position relative to A1.
17. A leukotriene antagonist as claimed in Claim 15, wherein the group R1.L- is attached to the benzene moiety of formula I in such a way that it bears a meta-relationship to the group X and bears a para-relationship to the group Z;

the group R1.L- stands for R1.W.CO.NH- in which either R1 is cyclopentyl and W is oxy or imino, or R1 is cyclopentylmethyl and W is a direct linkage;
A1 is methylene;
A2 is a direct link to M;
Q is p-phenylene substituted by methoxy in the ortho-position relative to A1; and M is carboxy, 1-H-tetrazol-5-yl or a radical of the formula -CO.NH.SO2R4 wherein R4 is phenyl which may bear 1 or 2 optional substituent.
18. A leukotriene antagonist as claimed in claim 17 wherein R4 is 2-methylphenyl.
19. A pharmaceutical composition having leukotriene antagonist properties comprising a pharmaceutically effective amount of a compound as claimed in Claim 1 and a non-toxic pharmaceutically-acceptable diluent or carrier.
20. A pharmaceutical composition useful in the treatment of allergic diseases, inflammatory diseases, endotoxic conditions or traumatic shock conditions comprising a pharmaceutically effective amount of a compound as Claimed in Claim 1 and a non-toxic pharmaceutically-acceptable diluent or carrier.
21. A composition as claimed in Claim 19 or 20 wherein said composition is in the form of a liquid or powdered aerosol.
22. A pharmaceutical composition having leukotriene antagonist properties comprising an effective amount of a leukotriene antagonist as claimed in any one of claims 15 to 18 and a non-toxic pharmaceutically acceptable diluent or carrier.
23. A pharmaceutical composition useful in the treatment of allergic diseases, inflammatory diseases, endotoxic conditions or traumatic shock conditions comprising a leukotriene antagonist as claimed in any one of Claims 15 to 18, and a non-toxic pharmaceutically acceptable diluent or carrier.
24. A salt of a compound claimed in any one of Claims 1 to 6 or 9 to 11.
25. A process for making any one of the compounds claimed in Claim 1, which process comprises a method selected from:
(A) For a compound wherein M is a carboxylic acid group, decomposing a suitable ester of formula III wherein Rh is selected from the group consisting of (a) (1-6C)alkyl optionally bearing an acetoxy, (1-4C)-alkoxy or (1-4C) alkylthio group; (b) phenyl; and (c) benzyl;
(B) Acylating an amine of formula IV, but wherein T is chosen from the values defined for M;
(C) For a compound of formula I wherein >X-Y-Z-, has the value ~CRc-CRaRb-NRd- or >C=N-Za-, but wherein Za is a substituted imino of the formula -N(Rd)-, reacting an imino compound of formula V, wherein >D-E-G- is a group of the formula >CRc-CRbRa-NH- or >C=N-NH-, but wherein T is chosen from the values defined for M, with an alkylating agent of the formula Rd.U, wherein U is selected from the group consisting of chloro, bromo, iodo, methanesulphonyloxy and p-toluenesulphonyloxy;
(D) For a compound of formula I wherein >X-Y-Z- is >CRc-CRaRb-NRd-, but wherein Rb and Rc, together with the existing carbon-to-carbon bond, form an unsaturated linkage, reacting an indole of formula VI
with an alkylating agent of the formula U.A1.Q.A2.M in the presence of a suitable Lewis acid, wherein U has the meaning as defined in (C) and the Lewis acid is selected from the group consisting of silver oxide, silver carbonate, silver fluoroborate, silver trifluoroacetate, silver trifluoromethanesulphonate, zinc chloride, ferric chloride and stannic chloride;
(E) For a compound of formula I wherein M
is a 1H-tetrazol-5-y1 radical, reacting a cyano derivative of formula VII
with an alkali metal azide;
(F) For a compound of formula I wherein R1.L- stands for a group of the formula R1.Wa.CO.NH-or R1.Wa.CS.NH- in which Wa is oxy, imino or thio, reacting an isocyanate or isothiocyanate of the formula VIII, but wherein T is chosen from the values defined for M
and wherein Xb is oxygen or sulphur, with an amine of the formula R1.NH2, an alcohol of the formula R1.OH or a thiol of the formula R1.SH;
(G) For a compound of formula I wherein M
is a group of the formula CO.NH.SOm.R3, reacting a compound of formula I wherein M is carboxy with a sulphonamide derivative of the formula R3.SOm.NH2) in the presence of a dehydrating agent;
(H) For a compound of formula I, wherein >X-Y-Z- is >CRc-CRaRb-NRd-, but wherein Rb and Rc, together with the existing carbon-to-carbon bond, form an unsaturated linkage, reacting an indole of formula VI with an alkylating agent of formula U.A1.Q.A2.M, wherein U has the meaning defined in (C);
(I) For a compound of formula I wherein >X-Y-Z- is >C=N-Za-, but wherein Za is a substituted imino of the formula -N(Rd)-, dehydrating an amino-oxime of formula IX, but wherein T is chosen from the values defined for M:
(J) For a compound of formula I, wherein >X-Y-Z- is >C=CRa-Zb-, but wherein Zb is oxy, by dehydrating an hydroxy compound of formula XI, but wherein T is chosen from the values defined for M;
(K) For a compound of formula I, wherein >X-Y-Z- is >C=N-Za-, but wherein Za is oxy, dehydrating an hydroxy-oxime of formula XIII, but wherein T is chosen from the values defined for M;
(L) For a compound of formula I wherein >X-Y-Z- is >C=CRa-Zb-, but wherein Zb is oxy or thio, reacting a benzofuran or a benzothiophene of formula XV
with an alkylating agent of formula U.A1.Q.A2.M, wherein U has the values defined in (C):
(M) For a compound of formula I wherein >X-Y-Z- is >CRc-CRaRb-NRd-, but wherein Rb and Rc are hydrogen, catalytic hydrogenation of an indole of formula I wherein >X-Y-Z- is >CRc-CRaRb-NRd-, but wherein Rb and Rc, together with the existing carbon-to-carbon bond, form an unsaturated linkage;
(N) For a compound of formula I wherein >X-Y-Z- is >C=N-Za-, but wherein Za has the value -N(Rd)- and A1 is methylene, cross coupling an indazole of formula XVI, wherein Hal is chloro, bromo or iodo, with a compound of formula Hal.CH2.Q.A2.T, but wherein T is COORh or CN, and wherein the Hal is chloro, bromo or iodo, to afford the corresponding compound of III or VII, wherein >X-Y-Z- is >C=N-Za-, but wherein Za has the value -N(Rd)- and A1 is methylene; followed by conversion of the COORh group or the CN group, respectively, into one of the values defined above for M by application of method (A) or -(E), respectively; and (o) For a compound of formula I wherein >X-stands for the group >N-, alkylation of an amino compound of formula XVII, with an alkylating agent of the formula U.A1.Q.A2.M
wherein U has the meaning defined in (C) in the presence of a suitable base.
26. A process as claimed in Claim 25(A) wherein said decomposition is effected by a method selected from the group consisting of (a) hydrolysis under acid or base conditions;
(b) decomposition by nucleophilic demethylation) when Rh is methyl;
(c) thermal decomposition; and (d) reduction, when Rh is benzyl.
27. A process as claimed in Claim 25(B) wherein an acylating agent used is selected from the group consisting of (a) when W is oxy, thio or a direct link, an acid halide of the formula R1.Xa.CO.HaI wherein Xa has the values defined for W;
(b) when W is imino, an isocyanate of formula R1.NCO; and (c) when W is a direct link, a carboxylic acid of formula R1.CO2H.
28. A process as claimed in Claim 25(C) wherein Rb and Rc, together with the existing carbon-to-carbon bond, form an unsaturated linkage.
29. A process as claimed in Claim 25(D) wherein said process is performed in a suitable solvent or diluent and at a temperature in the range of from about 15°C to about 100°C.
30. A process as claimed in Claim 25(E) wherein said process is performed in a suitable polar solvent and at a temperature i.n the range of from about 50°C to about 160°C.
31 . A process as claimed in Claim 25 (F) wherein said process is performed in a suitable inert diluent or solvent and at a temperature in the range of from about 0°C to about 60°C.
32 . A process as claimed in Claim 25(G) wherein said process is performed with a free acid of formula I in the presence of a suitable solvent or diluent and at a temperature in the range of from about 10°C to about 50°C.
33. A process as claimed in Claim 25(G) wherein said process is performed with a reactive derivative of formula I and an alkali metal salt of the sulfonamide derivative at or near room temperature in a suitable solvent or diluent.
34. A process as claimed in Claim 25(H) wherein said process is performed in a polar or ether solvent and at a temperature in the range of from about 50°C to about 160°C.
35. A process as claimed in Claim 25(I) wherein said process is performed by first reacting a compound of formula IX with a suitable acylating agent in the presence of a suitable solvent or diluent in the presence of an organic base, then heating the resulting O-acyloxime at a temperature in the range of from about 80°C to about 250°C.
36. A process as claimed in Claim 25(I) wherein said process is carried out by heating the amino oxime of formula IX at a temperature in the range of from 150°C to about 300°C.
37. A process as claimed in Claim 25(J) wherein said process is performed by treatment of said compound of formula XI with an acid in a suitable inert solvent or diluent, and at a temperature in the range of from about 50°C to about 150°C.
38. A process as claimed in Claim 25(M) wherein said process is performed under suitable catalytic hydrogenation conditions and at a temperature in the range of from about 15°C to about 100°C.
39. A compound of formula IV:
wherein T is M, COORh or CN in which Rh is (1-6C)alkyl optionally bearing an acetoxy, (1-4C)alkoxy or (1-4C)alkylthio substituent, or is phenyl or benzyl; and where in A1, A2, Q, R2, M and the group >X-Y-Z< are as defined in Claim 1.
40. A compound as claimed in Claim 39 wherein the group H2N- is attached to the benzene moiety of formula IV in such a way that it bears a meta-relationship to the group X and bears a para-relationship to the group Z;
A1 is methylene;
A2 is a direct link to T; and Q is p-phenylene substituted by methoxy in the ortho-position relative to A1.
41. A compound as claimed in claim 40 wherein T
is carboxy or COORh wherein Rh is methyl, ethyl, propyl, t-butyl, acetoxymethyl, methoxymethyl, 2-methoxyethyl, methylthiomethyl, or phenyl or benzyl.
42. A compound as claimed in claim 39, which is selected from methyl 4-(5-aminoindol-3-yl)methyl-3-methoxybenzoate and methyl 4-(5-amino-1-methylindol-3-ylmethyl)-3-methoxybenzoate.
43. A compound of formula IVa:
wherein T is M, COORh or CN in which Rh is (1-6C)alkyl optionally bearing an acetoxy, (1-4C)alkoxy or (1-4C)alkylthio substituent, or is phenyl or benzyl; and wherein A1, A2, Q, R2, M and the group >X-Y-Z< are as defined in Claim 1.
44. A compound as claimed in claim 43 wherein the group O2N- is attached to the benzene moiety of formula IVa in such a way that it bears a meta-relationship to the group X and bears a para-relationship to the group Z;
A1 is methylene;
A2 is a direct link to T; and Q is p-phenylene substituted by methoxy in the ortho-position relative to A1.
45. A compound as claimed in claim 44 wherein T
is carboxy or COORh wherein Rh is methyl, ethyl, propyl, t-butyl, acetoxymethyl, methoxymethyl, 2-methoxyethyl, methylthiomethyl, or phenyl or benzyl.
46. A compound as claimed in claim 43, which is selected from methyl 3-methoxy-4-(5-nitroindol-3-yl) methylbenzoate, methyl 3-methoxy-4-(5-vitro-1-methylindol-3-ylmethyl)benzoate, and 4-(5-nitroindol -3-ylmethyl)-3-methoxybenzoic acid.
CA000506885A 1985-04-17 1986-04-16 Heterocyclic amide derivatives Expired - Fee Related CA1340567C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8509882 1985-04-17
GB858509882A GB8509882D0 (en) 1985-04-17 1985-04-17 Heterocyclic amide derivatives
GB8525658 1985-10-17
GB858525658A GB8525658D0 (en) 1985-10-17 1985-10-17 Heterocyclic amide derivatives

Publications (1)

Publication Number Publication Date
CA1340567C true CA1340567C (en) 1999-06-01

Family

ID=26289139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000506885A Expired - Fee Related CA1340567C (en) 1985-04-17 1986-04-16 Heterocyclic amide derivatives

Country Status (26)

Country Link
US (6) US4859692A (en)
EP (1) EP0199543B1 (en)
JP (2) JPH0667904B2 (en)
KR (1) KR900004384B1 (en)
CN (1) CN1017425B (en)
AR (1) AR242569A1 (en)
AU (1) AU596582B2 (en)
BG (1) BG60471B2 (en)
CA (1) CA1340567C (en)
CS (1) CS399791A3 (en)
CY (1) CY1705A (en)
DE (1) DE3682698D1 (en)
DK (1) DK167354B1 (en)
ES (6) ES8802220A1 (en)
FI (1) FI83865C (en)
GB (1) GB8607294D0 (en)
HK (1) HK120994A (en)
HU (1) HU196968B (en)
IE (1) IE59140B1 (en)
IL (1) IL78569A (en)
NO (1) NO171452C (en)
NZ (1) NZ215850A (en)
PH (1) PH26763A (en)
PT (1) PT82389B (en)
SA (1) SA93140396A (en)
ZW (1) ZW8786A1 (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179112A (en) * 1985-04-17 1993-01-12 Ici Americas Inc. Heterocyclic amide derivatives and pharmaceutical use
DK496086A (en) * 1985-10-17 1987-04-18 Ici America Inc Heterocyclic Compounds
GB8623429D0 (en) * 1985-10-17 1986-11-05 Ici America Inc Carboximide derivatives
ZA892643B (en) * 1988-04-14 1989-12-27 Ici America Inc Carbocyclic compounds
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
ATE113581T1 (en) * 1990-05-04 1994-11-15 Ciba Geigy Ag SUBSTITUTED INDOLES.
GB9026427D0 (en) * 1990-12-05 1991-01-23 Ici Plc Chemical process
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
CA2062587A1 (en) * 1991-03-11 1992-09-12 Toshiaki Kumazawa Indole derivatives
DE4123341A1 (en) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K PHENYL ALKYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
IT1251144B (en) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia BENZIMIDAZOLONE DERIVATIVES
US5334597A (en) * 1991-10-17 1994-08-02 Merck Frosst Canada, Inc. Indole carbamates as leukotriene antagonists
EP0539329A1 (en) * 1991-10-25 1993-04-28 Ciba-Geigy Ag Acetenyl compounds useful as leukotrien antagonists
ATE122656T1 (en) * 1991-10-25 1995-06-15 Ciba Geigy Ag METHOD FOR PRODUCING SUBSTITUTED INDOLES.
US5272169A (en) * 1992-03-27 1993-12-21 The Dupont Merck Pharmaceutical Company (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
US5217983A (en) * 1992-03-27 1993-06-08 Du Pont Merck Pharmaceutical Company (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
GB9207236D0 (en) * 1992-04-02 1992-05-13 Grosvenor Power Services Ltd Treatment of liquids
US5280039A (en) * 1992-11-04 1994-01-18 Pfizer Inc. Bicyclic carbamates and methods of treating inflammatory diseases using the same
US5439929A (en) * 1994-03-01 1995-08-08 Pfizer Inc. Bicyclic carbamates, pharmaceutical compositions and use
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
EP0702004A2 (en) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives
ES2108641B1 (en) * 1995-07-31 1998-08-16 Menarini Lab QUINOLONIC SULFONIMIDES WITH ANTAGONIST ACTION OF THE LEUCOTRENEES.
PL328074A1 (en) * 1996-02-08 1999-01-04 Merck & Co Inc Therapeutical method and pharmaceutic composition
DE19610882A1 (en) * 1996-03-20 1997-09-25 Dresden Arzneimittel New 1,3,5-trisubstituted indazole derivatives with antiasthmatic, antiallergic, anti-inflammatory and immunomodulating effects, processes for their preparation and their use as medicines
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
AU2031799A (en) 1998-01-14 1999-08-02 Uab Research Foundation, The Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
JP3494990B2 (en) 1998-03-31 2004-02-09 ザ インスティテューツ フォア ファーマスーティカル ディスカヴァリー エルエルシー Substituted indolealkanolic acid
DE19821002A1 (en) * 1998-05-11 1999-11-18 Dresden Arzneimittel New indazole derivatives useful as antiasthmatic, antiallergic, neuroprotective agents and for treatment of inflammation and immune disorders
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6194432B1 (en) * 1998-10-13 2001-02-27 Fred D. Sheftell Prevention and treatment of migraine, cluster and other recurrent headaches using leukotriene antagonist drugs
TNSN99224A1 (en) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS
WO2001007031A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
IT1320162B1 (en) 2000-02-09 2003-11-18 Rotta Research Lab DERIVATIVES OF THYROSIN WITH ANTI LEUKOTRIENIC ACTIVITY, PROCEDURES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE.
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
EP1583748B1 (en) * 2003-01-13 2010-02-10 Dainippon Sumitomo Pharma Co., Ltd. Process for the preparation of 1,2-dichloroethane free crystals of zonisamide and the highly pure crystals of zonisamide
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
JP2007504123A (en) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Inhibitors of type IV phosphodiesterase
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
RU2445095C2 (en) * 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх New pharmaceutical compositions for sexual disorders
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
MX2007004976A (en) 2004-10-25 2007-06-14 Schering Corp M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders.
ES2395929T3 (en) * 2005-02-25 2013-02-18 Ono Pharmaceutical Co., Ltd. Indole compounds to treat respiratory disorders
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
JP2008531714A (en) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment and / or prevention of anxiety disorders
EP1858516A1 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2008540672A (en) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for treating sexual dysfunction caused by medical condition
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009503020A (en) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin in the treatment of obesity
ES2246742B1 (en) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. USE OF A DERIVATIVE OF IMIDAZOLE.
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
BRPI0617673C1 (en) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd phosphodiesterase type iv inhibitor compositions
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007096694A1 (en) * 2006-02-22 2007-08-30 Ramiro Vergara Combination of neuroactivating active principles
JP2009536176A (en) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin for the treatment of postmenopausal sexual desire disorders
JP2009541443A (en) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
CN101104601B (en) * 2006-07-14 2011-01-26 海南盛科生命科学研究院 Method for preparing zafirlukast important intermediate
NZ574375A (en) 2006-07-22 2011-06-30 Oxagen Ltd 2-(5-fluoro-2-methyI-3-(2-(phenylsulfonyl)benzyl)-1H-indol-1-yl) acetic acid derivatives having CRTH2 antagonist activity
EA200900264A1 (en) * 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх COMPOSITIONS OF FLIBANSERIN AND METHOD OF THEIR PREPARATION
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
AU2007287639A1 (en) * 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
MX2009003100A (en) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibitors of phosphodiesterase type-iv.
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
PT2124944E (en) * 2007-03-14 2012-05-17 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
CA2695008A1 (en) * 2007-07-30 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted indoles
PE20091188A1 (en) 2007-09-12 2009-08-31 Boehringer Ingelheim Int COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
BRPI0821647A2 (en) * 2007-12-21 2015-06-16 Schering Plough Healthcare Enhancement of oxymetazoline photo stabilization
SI2250161T1 (en) 2008-01-18 2014-04-30 Atopix Therapeutics Limited Compounds having crth2 antagonist activity
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2265581A1 (en) * 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509991A (en) * 2008-01-22 2011-03-31 オキサジェン リミテッド Compound having CRTH2 antagonist activity
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2300425A4 (en) * 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc Cycloalkaneýb¨indole angtagonists of prostaglandin d2 receptors
US20120004233A1 (en) * 2009-01-26 2012-01-05 Amira Pharmaceuticals, Inc Tricyclic compounds as antagonists of prostaglandin d2 receptors
EP2443134A2 (en) 2009-06-16 2012-04-25 Schering Corporation NOVEL [3,2-c]HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
JP6236068B2 (en) 2012-05-08 2017-11-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Tetrahydronaphthyridine and related bicyclic compounds for inhibiting RORγ activity and treating diseases
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (en) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 Amorphous zafirlukast and preparation method thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) * 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US20160339010A1 (en) 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
JP2017507950A (en) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Adoptive cell therapy using retinoic acid receptor-related orphan receptor gamma agonists and related therapeutic methods
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
KR20180025894A (en) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Benzo [B] [1,4] oxazinesulfonamides and related compounds for use as agonists of RORY and the treatment of diseases
JP2018531958A (en) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Heteroaryl-substituted benzoic acids and their use as RORγT inhibitors
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
EP3368539B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Substituted indazole compounds as ror gamma t inhibitors and uses thereof
EP3168570A1 (en) 2015-11-10 2017-05-17 Primetals Technologies France SAS Method and device for measuring the planarity of a metal product
KR101713303B1 (en) * 2015-12-24 2017-03-07 강원대학교산학협력단 Preparation method of 2H-Indazole derivatives
EP3585809A4 (en) 2017-01-30 2021-02-24 Western New England University Thiol isomerases inhibitors and use thereof
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
CN109438414B (en) * 2018-10-24 2021-03-16 常州大学 Method for preparing benzo 1, 3-oxathiane-4-ketone
CN110183371B (en) * 2019-04-11 2022-06-14 南京医科大学 Preparation process of zafirlukast intermediate
WO2021069542A1 (en) 2019-10-08 2021-04-15 Rigshospitalet Zafirlukast derivatives for use as contraceptive agents
WO2022243942A1 (en) 2021-05-19 2022-11-24 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2381935A (en) * 1940-11-16 1945-08-14 Eastman Kodak Co Process for producing morpholine compounds
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
GB1050302A (en) * 1964-02-19
FR4035M (en) * 1964-11-04 1966-03-28
DE1769018A1 (en) * 1968-03-21 1971-06-09 Bayer Ag Azo dyes and process for their preparation
FR7631M (en) * 1968-08-13 1970-01-26
US3470298A (en) * 1969-01-29 1969-09-30 Acraf Topical anti-inflammatory composition containing (indazole-3-yl)-oxyalkanoic acids
BE738727A (en) * 1969-09-11 1970-02-16 Anti inflammatory analgesic and antipyretic indolyalkanoic - acids and derivs
DE2854987A1 (en) * 1978-12-20 1980-06-26 Boehringer Mannheim Gmbh DIAGNOSTIC AGENTS FOR DETECTING PROTEOLYTIC ENZYMS AND CHROMOGENS SUITABLE FOR THIS
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids

Also Published As

Publication number Publication date
US5583152A (en) 1996-12-10
PT82389B (en) 1988-08-17
SA93140396A (en) 2005-12-03
EP0199543A3 (en) 1988-10-26
PT82389A (en) 1986-05-01
US5030643A (en) 1991-07-09
NO171452B (en) 1992-12-07
DK167354B1 (en) 1993-10-18
ES557645A0 (en) 1988-02-16
IE59140B1 (en) 1994-01-12
AR242569A1 (en) 1993-04-30
CY1705A (en) 1994-01-14
ES8802494A1 (en) 1988-07-16
KR860008136A (en) 1986-11-12
CN1017425B (en) 1992-07-15
ZW8786A1 (en) 1987-11-04
NO861481L (en) 1986-10-20
PH26763A (en) 1992-09-28
AU5616486A (en) 1986-10-23
IL78569A (en) 1990-02-09
HK120994A (en) 1994-11-11
FI861601A0 (en) 1986-04-16
ES8802220A1 (en) 1988-04-16
FI83865B (en) 1991-05-31
ES8802023A1 (en) 1988-03-16
NZ215850A (en) 1990-03-27
ES557642A0 (en) 1988-07-16
BG60471B2 (en) 1995-04-28
IL78569A0 (en) 1986-08-31
DK173486D0 (en) 1986-04-16
HUT40623A (en) 1987-01-28
CS399791A3 (en) 1992-09-16
GB8607294D0 (en) 1986-04-30
US5338734A (en) 1994-08-16
AU596582B2 (en) 1990-05-10
ES554027A0 (en) 1988-04-16
ES557643A0 (en) 1988-07-16
NO171452C (en) 1993-03-17
JPS6293274A (en) 1987-04-28
HU196968B (en) 1989-02-28
US5391758A (en) 1995-02-21
CN86103278A (en) 1986-12-17
FI861601A (en) 1986-10-18
JPH0667904B2 (en) 1994-08-31
JPH06279404A (en) 1994-10-04
DE3682698D1 (en) 1992-01-16
US4859692A (en) 1989-08-22
ES8802493A1 (en) 1988-07-16
DK173486A (en) 1986-10-18
KR900004384B1 (en) 1990-06-23
IE861000L (en) 1986-10-17
EP0199543A2 (en) 1986-10-29
ES8802220B9 (en) 2012-01-03
JPH0742270B2 (en) 1995-05-10
US5440035A (en) 1995-08-08
ES8801787A1 (en) 1988-02-16
EP0199543B1 (en) 1991-12-04
ES557644A0 (en) 1988-03-16
FI83865C (en) 1991-09-10

Similar Documents

Publication Publication Date Title
CA1340567C (en) Heterocyclic amide derivatives
CA1273934A (en) Heterocyclic amide leukotriene antagonists
EP0242167B1 (en) Heterocyclic carboxamides
EP0220066B1 (en) Carboxamide derivatives
US4837235A (en) Indole and indazole keto sulphones as leukotriene antagonists
US4898863A (en) Heterocyclic carboxamides
US5179112A (en) Heterocyclic amide derivatives and pharmaceutical use
DD251348A5 (en) PROCESS FOR THE PREPARATION OF HETEROCYCLIC AMID DERIVATIVES

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20150601